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SUMMARY OF THESIS
During the past eighty years, there has been much clinical 
and experimental evidence presented by a wide variety of 
investigations confirming the deleterious interplay of endocrine 
and genetic factors in the natural history of these diseases 
known as the porphyrias. The porphyrin-inducing 5p-H oxo- 
steroids that have been identified delineate one category of 
endogenous agents through which such an endocrine-genetic 
interplay may be affected in some subjects, and it is the 
purpose of this investigation to examine the relevance of the 
part played, if any, by some of these 5o:-H and Sp-H 17-oxo- 
steroids in the pathogenesis of the porphyrias in humans.
Preliminary experiments included the setting-up and 
evaluation of methods for the measurement of four 17-oxo- 
steroid sulphates and eight 17-oxosteroid glucuronides in 
urine and the measurement of their levels in urine in seventy- 
five normal subjects, consisting of thirty-eight males and 
thirty-seven females. A pattern similar to that dbtained by 
Hamburger (1948) for the total urinary 17-oxosteroids excretion 
of different age groups was Obtained for the individual urinary 
17-oxosteroid levels in this control group. These methods 
were then applied to the study of the urinary levels of these 
17-oxosteroids in patients suffering from acute intermittent 
porphyria (AIP), hereditary coproporphyria (HOP), variegate 
porphyria (UP) and porphyria cutanea tarda (PCT). In total, 
thirty-four patients with AIP, five patients with HOP, two
patients with UP and fourteen patients with PCT were investigated. 
Of the thirty-four patients with AIP, a total of twenty-three had 
elevated levels of certain of these 17-oxosteroids, especially 
dehydroepiandrosterone sulphate (DHAS) and aetiocholanolone 
glucuronide (EG) and sulphate (ES) in the urine. The seven 
patients with AIP who were investigated during or shortly after 
attack had levels of urinary 17-oxosteroids well beyond the range 
of the normal control group. Similar results were obtained with 
the five patients with HCP, with the exception that the elevations 
of these 17-oxosteroids were observed only in the urine of the 
three patients who were in attack and not in those who were in 
remission. In one patient with AIP and two patients with HCP 
from whom serial 24-hour urine specimens were obtainable, 
significant linear correlations were found between the values of 
the ratio of urinary aetiocholanolone to androsterone and the 
levels of 6-aminolaevulic acid (ALA) and porphobilinogen (PBG) 
in the individual urines. The two patients with UP who were 
investigated were in remission and did not show any elevations 
of these steroids in the urine. The fourteen patients with PCT 
who were studied did not show any elevations of the urinary levels 
of these 17-oxosteroids, but it was noted that this group tended 
to excrete lower levels of steroids than the similarly aged normal 
controls.
More specific investigations were undertaken with one male 
patient who had suffered from several acute attacks of porphyria. 
During those attacks, his DHAS and EG were the predominantly 
raised urinary steroids. After treatment with dexamethasone.
which suppresses the activity of the adrenal cortex, his clinical 
condition improved, his urinary 17-oxosteroid levels fell sharply, 
corresponding with an equally sharp fall in urinary porphyrins 
and precursors (ALA and PBG).
Having established these irregularities in the levels of 
17-oxosteroids in the urine of some of these porphyric patients, 
this pathway of research was further pursued by setting up and 
carefully evaluating a method for estimating the four main 17-oxo­
steroid sulphates in plasma. As with the urinary studies, a 
similar control group of wide age range consisting of fifty-three 
males and thirty-nine females was studied initially. Some of 
the subjects from the control group were investigated for 
fluctuations due to diurnal variation and for cyclic fluctuations 
due to different phases of the normal menstrual cycle. Having 
established normal values for the concentrations of these 17-oxo­
steroid sulphates in plasma, investigation of their concentrations 
in the plasma of patients suffering from hepatic porphyria was 
undertaken. As with the urinary results, no elevations of the 
levels of these steroids beyond the normal range were observed in 
the plasma of patients with PCT but,in the plasma of patients with 
AIP, elevations of these steroids, predominantly DHAS and ES, were 
observed, in most cases corresponding with similar urinary elevations.
These results, along with the observations of other investiga­
tions, do suggest that although the primary genetic defect may not 
be an endocrine one, the effects of many of the factors involved in 
the initiation, provocation and aggravation of the hepatic porphyrias 
may be mediated through interaction with an endogenous regulatory
system of steroid metabolism in the liver. This interference 
with normal endogenous steroid metabolism may result in direct 
overproduction and accumulation in the liver of a steroid with 
strong porphyrinogenic inducing activity (perhaps aetiocholanolone 
or dehydroepiandrosterone) or indirectly in antagonism of the 
hypophysis, hypothalamus and endocrine glands which form a 
functional unit for the homeostatic regulation of the plasma 
levels of hormones.
The suggestion is also put forward that dehydroepiandrosterone 
or a close metabolite may possibly act as a constant stimulus to 
haem biosynthesis in the human hepatic cell.
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SECTION I
INTRODUCTION
A. HISTORICAL BACKGROUND,
The porphyrias are a group of diseases, mainly hereditary 
in origin, which have many different symptoms. In some of 
them the only problem is an undue sensitivity of skin to sun­
light; in others the normal life of a patient may be shattered 
by devastating attacks of abdominal pain, paralysis of limbs 
and profound mental upsets Biochemically these diseases are 
characterized by excessive excretion of porphyrins andy^or 
precursors in the urine or the faeces.
The first actual reference to porphyrin in history was 
made by Scherer in 1841, when he added concentrated sulphuric 
acid to dried blood and washed the precipitate free of iron*
The iron-free residue, after it was treated with alcohol, took 
on a blood-red colour; thus, he was able to show that the red 
colour of blood was not caused by iron. Three years later, 
this purple-red fluid was named iron-free haematin by Mulder 
(1844)o The spectrum of this substance and its remarkable 
fluorescence were described by Thudichum in 1857» The word 
fporphyrin? (derived from the Greek 'porphyros?, meaning 
reddish-purple) was first used by Hoppe-Seyler in 1871 to 
describe the purple constituent of iron-free haematin. He 
named this substance haematoporphyrin. The first association 
of this pigment in urine with a disease in man was recorded by 
Baumstark (1874), who thoroughly investigated the urine of a 
case presented by Schultz in 1874. Schultz described this 
patient as a thirty-three year old weaver who had suffered 
from skin photosensitivity since the age of three months. His
spleen was enlarged and ha passed a wina-red urine « This case 
was described by Schultz under the name 'Pemphigus leprosus' but, 
from the description given, it seems clear that it was a case of 
congenital porphyria. This diagnostic interpretation is also 
made certain by the autopsy record of intense red-brown discolour­
ation of the skeleton.
Sulphonal was introduced in 18B8 into medical therapy as a 
hypnotic and tranquilliser. In 1889, Stokvis described the case 
history of an elderly woman who passed a dark red urine after 
taking sulphonal® The patient became paralysed and subsequently 
died, Ha considered that the pigment in her urine was similar 
to haematoporphyrin? In the following year, Harley (1890) 
described a fatal case of an unusual form of nervous disturbance 
associated with a dark red urine in a young woman, aged 27, at 
the Edinburgh Royal Infirmary, This woman had also been given 
sulphonal, and she showed many of the neurological features of 
porphyria. In the following years, an increasing number of 
publications appeared in Austria, Germany, Denmark, Sweden and 
England, concerning cases of 'Sulphonal poisoning'; the great 
majority in women and many of them lethal. The dark red urine,
like port or burgundy, was characteristic, Hammarsten (1091;
1892) reported that a pigment closely resembling 'haematoporphyrin* 
was present in these urines. In 1890, Ranking and Pardington 
described two women who excreted 'haematoporphyrin* and who 
exhibited the gastro-intestinal and neuro-psychiatric 
manifestations of the disease, which is now called acute 
intermittent porphyria. In both of these patients there was no 
association of the onset of the attack with drugs.
Aftor the introduction of barbiturates into clinical 
medicine in 1903, they were soon associated with the onset 
of acute attacks of porphyria* Dobrschansky (1906) 
described a casa with the usual distinguishing gastro- 
-intestinal and neuro-psychiatric symptoms of acute porphyria, 
occurring in a patient after prolonged administration of 
diethylbarbituric acid* Thirty years later, in 1937, 
Waldenstrom of Lund University put forward the theory that 
some barbiturates could precipitate latent porphyria into 
the acute form* It was also in this report that diseases 
of porphyrin metabolism were first referred to as the 
porphyrias rather than haematoporphyrias* In the following 
years, several other authors reported deterioration in the 
clinical and metabolic state of porphyric patients after 
administration of barbiturates (Eliasar and Kondo, 1942; 
Denny-Brown and Sciarra, 1945; Prunty, 1946; Whittaker 
and Whitehead, 1956)* It has now beon conclusively shown 
that barbiturates adversely affect the hepatic porphyrias, 
either by provoking attacks or, if taken after the beginning 
of an attack, by profoundly aggravating the severity of the 
neurological symptoms (Goldberg, 1959; Ealas, 1971)*
Gunther was the first to classify tits diseases of 
porphyrin metabolism in two papers in 1911 and 1922, and it 
is he who is credited with the first recognition that 
porphyria was an 'inborn error of metabolism' by Garrod in 
1923, in the second edition of his monograph* Gunther also 
defined and named for the first timo the very rare condition, 
'congenital haematoporphyria*, in which the predominating
symptom, skin photosensitivity, starts in early childhood.
It was the study of one of Gunther's congenital haemato- 
porphyric patients by Hans Fischer which led to the great 
advancement of the knowledge of porphyrin chemistry between 
the years 1915 and 1945, Fischer showed that the naturally 
occurring porphyrins of excreta, uroporphyrin and copropor­
phyrin , differed structurally from haematoporphyrin, which 
was considered to be a chemical artefact (Fischer et al,, 
1925; Fischer and Duesberg, 1932), The naturally-occurring 
porphyrin of haem was also differentiated from haemato- 
porphyrin by a number of investigators, including Laidlaw 
(1904), Fischer (1915a,b) and Schumm (1924), and the name 
protoporphyrin was suggested for this porphyrin by Fischer, 
Thus, the diseases of porphyrin metabolism came to be 
termed Porphyrias by Waldenstrom (1937) rather than Haemato- 
porphyrias (Gunther, 1911),
CLASSIFICATION OF THE PORPHYRIAS,
Hans Gunther was the first to classify the diseases of 
porphyrin metabolism in two comprehensive papers published 
in 1911 and 1922* Further surveys and reclassifications 
were published in the following years by Waldenstrom (1937), 
Schmid e t al, (1954), Waldenstrom (1957) and Watson (i960). 
The most helpful of the classifications of porphyrias was 
that introduced by Schmid et al* (1954). They divided the 
porphyrias into erythropoietic and hepatic groups, depending 
on whether the bone marrow or the liver respectively was the 
tissue in which the aberration of metabolism mainly occurred, 
The following classification in Table 1 will be used in this 
Thesis (Conference Discussion, 1963),
TABLE 1
CLASSIFICATION OF THE PORPHYRIAS
HEPATIC PORPHYRIAS
1) Acute intermittent porphyria»
2) Variegate porphyria*
3) Hereditary coproporphyria.
4) Cutaneous hepatic porphyrias;
a) hereditary type;
b) possibly genetically predisposed (alcoholism);
c) aquirod (e.g. hexachlorobenzens).
Il/
II, ERYTHROPOIETIC PORPHYRIA,
1) Congenital (erythropoietic) porphyria,
2) Erythropoietic protoporphyria,
3) Erythropoietic coproporphyria.
c* PORPHYRIN AND HAEM STRUCTURE AND BIOSYNTHESIS,
The porphyrins derive their name from the resemblance 
of their colour to porphyry, ultimately from the Greek word, 
porphyres, meaning crimson. They are widely distributed 
throughout the animal and vegetable kingdom. In the free 
form, the porphyrins occur in small amount but their métallo- 
protein complexes, for example haemoglobin, cytochromes and 
the chlorophylls, are quantitatively more important and play 
a vital role in the living cell.
The basic chemical structure (Fischer, 1927; 1930), which 
is the same for each porphyrin, is a macrocycllc structure.
This porphin structure consists of four hetero-cyclic rings, 
namely one pyrrole, two pyrrolenine and one maleinimide ring, 
which are joined together by rnethene bridges (Fig, 1)« The 
individual porphyrins are derived from porphin by substitution 
of the hydrogen atoms occupying the eight [3 {3* positions of 
the rings. Replacement of these hydrogen atoms by two 
dissimilar groups, for example by a methyl and ethyl group as 
in the aetioporphyrins, can be made in four possible ways 
leading to four position isomers (Fig. 2). Fischer (1927;
1930; 1937) synthesised all four aetioporphyrins and proposed 
that all porphyrins should be referred to them for designation 
of isomeric type. There are thus four possible coproporphyrins 
(substituent groups, -CH^ and -CHgcCHg.COOH) and four possible 
uroporphyrins (substituent groups, -CH^.ROOH and -CH^.CH^.CÜOH). 
In the protoporphyrins, the (3 (3' hydrogen atoms are replaced by 
four methyl, two vinyl and two propionic acid residues. This
Figure 1
THE BASIC CHEMICAL STRUCTURE OF THE PORPHYRINS
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gives rise to fifteen possible isomeric forms; but, so far, 
only the single protoporphyrin IX (Fig. 3) has been encountered 
in nature, either in the free state or as an iron complex, haem 
(Fig. 4). Similarly, only coproporphyrin I and III and 
uroporphyrins I and III have so far been found to occur in 
nature.
THE HAEM BIOSYNTHETIC PATHWAY.
Several good reviews of this work have been published 
(Shemin, 1956a,b; Rimington, 1956, 1958, 1959a; Stich, 1959;
Shemin, 1970). From these studies, the general pathway of 
haem biosynthesis may be regarded as firmly established.
Haem synthesis is initiated by the condensation of 
glycine and succinyl CoA in the presence of ALA synthetase 
(ALA.S) (shemin and Kumin, 1952) (Fig. 5). The co-factors 
for this reaction are pyridoxal phosphate (Schulman and 
Richert, 1956) and ferrous iron (Brown, 1958). The pyridoxal 
phosphate activates the methylene group of glycine, preliminary 
to Schiff base formation. This glycine and activated succinate, 
succinyl CoA, then condense to form a-amino-(3-keto-adipic acid 
which, being very unstable, readily decarboxylates to form 
6-aminolaevulic acid (ALA). ALA synthetase appears to be 
rate limiting in the pathway (Lascelles, 1964; Levere and 
Granick, 1965), and hence its regulation can determine the 
rate of hepatic haem formation from glycine and succinyl CoA 
(Granick and Levers, 1968). This enzyme has a relatively 
short half-life; one hour in mammalian systems (Marver et al., 
1966b; Stein et al., 1970) and four to six hours in avian
rig urc J.
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systems (Granick, 1966), FWcsnt studies provide evidence 
that haem is involved in the negative feed-back regulation 
of ALAoS, both by inhibiting the activity of the enzyme 
(Burnham and Lascelles, 1963; Scholnick et al,, 1969) and 
participating in the repression of its synthesis (Hayashi 
et al,, 1968; Marver, 1969; Sassa and Granick, 1970),
With respect to the former mechanism, haem, the end-product 
of the biosynthetic chain,would by binding to an allosteric 
site on ALA,S directly inhibit its enzymic activity. This 
mechanism has been clearly shown to operate in R, spheroides 
(Lascelles, 1960), This inhibition is reversible by the 
removal of the added haem. Since both ALA.S and the enzyme 
ferrochelatase, which forms haem from protoporphyrin, are 
localized in mitochondria, one might suppose on teleological 
grounds that this mechanism would permit control of ALA.S 
activity in mammalian cells as well, Evidence in support 
of this possibility has been presented by Karibian and London 
(1965), who demonstrated that hasmin added to iron-deficient 
rabbit reticulocytes inhibited by 50 per cent the incorporation 
of labelled glycine into the haem of haemoglobin; whereas ALA 
incorporation into haem was not significantly affected. In 
contrast to this, the increased ALA.S of mitochondria isolated 
from induced chick embryo liver cells is not inhibited by 
added haem (Granick, 1966). Similarly, Vavra (1967) did not 
observe such inhibition by haem in mitochondria derived from 
chicken reticulocytes.
The alternative mechanism for haem control of ALA.S,
i.e. end-product repression, has been demonstrated to be 
operative in both bacterial and animal species. In 
Ro spheroides, Burnham and Lascelles (1963) showed that 
haem can decrease by 60-80 per cent the induced formation 
of ALA.S. A similar demonstration of haem repression of 
ALA.S formation has been made in embryonic chick liver 
cells growing in primary culture (Granick, 1966). Kappas 
and Granick (1968) demonstrated that haem represses maximally 
when administered to hepatic cells at the same time as the 
enzyme inducers, but represses only weakly if added at a 
time when the induction process is well advanced. This 
effect is similar to that observed with inhibitors of nucleic 
acid synthesis, such as Actinornycin D. (Kappas et al., 1968). 
This time relationship of the haem blocking effect on 
porphyrin formation is good evidence that haem enters the 
cell but does not act by inhibition of the activity of the 
enzyme but acts rather at some early event in the induction 
process; possibly by repressing activity of the structural 
gene which codes for ALA synthetase. An in vivo study in 
the rat, showing results consistent with haem repression of 
induced synthesis of ALA.S, has also been reported by Waxman 
et al. (1966). More recent studies by Sassa and Granick
(1970) give evidence that haemin inhibits the synthesis of 
ALA.S in chick embryo liver cells in culture at the trans­
lational, rather than at the transcriptional level as had 
been previously hypothesized (Granick, 1966). They now
suggest that hasmin might inhibit by competing with an inducing 
chemical, by acting at some other site, or by causing a decrease 
in the lifetime of mRI\!A for ALA synthetase. This latter idea 
is disfavoured by Sassa and Granick (1970), as they noted that 
haemin did not stimulate an increase in ribonuclease activity.
After the formation of 6-aminolaevulic acid by ALA.S, 
the next step of the haem biosynthetic pathway is the 
condensation of two molecules of ALA with elimination of water, 
by the enzyme ALA dehydrase (ALA.D). This enzyme was first 
described by Dresel and Falk (1953) and then by Gibson,
Neuberger and Scott (1955). This condensation forms the 
rnonopyrrolB precursor of the porphyrins, porphobilinogen (PBG), 
which was first isolated from porphyria urine by Westall in 
1952, and its structure (Fig. 6) determined by Cookson and 
Rimington (1953; 1954).
The subsequent steps of this pathway involve formation 
of the tetrapyrrole porphyrin, uroporphyrinogen, from four 
units of PBG, followed by the successive decarboxylation of 
the octacarboxylic porphyrinogen thus formed, to dicarboxylic 
porphyrin, protoporphyrin IX, The initial step of this 
sequence is catalysed by IJRO-I-synthetase (PBG deaminase)» 
Bogorad (1958a,b) and Cornford (1964) have suggested that the 
mechanism of this reaction is firstly a condensation of the 
porphobilinogen monomer units into a polymer of intermediate 
length, followed by a cyclisation of this polymer into 
uroporphyrinogen I units» If the enzyme, URO-III-cosynthetase
(uroporphyrinogen isornerase), is present, this reaction 
proceeds with the production of the biologically viable 
series III isomer. If this enzyme is absent, it produces 
the series I isomer. In natural systems, the series I 
isomer cannot be converted into protoporphyrin and will 
only produce uroporphyrin I and coproporphyrin I, which are 
excreted in the urine. It has been reported that in 
congenital erythropoietic porphyria (Borst and Konigsdorffin, 
1929) and in some cases of porphyria cutanea tarda (Pathak 
and Burnett, 1964) excretion and accumulation of these 
series I porphyrins, especially uroporphyrin I, takes place 
in the skin. The partial absence of the URO-III-cosynthetaee 
is a possible explanation for these observations (Lockwood 
and Benson, 1960; Magnus, 1968).
Coproporphyrinogen, the subsequent substance on the 
pathway, is produced by the successive decarboxylation of 
uroporphyrinogen by uroporphyrinogen decarboxylase. In this 
sequence of reactions, the series III isomer is decarboxylated 
twice as rapidly as the series I isomer (Mauzarall and Granick, 
1958).
By the action of the mitochondrial enzyme, coproporphy- 
rinogen oxidase and decarboxylase, the tetracarboxylic 
coproporphyrinogen III is converted to protoporphyrin IX 
through the intermediate tricarboxylic and dicarboxylic 
porphyrinogen stages. It is these enzymes that cannot handle 
the series I isomer (Sano and Granick, 1961; Batlle et al., 
(1965).
The final enzyme of the pathway is haem synthetase
(ferrochelatase) (Goldberg et al,, 1956*. Labbe and Hubbard, 
1960; Porra and Oones, 1963). This enzyme catalyses the 
insertion of ferrous iron into protoporphyrin to form the 
important substance haem. The complete pathway (Fig. 7) 
is reviewed in detail by Goldberg and Rimington (1962.).
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SECTION II
THE INDIVIDUAL PORPHYRIAS
THE INDIVIDUAL HEPATIC AND ERYTHROPOIETIC PORPHYRIAS.
The porphyrias are metabolic disorders, mostly of 
hereditary nature, characterized by increased excretion of 
porphyrins and their precursors, which accumulate in largo 
excess within the body. In the porphyrias, the synthesis 
of these pigments is greatly increased on account of a 
failure of the control mechanisms that normally regulate 
the synthesis of haem. These disturbances should be 
regarded as disorders of the regulation of haem synthesis*
The normal urine usually contains trace amounts of 
uroporphyrin, coproporphyrin, ALA and PBG. Doth the 
faeces and blood normally contain small amounts of copro­
porphyrin and protoporphyrin. It has also been shown by 
French and Thonger (1966) that coproporphyrin and proto­
porphyrin are present in bile and meconium.
In the porphyrias, any of these porphyrins or their 
precursors may be over-produced and excreted in excess.
The two main tissues in which this aberration may occur 
are the bone marrow and the liver. This fact is used to 
divide the porphyrias into two major groups, the erythro­
poietic and the hepatic, according to whether the site of 
the disorder of haem synthesis is in the bone marrow or 
the liver, respectively.
A. THE ERYTHROPOIETIC PORPHYRIAS
ffcftWfVWiT&t»
Congenital (erythropoietic) porphyria: This is ono of
tho rarest of the porphyric group of diseases. There are 
now less than a hundred recorded cases with approximately 
equal numbers of males and females (Schmid, 1966; Kaufman 
et ale, 1967)o
The disease is characterized by marked photosensitivity 
and by increased excretion of uroporphyrin and coproporphyrin, 
predominantly of the unphysiological type I isomer. The 
bones and teeth are also discoloured reddish-brown because of 
their porphyrin content. About one-quarter of the reported 
patients had an onset from birth, and in all cases the 
condition was revealed before the sixth year (Schmid et al.,
1955)o The available data from the studies and reviews of 
this disease (Gray, 1925, 1926; Schmid et al., 1955; Watson 
et alo, 1958) are compatible with, but not proof of a Mendelian 
recessive heredity (Schmid, 1966; Romeo et al,, 1970). This 
view is strengthened by the definite genetic studies in 
bovine congenital porphyria,which closely resembles the human 
disease, by Fourie (1936, 1939) and Amoroso et al. (1957)»
The nature of the genetic abnormality is not yet determined. 
Taddeini and Watson (1968) assert that there is clearly 
induction of ALA.S in the young red cells of the bone marrow 
because of the marked overall increase of porphyrins, 
including uroporphyrin I and protoporphyrin IX. Lockwood and 
Benson (i960) proposed that a partial absence of URG-III-co- 
synthetase, which converts uroporphyrinogen I to uroporphyrinogen III,
could explain the accumulation of the physiologically ineffective 
uroporphyrin I in this condition. This hypothesis does not 
explain the actual increase in the overall formation of series 
III porphyrin which exists in this disease (Taddeini and Watson, 
1968). To overcome this, Kramer et al. (1965) have suggested 
a possible alternate mechanism; namely, a lack of suppressor 
of URO-I-synthetase (PBG deaminase) with overproduction of 
type I isomer, in addition to normal amounts of type III isomer.
Erythropoietic protoporphyria: This is the most common
of the erythropoietic porphyrias. The main biochemical 
feature is greatly increased amounts of protoporphyrin and, 
to a lesser extent, coproporphyrin in the erythrocytes. This 
may be accompanied by excessive quantities of coproporphyrin 
and protoporphyrin in the faeces. In the majority of cases, 
tho urine has a normal content of porphyrins (Magnus et al.,
1961). Haeger-Aronsen (1963) has shown that in one family 
the disease has been transmitted by a Mendelian dominant gene. 
Further reports by Bnitker and Lintrup (1967) and Haeger-Aronsen 
and Krook (1965) are in agreement with this observation.
The disease is characterized clinically by the onset of 
photosensitivity, usually commencing in the first two years of 
life and persisting throughout the patientas lifetime. The 
incidence of this condition is at present unknown, but it is 
probably not greater than two per cent of all causes of photo­
sensitisation (Prentice and Goldberg, 1969),
The site of the chief lesion in erythropoietic protoporphyria
is not yet known, and the euidenco that it is erythropoietic 
rather than hepatic is contradictory. Examination of the 
bone marrow smears under ultra-violet light reveals numerous 
red fluorescent normoblasts (Magnus et al., 1961), Prentice 
and Goldberg (1967) also reported fluorescence in the marrow 
in this disease but Runge, cited by Watson (1965), failed to 
demonstrate it in the marrow normoblasts from any of three 
patients with this disease, Kaplowitz ej^ _^al^. (1968) 
photohaemolyzed blood cells from patients with erythropoietic 
protoporphyria and isolated photoresistant erythrocytes. Two 
populations of cells appeared to be present; one protoporphyrin 
rich and photosensitive, and the other with a normal proto­
porphyrin level. Similar observations were presented by 
Schothorst et al, (1970), who found that the concentration of 
protoporphyrin in upper layers of centrifuged blood was greater 
than in lower layers.
There is also evidence that the liver in this condition 
forms excessive porphyrins and might be responsible for the 
increased porphyrins in the plasma and the faeces (Redeker 
et alo; 1963), The occasional occurrence of cirrhosis 
(Gajdos and Gajdos, 1969; Gray, 1970) and the path of 
incorporation of labelled glycine into faecal porphyrins and 
stercobilin in erythropoietic protoporphyria, supplies further 
evidence that there is also a hepatic defect of porphyrin 
biosynthesis (Gray et al,, 1964; Redeker and Bronow, 1964),
In 1968, Redeker and Sterling demonstrated that the faecal and 
plasma porphyrins increased markedly with fasting and decreased
with a rich provision of glucose. This suggests a hepatic 
source of the faecal and plasma porphyrins, since the liver 
has been the only site at which the glucose effect (catabolic 
repression) has been shown to be operative (Loomis and 
Magasanik, 1954). A significant increase in hepatic ALA.S 
in two patients with erythropoietic protoporphyria has been 
reported by Miyagi in 1967, In more recent investigations 
into erythropoietic protoporphyria, Schwartz and his co-workers
(1971) reported that in vitro data indicated a 30-fold increase 
in ALA.S activity in the patientas blood, with a relative 
deficiency of haem synthetase activity. They also showed by 
isotopic studies the presence of several pools of erythrocyte 
protoporphyrin, each with markedly different turnover rates. 
Those and other findings suggest that the most significant 
defects in this disease reside in the reticulocyte and late 
normoblast stages of erythroid development.
Congenital erythropoietic coproporphyria; This third 
type of erythropoietic porphyria was described by Heilmeyer 
and Clotten in 1964, Clinically, it is characterized by skin 
photosensitivity. In this porphyria, the urine and the faeces 
had a normal porphyrin content but the red cells contained 
excessive quantities of coproporphyrinogen series III isomer.
The same biochemical disturbance was also found in the mother 
of the patient, and the authors have suggested that this disease 
is transmitted as a Mendelian dominant character. No other 
patients with this disease have so far been reported.
There is no concrete evidence that these three disorders 
of porphyrin metabolism in the bone marrow can be affected by 
sedatives and by the other drugs tliat can influence the 
picture of hepatic porphyrias.
B, HEPATIC PORPHYRIAS.
The hepatic porphyrias are a group of disorders 
characterized by excessive levels of porphyrins and their 
precursors in the liver. This group is more common than 
the erythropoietic porphyrias. They are classified on 
the basis of clinical manifestations and unique patterns 
of porphyrin and porpfiyrin precursors excretion (Fig« S) 
(Waldenstrom, 1957; Schmid, 1966). The defect responsible 
for each of these diseases is inherited as a Mendalicn auto- 
somal dominant character (Goldberg e^t^^l., 1967), with the 
exception of porphyria cutanea tarda which appears in most 
cases to be acquired (Eales, 1961)»
The hepatic porphyrias can be designated into four 
main groups, which are ™ (1) acute intermittent porphyria
(latent and manifest), in which the skin is not photo­
sensitive, but intermittent abdominal pain and neuro­
psychiatrie manifestations are the main clinical symptoms;
(2) variegate porphyria (the genetic type of porphyria of 
South Africa), in which there is a combination of photo­
sensitivity with manifestations of acute intermittent 
porphyria within the same family and sometimes within the 
same individual; (3) the cutaneous hepatic porphyrias 
(porphyria cutanea tarda, porphyria cutanea tarda hereditaria, 
various acquired porphyrias), in which skin photosensitivity
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is the predominant clinical feature; (4) hereditary 
coproporphyria5 which usually presents in the same way as 
AlPÿ although a few patients with this condition have 
presented photosensitivity*
Acute Tntermittont Porphyria,
Thera have been several comprehensive clinical reviews 
on this subject (Gunther, 1911, 1922; Waldenstrom, 1937; 
Goldberg and Rimington, 1962), It is clinically distingui­
shable from the other hepatic porphyrias by the dominance 
of gastro-"intGstinal and neuro-psychiatric symptoms and 
the absence of photosensitivity. The most important 
symptoms are abdominal pain, vomiting and constipation with, 
less commonly, paralysis or paresis and psychological 
manifestations of various types. The diagnosis of this 
condition is usually made by the detection in the urine of 
excessive quantities of ALA and PBG, It has been established 
that patients have in their liver a marked increase in the 
enzyme ALA®S (Tschudy et al,, 1965),
The main characteristic of this disease is its 
intermittency. The cause of the intermittent attacks has 
been partly ascribed to the administration of drugs such as 
barbiturates (Waldenstrom, 1939, 1940; With, 1957;
Goldberg, 1959; Schmid, 1966; Eales, 1971), alcohol 
(Goldberg and Rimington, 1962; Ferguson et al,, 1970), 
certain steroids such as are contained in contraceptive
pilla (Wetterberg, 1964; Rimington and Da Matteia, 1965), 
pregnancy (Nielson and Nielson, 1958) and a diet low in 
carbohydrate and protein (Welland at al», 1964; Felsher 
and Rodeker, 1967; Knudsen » '1967) * In 1954,
Goldberg demonstrated that out of nine barbiturates given 
to rabbits, six had a significant effect on the urinary 
excretion of coproporphyrin. These samo nine barbiturates 
all caused a significant elevation of hepatic ALAc-S in rats 
(Moore et al,, 1970),
There is now ample evidence that oral contraceptives 
can provoke attacks of acute intermittent porphyria 
(Wetterberg, 1964; Rimington and De Matteis, 1965;
Redeker, 1965) and also of var‘agate porphyria (Watson 
_et^ _£l, , 1962), In contrast to this, there have been some 
reports of the use of these combined contraceptive prepara­
tions to alleviate the symptoms of porphyria in some female 
patients in whom the attacks of porphyria could be associated 
with pregnancy or onset of menses (Haeger-Aronsen, 1953b; 
Welland et al,, 1964; Perlroth et al,, 1965),
The effect of diet has also been stressed by Welland 
et alo (1964), A diminution of carbohydrate and protein 
intake may provoke an acute attack, Knudsen and his 
co-workers (1967) reported an 18-year old patient who was 
provoked into a severe attack when placed on a water diet 
for obesity. A similar case has also been noted by Felsher 
and Redeker (1967),
Porphyria Variegate,
This porphyria was so named because it could present 
itself in a variety of ways, with skin lesions or with an 
acute attack, or with both these states. It has been 
described in Sweden (Hamnstrdm jst^^l,, 1967), in the U.S,A« 
(Taddeini and Watson, 1968), in the United Kingdom (Rimington 
et alo j, 1968; Cochrane and Goldberg, 1968) and in South 
Africa by Dean and Barnes (1959), The latter two 
investigators stated that there is a prevalence rate of 
three in one thousand of the white population in South Africa* 
This type of porphyria in white South Africans is apparently 
inherited as a Plendelian dominant character (Dean and 
Barnes, 1955)*
The symptoms of the acute attack are very similar to 
those of AIP but variegate porphyria differs from AIP in two 
main respectas 1) cutaneous manifestations in the form of 
photosensitivity and increased skin fragility can occur with 
acute attacks in the same patient, or in other members of the 
patient's family; 2) there is a high excretion of faecal 
coproporphyrin and faecal protoporphyrin in states of 
remission (with an increase in the urinary coproporphyrin,
PBG and ALA during the acute attacks, but which often returns 
to normal or near normal during quiescence (Dean, 1963)).
Bloch (1965) concluded from his study of pregnancy in 
sufferers from porphyria variogata that the disease has no 
effect on pregnancy nor does pregnancy adversely affect the
disease. The investigations of Goldsuain and Eales (1971) 
seem to be in agreement with this* In 1965, Dean reported 
a patient with porphyria variegata who was adversely affected 
by the contraceptive pill. In the large study of patients 
with variegate porphyria by Eales (1971), oral contraceptives 
were found to be associated with acute attacks in four patient; 
but in each case other drugs had also been administered*
In this forementioned publication, Eales reports the drugs 
and other factors involved in the induction or potentiation 
of 145 acute attacks in 120 patients, 107 of whom were VPs 
and the rest AIPs* The cardinal role of the barbiturates in 
the genesis of the severe attack in AIP and VP is emphasised 
by this report that over 50^ of the acute attacks were 
associated with barbiturate medication and in more than 20^ 
of attacks they were the only drug involved*
Dowdle et al* (1967) and flasuya (1969) have demonstrated 
excessive ALA.S activity in the livers of patients with VP.
In further metabolic studies with labelled ALA in normal and 
porphyric human subjects including two patients with porphyria 
variegata, Dowdle et al*(1968) concluded that excessive ALA 
synthetase activity is common to AIP, VP and symptomatic 
porphyria* Similar investigations were undertaken by Strand 
et alo (1971), who determined the hepatic activity of ALA.S 
and uroporphyrinogen I synthetase (URD™I-synthetase) in 
specimens of liver from normal and porphyric subjects* These 
workers reported that ALA.S activity was markedly increased
in three patients with AIP and two with VP, but was normal in 
four patients with porphyria cutanea tarda* The studies of 
URO"”I“Synthetase revealed that in AIP the activity of this 
enzyme was less than 50^ of the controls, in contrast to the 
normal values of the patients with other forms of porphyria. 
Taking into consideration the excretory pattern of AIP,
Strand and his co-workers suggested that these rasuits favour 
a primary defect at the level of the enzymatic conversion of 
PBG to uroporphyrinogen by IJRO-I-synthetase, which secondarily 
leads to induction of ALA synthetase. If AIP is a consequence 
of a gene defect affecting enzymatic conversion of PBG to 
porphyrins, it would appear likely that the enzymatic 
differencss characterizing each of the other genetically 
transmitted hepatic porphyries rssult from independent 
mutations.
Hereditary Coproporphyria*
The salient biochemical abnormality of this type of 
hepatic porphyria is the excessive excretion of copro­
porphyrin III in faeces and urine at all times* The 
condition may remain syrnptomless, but it may be provoked 
by drugs such as barbiturates and sulphonamides (McIntyre 
et al* j, 1971); oestrogens and pregnancy, into acute attacks 
resembling those of AIP and VP* The patients described by 
Goldberg st al* (1967), Cannon and Turkington (1968), Dean 
et al* (1969) and Hunter et el* (1971) developed acute 
manifestations during pregnancy* This evidence suggests 
the involvement of endocrine substances in the episodic
exacerbations of this dissasB in certain patients. During 
the acute attacks, there is an excessive excretion of PBG 
and ALA in the urine. Despite these similarities to AIP 
and UP, the three hereditary hepatic porphyrias can be 
distinguished by the pattern of faecal porphyrin excretion*
In HCP, large amounts of coproporphyrin are constantly 
present in the faeces; in UP, faecal excretion of both 
coproporphyrin and protoporphyrin is excessive, while in 
AIP there is only a slight increase in excretion of both 
of these substances.
There is evidence that, as with AIP and UP (Tschudy 
et al,, 1965; Nakao et al,, 1966; Dowdle et al., 1967; 
Masuya, 1969), the activity of hepatic ALA.S is increased 
during an acute attack (Kaufman and Flarver, 1970; McIntyre 
e^t_^1,5 1971), The inheritance pattern of hereditary copro­
porphyria strongly suggests that it is transmitted as a non» 
sex-linked Mendelian dominant character (Goldberg Gt__al*, 
1967; Haeger-Aronsen £t_alop 1968), In this last mentioned 
publication, the authors put forward the hypothesis that 
HCP is caused primarily by a structural defect in the 
mitochondrion, either in wall structural proteins or in 
respiratory chain enzyme activity; i.e. a deficiency in 
coproporphyrlnogen oxidase* A similar hypothesis was 
proposed by Kaufman and Marver (1970), who suggested that 
the primary abnormality in HCP, AIP and UP is a partial 
block in haem biosynthesis, the block being at a. different 
point in the pathway in each of the three diseases* In
the case of HCP, the dofect would be in the conversion of 
coproporphyrinogen III to protoporphyrinogen by the enzyme 
coproporphyrlnogen oxidase. Since haem inhibits the 
synthesis of ALA.S, an increase in enzyme activity would 
result if free haem levels dropped due to the block in haem 
synthesis. Secondary elevation of ALA.S could account for 
the increase in ALA and PBG excretion which occurs in all 
three diseases, while the site of the block would explain 
the differing patterns of porphyrin excretion.
Cutaneous Hepatic Porphyria.
The group of cutaneous porphyrias which are of hepatic 
origin have been named 'cutaneous hepatic porphyrias* 
(Goldberg and Rimington, 1962). They represent a very 
heterogeneous group of diseases and include a number of 
conditions usually considered under the name of symptomatic 
porphyria. They may result from many different aetiological 
factors such as, an hereditary defect of the porphyrin 
metabolism of the liver (Tio, 1956; Waldenstrom, 1957;
Holti et al., 1958); a variety of hepatoxic processes 
including alcohol (Canivet and Rimington, 1953; Bolgert - ■ 
et al., 1953; Prato, 1964); liver poisons such as hexa- 
chlorobenzene (Cetingil and Ozen, 1960; Schmid, 1960a) 
or a simple neoplasm of the liver (Tio et al., 1957).
Prolonged intake of adulterated alcohol is thought to 
be the causative factor of the cutaneous hepatic porphyria 
observed in the Bantus of South Africa (Bales, 1963). As
only a small proportion of chronic alcoholics and patients 
with liver disease develops symptoms of cutaneous porphyria, 
the existence of an underlying genetic disposition is 
suspected but, with a few possible exceptions (Waldenstrom 
and Haeger-Aronsen, 1963; Prato and Zina, 1965), it has not 
been conclusively demonstrated. In contrast to this, the 
toxic porphyria brought about by hexachlorobenzene is a 
clearly acquired condition occurring without a genetic 
disposition to porphyria. In 1956, an outbreak of cutaneous 
porphyria, involving several thousand persons from three 
different ethnic groups, was reported in South Eastern 
Turkey. Affected persons, predominantly children, 
exhibited photosensitivity, hepatomegaly and marked porphyrin­
uria, but no abdominal or neurological symptoms (Cam, 1959; 
Schmid, 1960; Cetingil and Ozen, 1960). Poisoning by 
hexachlorobenzene, a fungicidal agent introduced in bread 
• made from dressed wheat intended for sowing, was suspected 
as the cause of these disturbances* This suspicion was soon 
confirmed by the finding that hexachlorobenzene could cause 
a condition of porphyria when fed to the rat and rabbit 
(Db Matteis et al., 1961; Ockner and Schmid, 1961), In 
1959, the treatment of wheat with hexachlorobenzene was 
discontinued in Turkey and, after this measure, no new cases 
were reported (Cam and Nigogosyan, 1963),
Several cases have also been described in which a 
marked increase in porphyrin excretion and the appearance of 
clinical symptoms of photosensitivity have been observed in 
association with the administration of certain hormonal
preparations (liiarin, 1963; Becker, 1965; Copeman et ai*, 
1966; Felsher and Redeker, 1966; Zimmerman et al*, 1966; 
Thivület et al., 1967; V/ail, 1967), The majority of these 
cases were elderly male patients receiving oestrogen prepara­
tions for treatment of prostate carcinoma, and an interval of 
several months or years had elapsed between the starting of 
the therapy and the appearance of the cutaneous symptoms. 
Withdrawal of oestrogens led to a gradual improvement in the 
cutaneous symptoms (Zimmerman 1966), although
porphyrin excretion remained elevated in all six patients 
in which it was followed (Warin, 1963; Becker, 1965;
Copeman et al«, 1966; Zimmerman et al,. 1956)*
In all these cutaneous hepatic porphyrias, the liver 
forms excessive porphyrins which are normally excreted in the 
bile and pass into the faeces (Rimington, 1959b), As long 
as the excretion route is efficient, symptoms are unlikely, 
but in the event of hepatic dysfunction the excessive 
porphyrins are deviated to the systemic circulation and are 
then excreted, mainly in the urine but also in the skin 
(Schuck and Berman, 1956), As a result of this deviation 
of the porphyrins, the main skin manifestations occur; 
namely, photosensitisation, excessive skin fragility, hyper­
pigmentation and hypertrichosis. In this group of diseases 
there are no fluorescing normoblasts in the bone marrow 
(Schmid , 1954), and the erythrocyte protoporphyrin is
normal (MacGregor ^t^l., 1952), The plasma may contain 
excess porphyrins fluorescing in ultraviolet light (MacGregor 
et al,, 1952; Wells and Rimington, 1953; Tio et al., 1957),
Moore et al,, (1972a) has reported the excessive excretion of 
X porphyrin in the faeces of patients with PCÏ* This 
porphyrin-peptide complex has previously been reported by 
Rimington et al* (1968) to be elevated in UP, slightly elevated 
in AIP and HCP, and normal in erythropoietic protoporphyria*
In addition to the cutaneous symptoms, manifestations 
characteristic of AIP may be present, particularly in these 
forms which are hereditary (Watson, 1951; Calvy ej:^ al„, 1951; 
Schmid eh al*, 1954). This may be related to the fact that 
the liver is the seat of the disordered porphyrin metabolism 
and, as in other forms of hereditary hepatic porphyria, 
hepatic ALA synthetase activity is elevated (Levere, 1965; 
Dowdle et al*, 196?)* There is some disagreement about 
this observation, as Zail and Jouhert (1968), Kaufman and 
Marver (1970) and Strand et al. (1971) have reported that 
in their investigations they have found the activity of ALA 
synthetase to be within the normal range. In contrast to 
this, the results obtained by Moore et al* (1972b) demonstrate 
that hepatic ALA.S activity is elevated at all times in 
acquired PCT, as compared with normal activities. They 
further showed that, after treatment by venesection, this 
activity is lowered but not to normal levels* This lowering 
of activity is associated with a depression of porphyrin 
excretion, both in urine and faeces, and a large lowering of 
the serum iron saturation.
Taddeini and Watson (1968) have suggested that the various 
peculiarities in cutaneous hepatic porphyria in terms of
chemical sensitivity point to a constitutional or occult 
genetic abnormality of the liver cells, possibly microsomal 
in location with diminished activity of drug metabolising 
enzymes. They suggested that failure of the constitution­
ally inferior liver cell to dispose of alcohol or oestrogen 
might account for induction of ALA synthetase by these 
compounds.
SECTION III
THE STEROIDS AND PORPHYRIA
STEROIDS AND PORPHYRIA
The association of the acute porphyric attack with the 
adrenal gland and hormones first began in 1889 with Urquhart's 
suggestion that adrenal extracts might be administered to 
patients with porphyria, since diseases of the adrenals had 
been observed in this condition. More recently, in 1947, 
Abrahams et al», and Linder, suggested that the clinical 
state of hypotension with low serum sodium and chlorides, 
which was observed in many cases of acute porphyria, might 
be due to adrenal insufficiency. Evidence of adrenal 
cortex hyperplasia in three patients with porphyria was 
reported by Prunty in 1949. A year later, Rawlings (1950) 
reported the case of a young woman suffering from acute 
porphyria who showed remarkable clinical improvement on 
becoming pregnant. Adrenocorticotrophic hormone (Goldberg
et al.9 1952) and cortisone (Watson, 1954) have been used 
in the treatment of porphyria with variable success.
Further suggestions of hypothalamic involvement in acute 
hepatic porphyria were made by Heilman et al. (1962) and 
by Ludwig and Goldberg (1963). The studies of Tschudy 
(1968) demonstrate that excessive levels of antidiuretic 
hormone (ADH) in circulation and inappropriate release of 
growth hormone occur frequently in AIP, This evidence 
further substantiates the involvement of the hypothalamus 
with acute hepatic porphyria.
There are many clinical observations which suggest 
that certain endocrine secretions, specifically steroids, 
may be implicated in some way in the pathogenesis of this
group of diseases in man* Levit et al* (1957), Watson 
(1960) and Zimmerman et al* (1966) have summarized the 
clinical characteristics of the hepatic porphyrias which 
suggests the deleterious interplay of endocrine factors in 
the exacerbation of these diseases* The acute attacks 
occur predominantly in the third and fourth decades, when 
steroid excretion and production is at its peak (Fig, 9a,b); 
they have a marked female preponderance; they rarely 
become manifest clinically or biochemically before puberty, 
when steroid levels are low (Fig* 10); they are infrequent 
after the menopause, when once again steroid levels in the 
blood fall to lower levels (Fig, 11), As far back as 1937, 
Waldenstrom noted an apparent relation of the onset of 
clinical symptoms to menstruation* The cyclic exacerbation 
of acute (neurologic) symptoms in association with a phase 
of the menstrual cycle has been noted by Corrol £t_^ al* (1942), 
Grossfield (1951), Levit et al* (1957), Kelenyi et al. (1960), 
Outzler et al. (1964), Perlroth et al. (1965) and Zimmerman 
et al* (1966). Kelenyi et al. (i960) noted an increase of 
urinary PBG with the cyclic premenstrual symptoms in their 
patient. Zimmerman et al. (1966) reported that, in their 
patient who had striking association of attacks with the 
luteal phase of the cycle, the excretion of PBG and porphyrin 
remained remarkably constant throughout the first cycle but 
appeared significantly increased in the second. These 
reports of cyclic appearance of symptoms in association with 
the menses suggest a hormonal relationship, but the nature
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of this is not clear. Levit et al. (1957) reported a young 
woman with exacerbations in the premenstrual phase of the 
cycle. With this case it was possible to precipitate 
attacks with progesterone, and Levit and his co-workers 
believed that this was due to increased progesterone in 
the luteal phase of the cycle. The magnitude of the 
increase of progesterone and its metabolites during the 
normal menstrual cycle is shown in Fig. 12. Oestrogen 
secretion, however, is also increased in the luteal phase 
(Fig. 13), and Redeker (1963) has precipitated acute 
attacks by the administration of a variety of exogenous 
oestrogens.
There is some disagreement whether onset or provocation 
of porphyria occurs in pregnancy. Certainly, there is a 
rise in the production and excretion of oestrogens and 
progestérones as pregnancy proceeds (Fig. 14a and b), and 
in general most investigators feel that a detrimental 
relationship exists between these two conditions .(Reidenberg, 
1955; Nielson and Nielson, 1958; Petrie and Mooney, 1962; 
Rimington and De Matteis, 1965; Tweedie and Mattox, 1965; 
Rovinsky and Guttmacher, 1965). One report by Nielson and
Nielson (1958) of forty patients mostly with AIP in pregnancy 
revealed an exacerbation of symptoms in 95^ and an alarming 
maternal death of 42.5%, with 58% of these deaths in prima- 
gravidas. Another study of fifty-five pregnant patients 
with porphyria by Rovinsky and Guttmacher (1965) showed that 
more than 75% of pregnancies coincided with exacerbations of
.evels of progesterone and a metabolite  
during a normal menstrual cycle
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symptoms. The overall maternal mortality rate cited in 
this publication was 22.4%, 15 of the 17 deaths occurring 
in primagravidas and 8 occurring with the first attack. 
Development of acute manifestations during pregnancy has 
also been described in patients with HCP by Goldberg et al. 
(1967), Connon and Turkington (1968) and Dean et al. (1969) 
and in patients with UP by Linas et al. (1947), Coleman 
(1948), Dean (1953) and Neilson and Neilson (1958), In 
contrast to this, Bloch (1965) concluded from his study of 
pregnancy in sufferers from porphyria variegata that the 
disease has no effect on pregnancy, nor does pregnancy 
adversely affect the disease. There have also been 
reports of patients suffering from acute intermittent 
porphyria showing remarkable clinical improvement on 
becoming pregnant (Rawlings, 1950; 0 * Dwyer, 1955).
0*Dwyer was of the opinion that adrenal insufficiency was 
partly responsible for the clinical symptoms of porphyria 
and that pituitary hyper-activity in pregnancy compensated 
for this deficiency, resulting in a favourable outcome for 
his patient.
The relation of steroid hormone administration to 
hepatic porphyria appears to be a complex one, since they 
can either precipitate acute attacks or, in some patients 
in whom exacerbations of clinical symptoms occur regularly 
with menstruation, prevent the appearance of acute attacks,
Watson (1964), Eales (1963) and Dean (1965) have 
observed both exacerbations in skin lesions and haem
precursors in variegate porphyria following administration 
of oestrogen and/or progesterone compounds. Similarly, 
there has been a number of cases recorded in which a marked 
increase in porphyrin excretion and the appearance of 
clinical symptoms of photosensitivity have been observed 
in association with the administration of oestrogen and 
in which there was no obvious evidence of a genetic back­
ground (Hurley and English, 1963; Warin, 1963; Becker, 
1965; Copeman ^t_aT., 1966; Felsher and Redeker, 1966; 
Levers, 1966; Zimmerman et al., 1966; Thivolet et al.
1957; Vail, 1967). The majority of these patients were 
given the hormonal preparation for prostate carcinoma, 
and an interval of several months or years had elapsed 
between the starting of the therapy and the appearance of 
the cutaneous symptoms. No evidence for a familial 
occurrence could be obtained from the histories of the 
patients, and biochemical analysis of the excreta from 
their relatives revealed normal porphyrin excretion in 
the few cases in which these examinations were carried 
out. Mild impairment of liver function was not uncommon 
among the patients (Zimmerman et al., 1966). Withdrawal 
of oestrogens led to a gradual improvement in the cutaneous 
symptoms (Zimmerman et al., 1966), although porphyrin 
excretion remained elevated in all six patients in which 
it was followed (Warin, 1963; Becker, 1965; Copeman et^  al. 
1966; Zimmerman et al., 1966). Levere (1966) reported 
a considerable increase in the activity of liver ALA.S in
a case of cutaneous porphyria which followed the administra­
tion of oestrogens.
A number of observations have been recorded on the effect 
of oestrogens and progestogens (administered either separately 
or in combination, as frequently used in oral contraceptives) 
on the biochemical picture and clinical state of patients with 
AIP. Increased excretion of porphyrin precursors and also, 
less frequently, appearance of symptoms indicative of a 
clinical exacerbation have been observed in several patients 
of both sexes by Levit et al. (1957), Redeker (1963), Welland
' wire IT.T1T- ' * *
_et_al... (1964) and Wetterberg (1964). In complete contrast, 
in the patient described by Haeger-Aronsen (1963) and in the 
three cases reported by Perlroth et al. (1965), the exacerba­
tion of AIP occurring in association with menstruation was 
prevented by the administration of synthetic sex hormones.
In these four cases, different hormonal preparations, each 
containing an oestrogen together with a progestogen, were 
used.
This striking difference in response to the hormonal 
treatment in the two groups of patients and the periodic 
exacerbation of the disease with menstruation and pregnancy, 
which can be observed in some porphyric patients, emphasize 
the importance of the hormonal state in the pathogenesis of 
the attacks of the disease. It is not known in what way 
the hormonal state is implicated or which endocrine system 
is primarily involved. In one of the patients described by 
Perlroth et al. (1965), complete control of the porphyric
symptoms was obtained by treatment with either an androgen or 
an oestrogen alone, as wall as by administration of a combina­
tion of an oestrogen with a progestogen,. Androgenic therapy 
was similarly effective in another patient described by Schmid 
(1965)o These observations suggest that a physiological 
response common to all three hormonal treatments may prevent 
the acute attacks in these patients. Perlroth et al. (1965) 
have suggested the inhibition of the secretion of the pituitary 
gonadotrophins, with stabilization of endogenous steroid 
production at a low level, may bo the effective mechanism.
This interpretation presupposes that a high level of endogenous 
steroids may be conducive to an attack of acute porphyria, 
whereas a high level of exogenous synthetic steroids may not. 
This concept is not supported by the finding by Redeker (1953) 
and Wetterberg (1964) of acute episodes after administration 
of synthetic steroids.
The inimical effect of oestrogens on cutaneous porphyria 
appears to be more consistent, and it seems probable that the 
cutaneous symptoms observed might be explained by the impair­
ment of liver excretory function by prolonged administration 
of these oestrogenic compounds. It has been demonstrated by 
Mueller and Kappas (1964) that increased sulphofaromophthalein 
(BSP) retention occurs in human subjects after parenteral 
administration of oestriol and oestradiol. Further studies 
by Kottra and Kappas (1957) have shown that this retention was 
not due to major hormonal impairment of conjugation processes 
for BSP. Combes and his associates (1963) have reported that
hepatic excretory activity is regularly depressed during 
pregnancy and that this functional defect can be attributed 
largely to the pharmacological consequences of the large 
amounts of oestradiol, oestriol and related compounds 
produced during gestation (Fig. 14). Eisalo et al. (1964) 
described impaired liver function after administration of 
oral contraceptives, apparently due to their oestrogenic 
compound. A significant elevation of urinary coproporphyrin I 
and ALA has also been found in pregnancy, especially when 
associated with hepatic disease (Koskelo and Toivonen, 1968) 
and in women on oral contraceptives (Koskelo t_^ a.l«, 1966), 
These findings suggest that impairment of liver excretory 
function may be partly responsible for increased urinary 
excretion of porphyrins and precursors, and for the appearance 
of symptoms of photosensitivity in symptomatic porphyria (PCT 
symptomatica). This opens the question of whether or not the 
mechanism of induction of porphyria by oestrogenic compounds 
may occur, in part at least, indirectly by establishing a 
condition of liver damage in these people with an inherited 
susceptibility for porphyria. An indirect mechanism of 
this type may perhaps explain the reason for the length of 
time taken by the majority of these oestrogenic agents to 
cause increased porphyrin excretion and symptoms of cutaneous 
porphyria (bJalshe, 1963; Copeman 1966; Lovere, 1966;
Degos et al., 1969; Roenigk, 1970), and also the reason for 
the persistence of the biochemical manifestations in spite of 
the withdrawal of the causative agent once the metabolic
disorder is established (Becker, 1965; Copeman et al., 1966; 
Zimmerman et al., 1966). Further support for this suggestion 
is provided by the observations that the clinical and bio­
chemical evidence of liver damage is much more common in 
symptomatic porphyria than in the other varieties of hepatic 
porphyria, and by the reports that increased porphyrin 
excretion and appearance of symptoms of photosensitivity are 
observed in chronic liver disorders in which there is no 
history of alcoholism, or of prolonged exposure to any of the 
hormonal preparations, drugs or other toxic factors associated 
with hepatic porphyria (Brunsting, 1954; Tio £t_al., 1957; 
Braun and Berman, 1959). Shanley et al. (1969) have reported 
that conjugation of aetiocholanolone, a potent inducer of 
porphyrin formation in chick embryo liver cell culture 
(Granick and Kappas, 1967), was found to be impaired both in 
patients with symptomatic porphyria and in non-porphyric 
patients with liver disease compared to normal subjects.
They suggest that faulty regulation of steroid conjugation 
might play a secondary role as an aggravating factor in 
symptomatic porphyria® Similarly, Zumoff et al, (1967 and 
1966) have reported that steroid glucuronide formation in 
patients with liver cirrhosis was reduced between 41^ and 87^ 
of normal.
The induction of ALA*,5 in chick embryo liver culture by 
some of these sex hormone preparations has been investigated 
by Rifkind et al. (1970), They reported that the active 
inducer component of these contraceptive steroids was the
progestogen, whilst no oestrogen significantly altered the 
level of the enzyme on its own. In contrast to this, 
oestradiol, a naturally secreted oestrogen, has been shown 
by Tschudy et al. (1967) to produce a series of oscillations 
of the level of hepatic ALA.S in ovariectomized rats. These 
oscillations continued for as long as 90 hours, and Tschudy 
and his associates suggested that they resulted from a 
perturbation of the closed negative feedback loop which 
controls the synthesis of hepatic ALA,S.
Granick (1956) was the first to report that several 
steroids of physiological origin in man have significant 
capacity for induction of porphyrins in primary culture of 
chick embryo liver cells. In subsequent publications,
Granick and Kappas (1967a,b) and Kappas and Granick (1968) 
described more exhaustively the effects of a series of 
steroids on porphyrin metabolism. They found that the most 
potent inducers of porphyrin synthesis in chick embryo liver 
culture were the and |3-H neutral steroids (Fig* J5a,b)
These certain steroids all share the basic nuclear structure 
of 5 (a Ï B cis) compounds in which the junction of the 
A and B rings is highly angular rather than planar, and they 
are all derived from the in vivo biotransformation of steroid 
hormones or intermediates rather than being primary endocrine 
secretions themselves (Fig. 16), Several of them, such as 
aetiocholanolone, pregnanediol and pregnanolone, are produced 
in significant amounts daily from the metabolic conversions 
of such precursor hormones as testosterone and progesterone.
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They further showed that in the conjugated glucuronide form 
these steroids did not induce porphyrin synthesis in culture, 
and also that this induction of porphyrin synthesis by these 
free steroids was abolished by uridine diphosphcglucurcnic 
acid (UDPGA) and by inhibitors of nucleic acid and protein 
biosynthesis, like actinomycin D and puromycin. This 
prevention of the inducing action of free steroids by the 
concomitant addition to the culture of UDPGA is considered 
to reflect the enhanced conversion in the culture of the active 
free steroid to the inactive glucuronide conjugate, since this 
nucleotide (UDPGA) is the immediate donor of glucuronic acid 
in conjugation reactions catalysed by UDP glucuronyl trans­
ferase (Dutton, 1966)o Granick and Kappas (1967a) further 
suggested that any process which led to - a) impaired glucu- 
ronidation of the steroid due to inhibited or defective UDP- 
glucuronyl transferase, or limited UDPGA formation; 
b) enhanced intracellular hydrolysis of formed conjugates by 
excessive p-glucuronidase activity; c) steroid production 
in amounts exceeding the body’s capacity to dispose of them;
- would result in induction of ALA.S and increased production 
of ALA and other precursors of haem. The diminishing of the 
inducing effect of drugs and steroids on porphyrin formation 
by a high glucose administration (Rose et al», 1961;
De Matteis, 1964) is thought to be partially due to an increase 
in the products of the glucose phosphate-pentose-P pathway, 
especially UDP-glucuronic acid which may serve for glucuroni- 
dation and thus solubilize the drug or steroid so that it is
readily removed by excretion (Sassa and Granick, 1970).
Similar effects of fasting and high carbohydrate intake have 
been observed in patients with AIP by Welland et al. (1964),
It is of interest that 5 p-H steroids like pregnenolone 
may have an inhibitory activity on glucuronyl transferase 
(Lathe and Walker, 1958), so that theoretically the increase 
in such a steroid which induces ALA*S may tend to block 
glucuronidation by setting up a self-sustained cycle of 
progressively increasing steroid concentration, resulting 
in clinical relapse of acute porphyria (Kappas and Granick, 
1968).
The synthesis of the individual porphyrins in chick 
embryo liver cells growing in culture following induction 
by meprobamate and aetiocholanolone has been investigated 
by Doss and Kaltepoth (1971), They showed that with either 
of these two inducing substances, protoporphyrin (proto), the 
end product of the porphyrin chain was the first to accumulate 
and, after stimulation of porphyrin synthesis, proto 
predominated over the higher carboxylated porphyrins. Similar 
relatively high values of proto in the livers of animals with 
experimentally induced porphyria have been reported by 
various investigators (Schmid et al,, 1955b; Granick and 
Urata, 1963; Onisawa and Labbe, 1963; danousek, 1970).
These findings serve to demonstrate that chemically induced 
porphyrin synthesis in liver cells in vivo and in vitro shows 
striking similarities.
As a result of their investigations, Granick and Kappas 
(1967a) and Kappas and Granick (1968) suggested that certain 
steroids of physiological origin in man induce the ’de novo* 
synthesis of ALA.S in chick embryo liver cell culture, and 
a hypothesis involving the repressor-inducer mechanism for 
gene activation proposed by Jacob and Monod (1961) was 
presented for the control mechanisms of synthesis; one at 
the transcriptional and the other at the translational level 
(Sassa and Granick, 1970). They showed that aetiocholano­
lone (5(3-H oxosteroid) and DDC (3,5-diethoxycarbonyl-1,4- 
-dihydrocollidine) induce at the transcriptional level, 
whereas AIA (allyl-isopropylacetamide) and Lindane (a 
non-planar insecticide, hexachlorohexahydrobenzene) induce 
primarily at the translational level. In this publication 
they also reported that haem inhibits at the translational 
rather than at the transcriptional level, as had been 
previously hypothesized (Granick, 1966). The results 
obtained by Sassa and Granick (1970) suggest that haem 
inhibits either by shortening the lifetime of the mRNA for 
ALAoS or by interfering specifically with the synthesis of 
ALA.synthetase. As a result of their investigations, 
Granick and Sassa (1971) suggested that the dominant 
Mendolian inheritance of AIP is most simply explained as a 
defect in an operator gene that controls the operon for the 
synthesis of mRNA for ALA.S (Fig. 17). On the basis of 
this assumption, they proposed an oparator-repressor 
mechanism at the transcriptional level, with inducers like
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5|3-H steroids or chemicals like DDC reacting with the 
repressor to derepress or unblock the operator. The free 
operator would then allow transcription of the structural 
gene to take place, resulting in mRNA for ALA.S. At the 
translational level, they proposed a haemoprotein as a 
repressor with haem serving as a co-repressor. The action 
of this haemoprotein would prevent the mRNA of ALA.S from 
being activated or translated. Inducers like AIA or 
Lindane would act indirectly to derepress the haemoprotein, 
perhaps by causing the destruction of the haem. Thus, this 
*silent* mRNA, conceived as a complex of the repressor haemo­
protein with the specific mRNA, might be converted to active 
mRNA. In addition to this hypothesis, Kurashima et al. 
(1970) have suggested that haemin might inhibit the activity 
of ALA.S by interfering with its transport into the mito­
chondria. Additional evidence of some control mechanism 
operating at the transcriptional level in the liver cell is 
presented by Incefy and Kappas*s (1971) study of the effect 
of a-Amanitin, a highly specific inhibitor of mammalian RNA 
polymerase, on the induction of ALA.S by aetiocholanolone 
in chick embryo liver.
It was found by Levere et al. (1967) that the same 
Sp-H oxosteroids that actively stimulate the synthesis of 
ALA.S in chick embryo liver cells, also stimulated haemo­
globin synthesis in chick embryo blastoderm cells. These 
investigators inferred that this stimulation of haemoglobin 
synthesis by the steroids in the blastoderm cells is brought
about by the same mechanism as that far the liverj namely, 
induction of the synthesis of ALA&S at the transcriptional 
level, Gorschein and Gardner (1970) observed that in mice 
made polycythemic and then treated with steroids and finally 
with labelled iron, there was increased label in the peri­
pheral circulation. The controls contained 1^ of the labelled 
iron in haemoglobin, whereas those treated with Bp-pregnane- 
-11,20-dione contained up to 15^ of the labelled iron. No 
stimulation of this uptake of labelled iron was observed in 
those mice treated with 5a-H steroids, Gordon et_al, (1970) 
carried these investigations further. They noted that testo­
sterone increased erythropoiesis by stimulating erythropoietin 
formation. They also showed, by preventing the induction of 
erythropoiesis by erythropoietin with antibody for this hormone, 
that the 5p~H oxosteroids (ll-ketopregnenolone, aetiocholanolone) 
stimulated erythropoiesis independently of erythropoietin*
Studies of the stimulating effect of these oxosteroid
metabolites on haem formation in human bone marrow cells were 
reported by Necheles and Rai (1969), They observed that 
aetiocholanolone (Sp-androstane-Sa-ol,17-one), but not andro- 
stanolone (5a-androstane-17p-ol,3-one) was effective in 
stimulating the incorporation of labelled glycine into haem.
Their finding that this 5p-H oxosteroid-induced stimulation 
of haem synthesis is completely abolished by both actinomycin 
D and puromycin suggests that tho stimulating effect is 
mediated by newly formed RNA-dependent protein synthesis.
All these observations indicate that 5p--H oxosteroids of
the androstane, pregnane and perhaps longer carbon skeleton 
series are active in the control of haem synthesis in both 
the hepatic and erythroid cells and could possibly act as 
persistent stimulants to porphyrin and haem production.
This action could presumably intensify at times; for 
example, in the luteal phase of the menstrual cycle and 
pregnancy, in which, in certain patients, steroid production 
is increased beyond the capacity of the liver to metabolize, 
conjugate and excrete such substances. If this is the case, 
it would appear likely that these Sp-H oxosteroids play a 
significant role in susceptible persons in determining the 
time of onset of the disease; for example, at puberty, when 
there is a great rise in the production of steroids (Fig, 9).
These proposals indicate that steroid imbalance of some 
type might be associated with the porphyrias. Tschudy (1968) 
investigated the urine of several patients with hereditary 
hepatic porphyria but could find no evidence of elevated total 
urinary IV-oxosteroids, In the following year, Goldberg et al, 
(1969) reported elevated fractions of some urinary 17-oxc- 
steroids in patients with AIP, although the total urinary 
17-oxosteroids were within the normal range. In this 
investigation, the most striking steroid abnormality detected 
was the increased excretion of dehydroepiandrosterone (Fig* 18) 
(DHA), and it was shown that on injecting DMA or its sulphate 
conjugate into rats, a striking rise of hepatic ALA.S was 
obtained. In further studies in this system by Moore (1970), 
ITcÈ-hydroxypregnenolone, androstenedione and aetiocholanolone
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were shown to have porphyrinogenic activity in the rat liver.
In that same year? Kappas (1969) demonstrated that the
plasma from patients in attack of AIP was capable of strongly 
inducing the synthesis of porphyrins in chick embryo liver 
culture, and again nucleic acid and protein biosynthesis 
inhibition abolish this effectr The plasmas which contained 
the most potent porphyrin-inducing activities were derived from 
several patients with AIP during acute relapses of their disease; 
whereas, the plasmas of patients with hepatic porphyria in 
remission did not display significant inducing activity. It 
was also shown that a similar induction effect was produced by 
the plasma of some normal subjects receiving contraceptive 
steroid mixtures. Further, evidence that some type of steroid 
imbalance exists in certain hepatic porphyrias was given by 
Gillette et^al, (1970), They reported consistent increases 
of the 5(3-H steroid metabolites as compared with the 5«-H 
steroid metabolites (which are normally excreted in equimolar 
amounts) in the urine of several patients with AIP, They 
suggested that this might be due to a deficiency of a 
A ^ -Soi-reductase enzyme activity.
There is also evidence that the glucocorticoids may be 
secondarily involved in the induction of porphyrin synthesis, 
flarver et al, (1966c) found that adrenalectomized mice did not 
become porphyric when treated with both AIA and hydrocortisone. 
Although the glucocorticoids cannot themselves induce, they 
may be important to bring about the metabolic conditions, like 
stimulation of gluconeogenesis during fasting, which permit the
inducing steroids or chemicals to induce, Fiatsuoka et al, 
(1966) observed a doubling of ALA.S activity in rat liver 
when, simultaneously with AIA, either hydrocortisone or 
triiodothyronine was administered.
Tliese clinical and experimental observations mentioned 
in this and the previous sections present a substantial amount 
of evidence for the occurrence of a deleterious interplay of 
endocrine and genetic factors in the natural history of these 
hereditary porphyrias, especially those of the hepatic group. 
The porphyrin-inducing sp-H oxosteroids that have been 
identified, delineate pne category of endogenous agents 
through which such an endocrine-genetic interplay may be 
effected in some subjects, and it is the purpose of this 
thesis to examine tho relevance of the part played by some 
of these oxosteroids in the pathogenesis of the hepatic types 
of porphyria.
SECTION IV
THE URINARY 17-OXDSTERDIDS
A. INTRODUCTION.
The 17“oxost0roids comprise of a group of steroidal 
compounds which have in common a ketone group at the C-17 
position of the steroid nucleus. Some have androgenic 
properties (androsterone and dehydrospiandrosterone)? 
whereas others, such as aetiocholanolone, are not known to 
be biologically active. All are derivatives of two parent 
hydrocarbons, 5ct-androstane and 5(3-androstane (aetiocholane), 
which differ in the spatial configuration of the hydrogen 
atom at the C-5 position and in the fusion of rings A and B 
in the steroid molecule (Fig, 19), Eight of the more 
important urinary 17-oxosteroids are shown in Figure 20,
Four of these have an oxygen substituent at the C-11 
position in the form of either an oxo (=0) or an hydroxyl 
(-OH) group. Isomerism at C-3 position is encountered 
relatively frequently in the 17-oxosteroids, This is well 
illustrated by comparing the structure of the two compounds, 
androsterone and epiandrosterone. When a group such as 
3-OH is attached to the steroid nucleus above the plane of 
the molecule, i.e, on the same side as the angular methyl 
group at C-10 and C-13, suoh a linkage is termed (3 and is 
depicted as being connected to the rest of the molecule by 
a solid line. When the -OH group is below the plane of 
the molecule, this is designated a and the linkage is shown 
by a broken line, Epiandrosterone and DHA are the principal 
17-oxosteroids with the 3(3-hydroxy group, whereas androsterone 
and aetiocholanolone are the two most important compounds
LEGEND FOR FIGURE 19
1. Androsterone and aetiocholano­
lone differ in the spatial 
configuration of the hydrogen 
atom at the C-5 position and in 
the fusion of rings A and B as 
shown by the top two steroid 
molecules on the opposite page.
2. Androsterone and epiandroster- 
one differ only in the spatial 
configuration of the hydroxyl 
group at the C-3 position.
3, Dehydroepiandrosterone is 
unsaturated between the C-5 
and C-6 positions, and this 
results in a bending of the 
steroid molecule between 
rings A and B.
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with the 3a~hydroxy structure. It should be noted that the 
□estrogenic steroid, oestrone, is also a 17-oxosteroid,
However, this compound, due to its phenolic structure in 
ring A, is acidic in nature and is removed from urinary 
extracts when these are washed with alkali. Accordingly,
□estrone is not included in the terms ^neutral* 17-oxo- 
steroids, which are the compounds under examination in this 
thesis.
The 17-oxosteroids are excreted in conjugation with 
glucuronic and sulphuric acids, rather than in the free 
form in the urine. It is generally believed that the 
urinary 17-oxosteroids originate from precursors such as 
DHA, DMAS, A^^-androstenedione and testosterone, which have 
been excreted by the adrenal cortex, by the testes and 
possibly to a small extent by the ovaries (Van de Uiele 
et al,, 1963; Baulieu ej^al,, 1965; Dorfman and Sharma,
1965; Mikhael, 1970), Both DHA and testosterone are 
converted to androstenedione, which is converted into equal 
portions of androsterone (a ) and aetiocholanolone (e ) by 
A'^ ” reductase (5a: and 5(3) of the liver (Baulieu and Mauvais- 
-Barvis, 1964a,b). These enzymes are susceptible to various 
precursors and hormonal influences and the E : A ratio may be 
shifted as a result of these influences. Exogenous DHA suppresses 
A^-Soc-reductase, and a rise in aetiocholanolone (E) develops, 
much as in malignancy of adrenals with excess DHA formation 
(Kirschner and Lipsett, 1964), Triiodothyronine stimulates 
A^-Ba-reductase, resulting in an increase of androsterone.
Deoxycortisol and other corticoids aro metabolized to 
aetiocholanolone (MacDonald 1962; Wilson and
Schenker, 1964), In males, approximately one-third of 
the total urinary 17-oxosteroids are thought to represent 
metabolites of the testicular hormone, testosterone, while 
the remaining two-thirds are derived from steroids which 
have been elaborated by the adrenal cortex. In females, 
who usually excrete smaller quantities than males, the 
main site of production of the precursors of the urinary 
17-oxosteroids is the adrenal cortex (Loraine and Bell,
1971),
The urinary 17-oxosteroids which are of adrenal origin 
arise in two different ways, being formed partially by 
oxidative removal in the tissues of the side-chain of 021 
steroids and partially from C-19 steroids which have been 
secreted by the adrenal .gland itself (Loraine and Bell,
1971), The four main 17-oxosteroids secreted by the 
adrenal cortex are 11 (3-hydroxyandrostenedione (Griffiths 
et al,, 1963), androstenedione and DHA (Cohn and Mulrow, 
1963), DMAS (Baulieu, 1962; Wieland et al,, 1963) and 
androsterone (Bush et al,, 1956; Short, I960). Current 
views suggest that the principal C-19 steroid synthesized 
by the human adrenal cortex is DHAS (Wieland et al., 1963; 
Baulieu et al., 1965). In addition to the adrenals, DHAS 
can be formed from free DHA and other steroid precursors by 
the liver (Schneider and Lewbart, 1956) and by tiie intestinal 
wall (Baulieu, 1963b); DHA can also be sulphoconjugated by
the foetus (Wengle, '1964). The results obtained by 
Chapdelaine et al. ('1965) also indicate that free DHA but 
not DHAS is secreted by the testes.
DHAS is far from being an end product; it undergoes 
metabolism either directly luithout splitting of the ester 
link to other steroid sulphates or indirectly by other 
catabolic pathways initiated by hydrolysis, leading 
essentially to the formation of androsterone and aetio- 
cholanolone in the liver, which are then conjugated either 
with sulphuric or glucuronic acid and eventually excreted 
in the urine (Baulieu .G^^al., 1965). The total urinary 
excretion of the conjugates of androsterone and aetio­
cholanolone includes a contribution from a testicular 
origin. This mainly arises from the metabolism of 
testosterone in the liver by two major pathways, both 
leading to the production and excretion of the conjugates 
of the neutral 17-oxosteroids (Van de Wiele et_al., 1963; 
Dorfman, 1969). In women, a very small amount of testo­
sterone is secreted both by the ovaries and the adrenals 
(Ismail and Harkness, 1966; Horton, 1966; Horton ,
1966). In addition, the ovaries secrete relatively large 
quantities of the C-19 steroid, androstenedione, which is 
believed to be an important precursor of testosterone 
(Horton et al., 1966),
The major sources of the urinary 11-oxygenated 17-OS 
are the adrenal production of 1ip-hydroxyandrost-4-ene-3,17- 
dione and the peripheral metabolism of hydrocortisone and
possibly certain of its reduction products (Goldzieher and 
Beering? 1969). The results of their investigations indicate 
that within this sub-group of 11-oxy 17-OS, compounds with a 
5p configuration are likely to be metabolites of the cortico­
steroids, whereas 5a' compounds are chiefly derived from 11(3” 
“hydroxyandrostenedione, a substance of unknown physiological 
significance. Tl'iis short summary of the precursors of tl'ie 
urinary neutral 17-OS conjugates indicates thoir complex and 
diverse origins.
A method was set up to measure the most important 
sulphate and glucuronide conjugates of these neutral 17-oxo- 
steroids in urine. This method, adapted from the method 
of 0^Kelly (1968), permits the measurement of individual 
17-OS as the separated steroid glucuronide and sulphate 
fractions of 24-hour urine specimens.
B. MATERIALS AND METHODS EOR DETERMINATION OF URINARY 
17-OXGSTEROID CONJUGATES.
Reagents,
Anhydrous sodium sulphate, ammonium sulphate, potassium 
dihydrogen orthophosphate and sodium chloride were all BOH 
analar grade reagents.
The alumina, Woelm neutral activity grade 1, was 
obtained from Camlab, Cambridge.
The gas chromatographic column packings {?f/o QF-X by 
weight on 100/120 mesh Gas-Chrom Q and the 3^ NGS by weight 
on 100/120 mesh Gas-Chrom S), the trimethylchlorosilane and 
the dimethyichlorosilane were obtained from Applied Science 
Laboratories, P.O. Box 440, State College, Pennsylvania, 
U.S.A.
Radioactive compounds.
The Ta-^H-pregnenolone (specific activity 5 Ci/mmol), 
the 7(X- H-pregnenolone sulphate (specific activity 16 Ci/mmol) 
the 7a- H-dehydroepiandrosterone (specific activity > 10 Ci/ 
/mmol) and the 7a-^H dehydroepiandrosterone sulphate (specific 
activity 1 Ci/mmol) were obtained from the Radiochemical 
Centre, Amersham, Bucks,
Solvents,
Ethanol and methanol (Burroughs Analar grade) were used 
without further purification.
Acetone, ether and toluene (BOH analar grade) were used 
without further purification.
Ethyl acetate and benzene were obtained from Reeve Angel 
Scientific Ltd. These solvents come in 500 ml packs and 
are specifically purified for chromatography5 the g.l.c, 
purity being better than 99.7^. These solvents were used 
without further purification.
Hexane (BDH analar grade) was washed three times with 
100 ml of conc. HgSO^ per litre for one hour on a mechanical 
shaker, followed by two washes with 100 ml of 2 N NaOH per 
litre, and finally with water until neutral. It was then 
dried with calcium chloride and distilled through a 
fractionating column.
Diethylamine (BDH analar grade) was stored over KOH pellets.
Choice of J.ntcrnal standard.
The choice of an internal standard is subject to the 
following considerations:
a) It must have a detector response which is linearly
related to the amounts present.
b) The ratio of its amount to the steroids being measured 
must remain constant throughout the analytical procedure,
c) It must be separable by gas-liquid chromatography from 
the other steroids to be investigated.
d) The position at which it emerges on the gas chromato­
graphic trace must be free from other contaminating 
peaks.
b ) It must not occur in urine,
f) It must be as similar as possible in chemical structure,
to the compounds under investigation.
g) It must be eluted from the alumina column in the same
fraction as the other steroids under investigation.
Pregnenolone appeared to fulfil these requirements.
It is not present in urine in detectable quantities ; it is 
eluted in the same fraction as the 17-oxosteroids from the 
alumina columns; the ratios of peak heights obtained by 
g.l.c. for the control solutions and for the processed 
solutions were constant (Table 4a,b); it is easily 
separable from the 17-OS by gas liquid chromatography on a 
variety of columns and is free of extraneous contamination. 
Its structure is very similar to DHA, which is the most 
labile of the 17-oxosteroids, Under the conditions 
employed, no significant degree of breakdown has been 
observed for any of the steroids investigated.
Preparation of {3-glucuronidase from limpet visceral sacs.
Limpets were collected, the visceral sacs were removed 
and homogenized in water. Four volumes of ice-cold acetone 
were added with continuous stirring. The mixture was allowed 
to stand for thirty minutes and was then filtered through 
Whatman No, 1 paper in a Buchner funnel. This material was 
resuspended in the same volume of ice-cold acetone, allowed 
to stand for a further 30 minutes and again filtered. It
was thsn washed with acetone on the filter paper until the 
filtrate was colourless,. The resulting acetone powder was 
air dried overnight and then placed in a desiccator to remove 
the last traces of acetone.
The (3-glucuronidase content of the powder was assayed 
by the method of Fishman (1963), using phenolphthalein 
glucuronide as a substrate. The glucuronidase activity was 
expressed as the number of pg of phenolphthalein liberated 
by 1 g of powder under the conditions of the assay. The 
powder prepared in this manner was found to contain approximately 
■^ --million units of (3-glucuronidase activity per gram.
Collection and Storage of Urine,
Specimens for gas-liquid chromatography and chemical 
analysis were collected and stored in the cold room. To 
minimize any alterations which have been found to occur with 
repetitive thawing and freezing, the urines were stored in 
200 ml aliquots. Specimens for 17-oxosteroid analysis at 
normal urine pH undergo little or no change after one month 
in the cold. Some hydrolysis of steroids has been reported 
to occur during extended storage in the deep freeze, which is 
intensified by thawing and refreezing (Patti & Stein, 1964),
Solvolysis of 17-oxosteroid sulphates.
Steroid sulphates were hydrolysed by the method of 
Burstein & Lieberman (1958), Pregnenolone sulphate (40 pg) 
was added as an internal standard to 25 ml of a complete
24-hour urine. I\!a Cl was added to this to give a 20^ (w/v) 
solution and the pH was adjusted to 1 by the addition of 
4NoH^S0^. The solution was then extracted twice with an 
equal volume of ethyl acetate and the combined extracts 
incubated, for approximately 20 hours at 37°C. The extract 
was then washed two or three times with 0.1 volume N.NaOH 
until no further pigments were removed, and finally three 
times with 0.1 volume distilled water. The washed extract 
was dried by passing through anhydrous sodium sulphate on a 
filter and evaporated to dryness under a stream of air.
Hydrolysis of 17-steroid glucuronides.
Steroid glucuronides were hydrolysed by the following 
method.
A suitable steroid glucuronide for use as an internal 
standard is not readily available. Accordingly, 50 pg 
pregnenolone was added to 25 ml of urine from a complete 
24-hour specimen. In order to avoid inhibitors of 
P-glucuronidase which are present in the urine, the 
glucuronide conjugates were extracted by the method of 
Edwards, Kellie & Wade (1953). Ammonium sulphate was 
added to give a 50^ (w/v) solution and the pH was adjusted 
to less than 5 by the addition of glacial acetic acid.
The solution was then extracted three times with equal 
volumes of ether/ethanol, 3:1, and the combined extracts 
evaporated under reduced pressure. The residue was leached 
twice with 10 ml of ethanol to remove the internal standard
and the glucuronides, and than filtered through Whatman No. 1 
paper. This is necessary, since ammonium sulphate inhibits 
P-glucuronidasB. The combined ethanol extracts were 
evaporated under a stream of air. The residue was mixed 
with 5 ml of the following enzyme preparation : an acetone
dried powder containing (3-glucuronidase from the common 
limpet was suspended in Ü.GM acetate buffer (pH 4.7), 
containing 0.05M sodium or potassium phosphate.to give 
20,000 enzyme units/ml. The phosphate inhibits any steroid 
sulphatase present (Roy, 1956), The mixture was incubated 
at 37°C for 2 days. After hydrolysis, 20 ml of distilled 
water were added and the liberated steroids wore extracted 
twice with an equal volume of ether/ethyl acetate (1:1),
The combined extract was washed two or three times with 0.1 
volume N.NaOH until no further pigments were removed and 
finally three times with distilled water to remove the alkali, 
dried by passage through anhydrous sodium sulphate on a filter 
and evaporated under a stream of dry air.
From this stage, the residues containing steroids from 
the sulphate and glucuronide fraction are treated in the same 
way.
Alumina colurnn chromatography.
Columns (10 x 5 mm) containing 1 g alumina weakened by 
addition of à% water were prepared in dry benzene. They 
were then tested with a mixture of 50 pg of each of the 
following steroids in 3 ml of dry benzene ;androsterone (A),
ll-oxü-A, 11 [3-DH-A, aetiocholanolone (E), H - o x o -E, 11P-OH-E, 
dehydroepiandrosterone, epiandrosterone and pregnenolone (the 
last mentioned is the g«l.c. internal standard). The test 
mixture was transferred to the column and washed in a further 
3 ml dry benzene. The column was washed with 7 ml benzene 
and eluted with 25 ml 1.4% ethanol in benzene. The last 
solvent should remove all 17-oxosteroids from the column.
This was checked by comparison on the g.l.c. after TflSE 
formation, with a similar mixture subjected to éthérification 
but without putting through the alumina column. When the 
correct volume of eluting solvent was determined for the 
batch of alumina in use, the urine extract was transferred 
to the alumina column with 2. x 3 ml benzene, and the column 
washed and eluted as already described. The 1.4% ethanol 
in benzene elutes both 11-oxy- and 1l-deoxy-17-OS (see 
Heyns & de Moor, 1965).
Preparation of trimethylsilyl ethers (TMSE).
The trimethylsilyl ethers were prepared by the method 
of Thomas & Walton (1968). The steroid residue in a 3 ml 
conical tube was further dried in vacuum for several hours, 
Traces of water prevent quantitative preparation of TMSE 
(Lau, 1966). Five ml hexane containing 0.7 ml trimethyl- 
chlorosilane were added to 5 ml hexane containing 0.4 ml 
diethylamine, shaken vigorously and centrifuged. About 
0.4 ml supernatant solution was added to the dry steroid 
residue, the tube was stoppered and left overnight. The 
reaction mixture was then evaporated with the tube in a
vacuum desiccator. Trimethylsilyl ethers of the steroids 
in the residue were dissolved in hexane to give a concentra­
tion of pregnenolone internal standard of about 0.5 pg/pl. 
The insoluble ammonium chloride was centrifuged down, since 
traces interfere with subsequent gas chromatography. Along 
with the unknown urine samples, residues containing equal 
amounts of 17-05 and pregnenolone, were put through the 
preparation procedure, to check TMSE formation and correct 
peak height ratios.
Gas-liquid chromatography.
The instrument used in this present work was a Pye 
Series 106, Model 6, Automatic Analytical Gas Chromatograph 
equipped with an automatic solids injection system, injection 
port heater and a flame ionisation detector. Glass columns, 
spiral-shaped, 2.23 metres long and with an internal diameter 
of 2 mm, were specially made by Aimer Products Ltd., 56-58 
Rochester Place, London, N.liJ.I. A Leeds and Northrop 
Speedomax liJ Recorder was employed with a chart speed of 10 in/ 
/h. Purified nitrogen was used as the carrier gas, with an 
inlet pressure of approximately 40 psi, giving a flow rate of 
45 ml/min. The hydrogen and air flow rates were 50 rnl/min 
and 500 ml/m in respectively. All flow-rates were measured 
at the detector outlet by means of a soap-bubble flow-meter.
Packing of columns.
Before packing the columns with the precoated support,
both the glass columns and ths glass wool to bo used were 
treated overnight with 5% (w/v) dimethyldichlorosilane in 
toluene; then washed with methanol and thoroughly dried.
This process removes any 'active sites' on the glass wool 
or the internal wall of the glass column which might absorb 
the polar steroid molecules causing loss of sample or tailing 
of the chromatographic peak.
The glass column was then packed as follows; one end 
of the column is plugged with silanized glass wool and 
attached to a relatively high capacity vacuum pump. The 
packing can then be carefully drawn into place through a 
suction procedure. During the packing process, the column 
should be tapped firmly with a rubber-covered rod to ensure 
dense and even packing. It is also possible to use a 
mechanical vibrator, but excessive vibration should be 
avoided, since the packing may be partially shattered.
Before use, a conditioning period is necessary for all newly 
packed columns. To this end both types of columns (NGS and 
QFl) were heated to 250°C in a stream of nitrogen for 24 hours. 
This pretreatment of the column ensured the removal of volatile 
products which may contaminate the detector and prevent a 
stable recorder baseline.
Introduction of samples into the gas chromatograph.
Solutions of the TMSE derivatives of the steroids were 
prepared in hexane, resulting generally in a concentration of 
0.1 1,0 pg of steroid per pi of hexane. Depending on the
concentration 5 volumes varying between 1 - 20 pi of the 
hexane solution were injooted by means of a syringe into 
the glass sample holders (maximum volume 40 pi), which were 
heated by the magazine heater for approximately 20 minutes, 
depending on the volume injected. When all the solvent 
had evaporated, the magazine containing the sample holders 
was transferred into the glass casing on top of the column «
A signal from the auto-solids injector controller actuated 
the mechanism which pushed a sample holder into the heated 
zone at the column inlet. The sample was quickly evaporated 
and flushed on to the column in a minimum of carrier gas and 
the used holder was ejected into the glass receiver. The 
injection sequence could be repeated at preset time intervals 
varying between ten and ninety minutes, for up to 36 sample 
holders.
Cleansing of the glass sample holders.
The sample holders were washed several times with the
purified hexane and then heated to about 300°C in an oven.
After cooling, they were immersed overnight in a 5% solution 
(w/v) of dimethyldichlorosilane in toluene. They were then 
rinsed twice with toluene, twice with methanol and dried in 
a moderately warm oven.
CALCULATION OF RESULTS.
The peak heights of all the steroids were measured in mm.
This was found to be simpler, quicker and just as accurate as
measuring peak areas. Standard solutions containing equal 
amounts of all the 17-oxosteroids to be measured, including 
the internal standard, were chromatographed at the beginning, 
tliG middle and the end of every batch of urinary analyses to 
monitor retention times and column performance. Their peak 
heights were also measured. The following formula was used 
to calculate the number of mg of each steroid in the 24-hour 
urine specimen.
mg of steroid in a d a f
=  X X X
24-hour urine sample b e g  1,000
Where :
a. -• peak height of 17-OS in the analytical specimen;
b = peak height of pregnenolone in the analytical
specimen ;
c = peak height of 17-OS in the standard;
d - peak height of pregnenolone in the standard;
e = number of pg of pregnenolone added initially
to the urine sample;
f = volume of 24-hour urine collection;
g ” volume of aliquot taken for analysis.
All the urinary values for the conjugated 17-OS are expressed 
in terms of the concentration of free steroid per 24-hour urine 
specimen, unless otherwise stated.
STATISTICAL PROCEDURE
't' test.
This is a test of significance and is used to compare 
the means of two independent samples and, from the results, 
conclude if the samples are from the same or different 
populations. For example, comparison of the steroid 
values obtained for normal subjects and for porphyric 
patients gives the *t' value;
ix - -y)
't'
S\/(- + 1)
n
whe re  ?
X is the mean of the n ormal subjects;
y is the mean of the po r ph y ri c  patients;
is the e s t i m a t e  of the vari a nc e  ob t ai n e d
2 1
from normal subjects, where S =
2
and (\1^ is the number of normal subjects. Having calculated 
't' and the number of degrees of freedom (d.f.) by the formula
where ;
n^ is the number of samples in the first group; and
n^ is the number of samples in the second group; 
the statistical significance of 'p' value is obtained 
from the 't-distribution* tables. The conditions
which must be satisfied to make the Student's 't' test
a powerful one and, in fact, before any confidence can
be placed in any probability statement obtained by the 
use of the 't' test, are at least the following:
1) The values must be independent.
2) The values must be drawn from normally distributed
populations.
3) These populations must have the same variance or, in 
special circumstances, they must have a known ratio 
of variance.
Correlation coefficient.
In measuring the association between two normal variables, 
it is convenient first to generalize the variance estimate used 
for measuring the variability of a single variable. Suppose 
that we have observed the variables x and y on n individuals,
obtaining values y^; x^ yg,-- -----------------y^.
The variance of x and y are estimated by
C ( x - x F
n - 1
C ( y  - ÿ)^
^ n - 1
A simple first measure of the association between x and y is 
the covariance which is estimated by
C ( x  - x)(y - Ÿ)
„  .. 1
The covariance estimate is a simple measure of association 
but it is not easy to interpret because it depends on the 
scale on which the variables are measured. A more useful 
quantity is the correlation coefficient estimated by
Covariance
(SoD. of x)(5oD„ of y) S S
X y
It may be shown that the correlation coefficient never 
exceeds 1 in numerical value, i.e. -1 ^ r <^1.
When r = 1, the sample relationship is a straight line with 
X and y increasing together and, when r = -1, the relationship 
is again a straight line with y now decreasing when x increases. 
Intermediate values of 'r' are less easy to interpret, but it 
can be accepted that the values of 'r' near to +1 or -1 
indicate a close relationship with little departure from 
linearity.
EVALUATION OF THE RELIABILITY OF THE METHOD FOR 
DETERMINATION OF THE URINARY 17-OXOSTEROIDS.
The 17-OS were separated and quantitated as their 
trimethylsilyl ether derivatives on the selective phases 
NGS and QF-1. Epiandrosterone TMSE was not separated 
from DHA TMSE on the NGS column. This metabolite (Epi- 
-TMSE), especially the glucuronide conjugate is usually 
a minor constituent of the urinary 17-OS and, if its 
estimation is desired, the liquid phase QF-1 must be used 
(Fig. 21)0 Similarly, it was not possible to wholly 
separate 11-oxoandrosterone, 11-oxoaetiocholanolone,
11-hydroxyandrosterone and 1l-hydroxyaetiocholanolone 
on the stationary phase QF-1, and it was necessary to use 
NGS (Fig* 22)0 By far the larger fraction of these fore- 
mentioned C^gO^ steroids are excreted as glucuronide 
conjugates, thus the NGS phase was used to separate and 
quantitate the glucuronide fraction of the urinary 17-OS, 
Similarly, since the sulphates of DHA and epiandrosterone 
are quantitatively more important than their glucuronide 
conjugates, the QF-1 liquid phase was used for separation 
and quantitation of the sulphate fraction.
Complete TMSE formation of the 17-OS was demonstrated 
on both QF-1 and NGS stationary phases. On both of these 
selective phases the TMSE had shorter retention times than 
their parent alcohols. Using the pure 17-OS mixture, no
L e g e n d  f o r  f i g u r e  21.
GLC s e p a r a t i o n  of a s t a n d a r d  m ix tu re  
of eight 17-oxosteroids and the in te rn a l  
s t a n d a r d
The peaks are i d e n t i f i e d  as f o l l o w s  ;
-- a = A n d r o s t e r o n e
b = Aet iocho lano lone
c = De hy droep iand ros te rone
d = E p i a n d r o s t e r o n e
e = Pregnenolone ( i nterna l  s tandard )
f = 1 1 oxoandros terone
g = - 1 1 - oxoaet iocholanolone
h = 11B-hyd roxyan  drosterone
I = 1113 ~ hydroxyaet iocholanolone
These l e t t e r s  are used to i d e n t i f y  the respective 
steroid peaks in all the g . l . c .  t r a c i n g s  shown 
in t h i s  t h e s i s .
F i g u r e  21.
GLC sepa ra t ion  of a s ta n d a r d  m ix t u r e
of 17-oxos te ro ids
Column 37oOF1 ; temp 169**C ; Nz f low rate SOml^min
= 3 # i :
E ( m in s )
11-Oxoaet  i o c h o l a n  ol  one ( g ) ,  11-h y d roxyae t i ocho (an ol one ( i )
and  11- h y d r o x y  a n d r o s t e r o n e  ( h )  a r e  no t  s e p a r a t e d  
on t h e  0 F 1 col  umn.
F i g u r e  22
GLC separation of a standard mixture of 17-oxosteroids 
Column 37oNGS ; tem p 200"C ; Ni flow rate 45ml/min
a
Tirhe
E p i a n d r o s t e ) are notd e h y d r o e p i a n d r o sand one
s e p a r a t e d  on t h e  NGS c o l u m n .
free steroids could be detected after derivative formation*
The response of the detector to the TMSE derivatives 
of the individual 17-OS to the response of the pregnenolone 
TMSE derivative was satisfactory* A straight line was 
obtained when the ratios of the masses of individual 17-05 
to pregnenolone (0,1 to 1O) were plotted against the ratios 
of the corresponding TMSE derivative peak heights (Fig* 23).
The retention time of individual TMSE derivatives 
relative to the retention time of the internal standard 
pregnenolone TMSE, was determined throughout the study. 
Although the g,l,c, conditions did not always remain constant 
from one series of analyses to another, the relative retention 
times of the TMSE derivatives were found to be constant for 
both the authentic and the urinary steroids (Table 2),
It was important to determine the value of each 
individual steroid derivative and its constancy over a period 
of time. Reference standard mixtures containing equal 
amounts of the eight 17-OS and the internal standard were 
chromatographed numerous times over the period of the study. 
The response to each steroid, measured as the ratio of its 
peak height to the peak height of an identical amount of 
pregnenolone, is shown in Table 3,
When an internal standard is used, it is necessary that 
the ratio of its amount to the steroids being measured 
remains constant throughout the analytical procedure. To 
establish whether this was so, aliquots were taken from a 
solution containing the sulphate esters of androsterone,
L e g e n  d f or  f i g u r e  23
C a l ib ra t io n  of the d e t e c t o r  response  
fo r  1 7 -o x o s te ro id s
The ratios of the TîvISE I7-OS derivatiye pealc heights 
to the peak height of pregnenolone TLISE derivative were plotted 
against the ratios of the masses of the corresponding individual 
free I7-OS to the mass of free pregnenolone. Straight lines 
were obtained for all the plots and thus the mass of the,free 
steroid is directly proportional to the pealc height of its TIvISE 
derivative. The plots of the ratios of the individual 17-08 
to pregnenolone are represented by the following symbols;-
-o o  “  A n d r o s t e ro n e
 A  = Aet iocho lano lone
-a-----D  = Dehydroepiandrosterone + epiandrosterone
-X----------- X----  = 11-oxoandrosterone
11-ox oaet iocholanolone 
11(3 -  hydroxy and roster one 
113 -  hydroxyaet iocholanolone
C a l ib ra t io n  curves for 17-oxosteroids
2 0 -
peak height 
ra t io
17-OyPreg1‘0 "
20 '
peak height 
ratio
17-OS/Pre g
0-2 0-4 0-6 0-8
mass ratio 17-OS
1 2 3 4  5 6 7 8 9  10
mass ratio 1 7 -O ^ P re g
Table 2.
RETENTION TIMES OF THE 17-ÜS DERIVATIVES RELATIVE 
TO PREGNENOLONE TMSE
STEROIDS
AUTHENTIC 
n X
STEROIDS
S.D, n
URINARY STEROIDS
X S o Do
COLUMN
A 30 Do 499 0.004 30 0,499 0.004
E 30 0o573 0,004 30 0,574 0,004
DMA 30 0,659 0,005 30 0,659 0.006 3^
EPI 30 0,756 0,007 30 0,756 0,007 QF-1
A 30 0,434 0.003 25 0.435 0,003
E 30 0,578 0.003 25 0,579 0,004
DHA -f EPI 30 0,686 0.005 25 0,686 0.005
11-OA 30 1.116 0,006 25 1,116 0.006 %
11 "OE 30 1,453 0,014 25 1,456 0,015 NGS
11-OHA 30 1,817 0.018 25 1.815 0.017
11-OHE 30 2.464 0.034 25 2.462 0.034
n n u m b e r  of d e t e r m i n a t i o n s
X mean rela ti v e r e t en t io n  time
S.Do " s ta n da r d dev ia t io n
Table 3,
GAS CHROMATOGRAPHIC RESPONSE TO 17-OS MEASURED AS 
PEAK HEIGHTS AND REFERRED TO PREGNENOLONE AS STANDARD
PEAK
HEIGHT
MASS RATIO
STEROIDS n RATIO X S.D.
A 25 1 2,201 0.032
E 25 1 1,830 0.028
DHA EPI 25 2 2.860 0.047
11."OA 25 1 0,900 0.019
11-OE 25 1 Oo 666 0.023
11-OHA 25 1 0.412 0.028
11-DUE 25 1 0.289 0.021
n - number of determinations
X - mean
SoDc “ standard deviation
aetiocholanolones DMA, epiandrosterone and pregnenolone. 
Some of these were solvolyzed and used as controls, and 
the remainder were put through the steps of the method,
The ratios of peak heights obtained by g.l.c. on the QF-1 
column for the control solutions and for the processed 
solutions were compared and the results are shown in 
Table 4a, These data show that there is little change 
in the peak height ratios throughout the procedure for 
quantitation of the sulphates. The suitability of 
pregnenolone as an internal standard for the glucuronide 
fraction was demonstrated by similar means (Table 4b),
In this case, the reference mixture was used as the 
control, as the 17-OS glucuronides were unobtainable.
The TMSE derivatives were chromatographed on the NGS column,
Specificity.
The specificity of the method depends upon the 
elimination of non-steroidal impurities and the adequate 
separation of steroids with similar chromatographic 
properties which may be present in the urine. The use 
of the alumina column ensures preferential isolation of 
the 17-DSe Evidence for the lack of interference from 
solvents and reagents was obtained by the analysis of 
distilled water and added steroids (Table 5a,b). The 
urinary steroid TMSE were identified by their retention 
times relative to pregnenolone TMSE, which were identical 
with authentic standard TMSE derivatives (Table 2). When
Table 4a.
SUITABILITY OF PREGNENOLONE SULPHATE AS AN INTERNAL STANDARD
RATIO
DMA
Prog.
WT5-F» WVaWWWM
n
RATIO
A
Prego
RATIO
E
Preg*
RATIO
EPI
Preg.
10 2.221 2.036 1.840 1.623
CONTROL
S o D o 0.060 0.060 0.050 0.050
10 2.200 2.015 1.763 1.599
TEST
S.Do 0.060 0.070 0*060 0.050
n - number of determinations 
SoDo >“ standard deviation
CO
b
CO
rh
D)n
CL
CÜ
l-J
CL
Q.cucp.
md*H-
o3
3c
5O-
CD
hi
o
CL
CD
d*
CD
hi
B
H-
3
P
d-
H-
O
3
CO
m
cn
CO
C3
CD
œ CD
a
o (3
(3
COCOCD CO(3
O CO
mCO
o
-<lCO
cn
(3
ID
COo
K)a CO 1\D
CD
CDCj^I
IDo
o a
TO
t-H
TOCO o CO CO
lO
CO CO CO CO
on
ID o
m
CD
CO CO
CO D (3 TO
CO CD
CO
CO
K>
a
CO
CO
ID CO
CO a CO CO
CO CO
CO
UO
COLD
CD 
(3  
f-H 
—1 0T5 
CD 1-1 
r~Id
H
•<
CO
•-T |
TJCO
m
CO
z
CO
r"
CO
z
n
0=
CD
m00
CD
-H
0=>
■<2
o03OG
D
pcri-'
CD
cr
Table 5,
ANALYSIS OF DISTILLED WATER AND ADDED STEROIDS
a) Recovery of A, E, DMA, EPI added to 25 ml Water by 
Sulphate Procedure,
Steroid
Added
p.g n pg Measured 
Moan
%
Recovery
SoDo
A 50 8 49 0 4 98.8 2.9
E 50 8 51,1 102,2 2.5
DMA 50 8 51.6 103,2 1,9
EPI 50 8 50,3 100,6 2,0
b) Recovery of A, E, DMA P EPI, 11-.0A, 11-OE; 11-OHA, 11-OHE
added to 25 ml Water by Glucuronide Procedure,.
Steroid |.Lg n |ig Measured f
....—....
SoD.
Added Added Mean Recovery
A 50 12 49,2 98,4 4,0
E 50 12 51.8 103,6 3,5
DMA + EPI 100 12 102.3 102,3 2,2
11-DA 50 12 50.2 100,4 3,8
11-OE 50 12 49.8 99.6 3,6
11-OHA 50 12 51,2 102,4 4.2
11-OHE 50 12 51.6 103,2 4.3
n " number of determinations 
S*D. - standard deviation
authentic steroids were added to the urine for recovery 
studiesj no new peaks were formed; only the increases of 
the respective peak areas were observed. Similarly, if 
no internal standard was added to the urine, no peaks were 
found on either gas chromatographic trace, which would have 
contributed to the peak height of pregnenolone TMSE.
The shapes of the peaks in both analytical and standard 
were identical, with no evidence of contamination from 
unknown peaks.
Finally, sulphate and glucuronide fractions were 
chromatographed on both QF-'i and l\!GS columns, and essentially 
identical results obtained (Table 6a,ta).
Precision,
The precision of the method was determined by repeated 
estimations on three urine pools. In Tables 7 and 8, the 
results obtained in the analyses of those pools are given.
From these values it can be seen that the precision of the 
methods is similar for all the steroids determined covering 
a wide concentration range.
Accuracy,
The accuracy of the method was assessed by the addition 
of known amounts of the free steroids or the steroid sulphates 
to pooled urine or distilled water, processing the aliquots 
by the methods described and calculating their recoveries.
The results are presented in Tables 5a and b, 9, 10 and 11,
In all the experiments, the mean percentage recovery
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Table 7,
Pool n A E DHA EPI
X 8 1.06 0.34 2.65 0.61
S*D, ' 4.7/o 8.8/ 3.0/ 6.5/
X 14 1c 05 0.36 2.72 0.57
SoD, Bo 7% 8.3/ 3.0/ 6c 5/
X 6 1,08 0.32 2.58 0,59
SoDo 7o4/o 9.4/ 3.9/ 6.8/
X 6 1.16 0.32 2.69 0,54
S 0 D o 4c3/a 7.1/ 4.2/ 6.2/
Y 8 2.57 1.28 3.81 1.53
S e D o 5, I/o 4.8/ 2.9/ 4,2/
Z 8 3.61 2.86 4.01 2.98
SoD. 4.2/ 3.5/ 2.3/ 2.4/
Table 7« Replicate analyses of three pools. Pregnenolone 
sulphate was added as internal standard and the steroids were 
hydrolyzed and extracted as described for steroid sulphate 
estimation. The final extracts were chromatographed on a 
'5% QF-1 column. The results are expressed as mg of free 
steroid per litre of urine pool,
n - number of determinations 
SoD, - standard deviation %
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RECOVERY OF 17-08
Table
SULPHATES 
OF URINE
9.
ADDED TO 
POOL
25 ml ALIQUOTS
A E DHA EPI
No. of Analyses 8 8 8 8
jj,g of steroid present 27.0 8.0 67.0 13.5
|ig added# 33.9* 33.9* 33.7* 33.9*
Mean pg measured 60.1 42.3 100.0 48.2
% Recovery 97.6/ 101.2/ 97.9/ 102.4/
S.Do 4.8 5.7 3.9 6.1
Recovery of AS, ES, DMAS and EPIS added to urine. Pregnenolone 
sulphate was added as an internal standard. The final extracts 
were chromatographed on a 3/ QE-1 column.
■^Calculated amount of free steroid added
Table 10.
RECOVERY OF INCREASING AMOUNTS OF DMAS ADDED TO 25 ml 
ALIQUOTS OF THE URINE POOL
SAMPLE n
R9
DHA
Present
pg 
DHA 
Added #
Mean 
pg DHA 
Measured
Mean 
/ Recovery S. D.
1 2 67 0 67 “
2 2 67 0.7 67.4 57.1/ 7.9
3 2 67 3.4 70.1 91.2/ 6.1
4 2 67 6.8 73.5 95.6/ 4.2
5 2 67 16.9 83.7 98.8/ 3.8
6 2 67 33.7 101.1 101.2/ 2,6
7 2 67 67.5 134.4 99.8/ 3.1
Pregnenolone sulphate was added as internal standard. The final 
extracts were chromatographed on a 3/ QF-1 column.
^Calculated amount of free steroid added
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relative to the internal standard was within the range 
87c8 - 107c1 with a percentage standard deviation within 
the range 2*6 - 7*9, which J.s quite satisfactory*
The absolute recoveries of the internal standard were 
achieved by adding tritium labelled pregnenolone sulphate 
or tritium labelled pregnenolone to urine samples and 
estimating the recovery of radioactivity at the end of 
the méthode The results are shown in Tables 12a and bo
Similar absolute recovery experiments were repeated using
3 3
7a~"H-DHA and 7a- H-DHASo These results are also shown
in Tables 12a and b*
The mean overall recovery for the internal standard,
Preg* 50^, through the procedure described for determination
of steroid sulphates, was 86*3^ 1, with a standard deviation
of 2c3« This was very satisfactory and agreed with the
total mean percentage of radioactivity recovered when the
3experiment was repeated using H-DHAS* This gave a total 
mean recovery of 91*3% and, once again, the precision was 
very good with a standard deviation of 3o0c Overall 
percentage recoveries for the procedure required for estima­
tion of steroid glucuronides were not as high as those for 
the sulphate procedure * The mean recovery of added 
"H-pregnsnolone was 70.6%, and for DHA 68*6%, This fall 
is to be expected when the additional steps involved in the 
glucuronide procedure are taken into consideration* Once 
again, the precision was very good with a standard deviation 
of 3,8 for the mean recovery of the pregnenolone.
Table 12a,
RECOVERY OF 7a-^H-PREGNEN0L0NE SULPHATE (122, 621 d.p.m,)
AND la- H-DHA SULPHATE (144, 420 d.p.m.) ADDED TD URINE
Steroid
Mean
n d, p « m 0 % Recovery S.Do
^H-Preg. SO^ 10 105822
1
86.3% 2.3
^H-DHA SO, 20 104465 91c 3% 3.0
The above table shows the total recovery of tritiated Prog* 80^ and
tritiatsd DHA SD^ added to separate 25 ml aliquots of the urine pool. 
Pregnenolone 50^ was added as internal standard and the steroids were 
hydrolysed and extracted by the method described for the steroid 
sulphate estimation.
number of determinations
ScD, standard deviation
Table 12b,
RECOVERY OF Ycc-^H-PREGNENOLONE (151, 620 d.p,m,) AND
7a-^H-DHA (216, 321 d.p.m.) ADDED TO URINE
Steroid Neaii ^ Recovery S,D,
n d.p.m. '
H-Preg* 10 107044 70.6% 3.0
^H-DHA 10 148396 68.6% 4.3
The above table shows the total recovery of tritiated pregnenolone and 
tritiated DHA added to separate 25 ml aliquots of the urine pool. 
Pregnenolone was added as internal standard and the steroids were 
hydrolyzed and extracted by the method described for the steroid 
glucuronide estimation.
n - number of determinations 
S.D. - standard deviation
Sens jj: ivit ,
In the present method, 25 ml of urine were used in each 
analysis* The usual amount injected into the gas chromato­
graph and the usual setting of the attenuator allowed the 
measurement by planimetry of epiandrosterone TMS ether peak 
on the QF™1 column, when the concentration of this steroid 
was greater than or equal to 1 pg/25 ml urine. This peak 
was the last one of the quantitated steroids to emerge from 
the column, thus having a least favourable form for measure­
ment of peak height. Similarly with the procedure for 
estimation of the glucuronide fraction, the lowest value 
which could be distinguished from zero for 11(3“hydroxy- 
aatiocholanolone, whose TMSE derivative emerged last from 
the column, was 1 pg/25 ml urine. The sensitivity of both 
procedures may be increased by using a larger fraction of the 
24-hour urine specimen and less internal standard, or by 
increasing the volume of hexans solution of the final extract 
used for g.l.c. The gas-liquid chromatograph has the potential 
for a much greater sensitivity than that usually used, but the 
use of very high sensitivities puts great demands on the purity 
of the solvents. Thus, attempts were not made to further 
scale up the sensitivity of the method.
It can be concluded from all the forementioned investigations 
that these two procedures for the estimation of urinary 17-oxosteroid 
glucuronides and sulphates are very satisfactory. In order to check 
the continuing accuracy and precision of the two procedures throughout 
the study, a pooled urine sample of known 17-oxosteroid concentration 
was repeated in duplicate with each batch of analyses.
SECTION V
THE URINARY EXCRETION OF 17-OXOSTEROID 
GLUCURONIDES AND SULPHATES BY NORMAL 
MALES AND FEMALES
THE URINARY EXCRETION OF 17-OXOSTEROID GLUCURONIDES AND 
SULPHATES BY NORMAL MALES AND FEMALES.
A total number of seventy-five normal subjects were 
studied, consisting of thirty-eight males and thirty-seven 
females. They were mainly members of staff, friends and 
ambulant patients who were free from any disorders which 
might influence the levels of the 17-OS. Some of these 
disorders which have been reported to have an effect on 
the levels of 17-OS in the urine are, thyroid disease 
(Heilman et al., 1959), gout (Sonka et al., 1965), fever 
(Kappas and Palmer, 1965), obesity (Hendrikx et al., 1965; 
Lopez and Krehl, 1967), diabetes mellitus (Sonka and 
Gregorova, 1964; Charro-Salgado et al,, 1968), breast 
cancer (Bulbrook, 1972), lung cancer (Rao, 1972) and 
other endocrine abnormalities (Lorraine and Bell, 1971),
In the normal male group, the ages range from seventeen 
years through to sixty-five years. For comparative 
studies, this group of normal males was divided into 
smaller groups according to age, and the values for the 
individual males in their age groups along with the means 
and standard deviations for each group are shown in Tables 
13(a - e). In the normal females studied, the ages ranged 
from eighteen years to forty-nine years. It has been 
reported by Bulbrook and Hayward (1969) that women using 
oral contraceptives excrete less urinary 11-deoxy-17-bxo- 
steroids than women not using this form of contraceptive.
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As far as the author was able to ascertain, none of the 
normal women studied were using steroidal contraceptives*
The values for the individual urinary 17-OS sulphate and 
glucuronide levels of the individual females, and the 
means and standard deviations of the groups, are presented 
in Tables 14(a-e). From these tables, the very wide 
range of values in both sexes for all the steroids studied, 
especially for DBAS and DHAG plus EPIG, can be observed*
The overall coefficient of variation for DHA in both 
fractions in both sexes varies from 89% to 136%* These 
wide variations emphasise the difficulty encountered in 
obtaining suitable control data* To simplify the 
situation, any steroid level which was above the upper 
limit of the seventy-five normal individuals investigated 
was considered to be abnormal* Similar wide range values 
for the individual 17-OS, without distinguishing between 
the contribution made by sulphate and glucuronide fractions, 
have been reported by Keutman and Mason (1967). Despite 
this wide variation in excretion of the 17-OS by both sexes, 
males excrete significantly much greater amounts of each 
individual 17-OS than females, with the exception of 
aetiocholanolone sulphate and 11-hydroxyaetiocholanolone 
glucuronide where the mean values for males and females 
were very similar (Table 15). These higher excretion 
values are to be expected, since it is well known that 
total urinary 17-OS levels are much higher in males than 
females* Furthermore, the main precursors of the urinary
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Table 15
COMPARISON OF THE INDIVIDUAL 17-OS URINARY LEVELS OF 
NORMAL MALES AND FEMALES
Steroid Males (38)* Females (37)* p Value
Mean + s .□« Mean + S.D.
AS 1.11 + 0.96 0.34 + 0,28 <0.001
ES 0.28 t 0.23 0.21 4" 0.15 not significant
DMAS 1.68 t 1.70 0.28 4- 0.25 <0.001
EPIS 0.31 -I" 0.23 0.12 4- 0.10 <0.001
AG 4.23 t 2.88 1.62 •t" 1.11 <0.001
EG 3.25 t 2.06 1.58 ± 0.85 <0.001
DRAG + EPIG 0.58 0.79 0.11 + 0.12 <0.001
11-OAG 0.32 t 0.21 0.14 ± 0.08 <0.001
11-OEG 0.73 ± 0.43 0.49 ± 0.30 <0.01
11-OHAG 1.18 0.70 0.69 ± 0.36 <0.001
11-OHEG 0.44 ± 0.40 0.31 ± 0.23 not significant
No, of subjects in each group
17-OS; DHAS; DMA; testosterone and androstenedione, excluding 
androstenedione3 are secreted in larger amounts by males 
compared to females (MacDonald J^ l,® j 1965).
Figures 24 and 25 demonstrate that the period for maximum 
excretion of the individual 17-05 for both sexes occurs in the 
20 - 29 age group. This is in agreement with the results 
obtained by Hamburger (1948) for maximum excretion of the 
total urinary 17-OS.
The greater of the two urine fractions is undoubtedly 
the glucuronide fraction, consisting of approximately 76^ of 
the total urinary 17-OS in males and 83^ in females. A 
similar pattern is observed with the 11-oxygenatod 17-03.
In males they make up 19^ of the total urinary 17-OS but in 
females this rises to 28^ of the total. This group of C^gO^ 
(i.e. 1l-oxygenated) steroid glucuronides consists of 
approximately equal amounts of 11-oxygenated androsterone and 
11-oxygenated aetiocholanolone in both sexes, with 11-OE and 
11-OHA quantitatively the most prominent (Fig. 26a, b).
Theso graphs of the urinary excretion of the C^gO^ steroid 
glucuronides in different age groups indicate that the peak 
of 11-oxygenated androsterone excretion in males occurs in 
the 30 - 40 age range, whereas the peak of 1l-oxygenated 
aetiocholanolone excretion occurs in the 20 - 30 age range, 
with 11-OHE showing a second peak in the 40 - 50 age range.
In contrast to this, the excretion patterns of the C^^O^
steroids in women were much more uniform with all four steroids
I O'
Urinary excretion of individual 1 7 - oxosteroids  
in norm al males
Fig. 24b
Fig. 2^a
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U rinary  excretion o'f individual 17-oxosteroids
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showing maximum excretory levels in the 20 - 30 ago range, 
although it must be noted that the level for 11-OHA remained 
at this maximum into the 30 - 40 ago group. Of the whole 
glucuronide fraction, androsterone and aetiocholanolone were 
quantitatively the most important in both males and females.
In fact, these two steroids together constitute the major 
portion of the total urinary 17-OS in normal subjects. Of 
these two steroids, the more prominent in 71^ of the males 
was androsterone glucuronide, and aetiocholanolone glucuronide 
in 57^ of the females. The typical steroid glucuronide 
excretion patterns in males (A > E > DHA) and in females 
(E > A > DHA) are illustrated by the gas chromatographic 
tracings shown in Figs, 27 and 28,
Of the sulphate fraction, DHAS was quantitatively the 
most important in 53^ of the males, but only in 32j^  of the 
females. In 49^ of the females, AS was quantitatively the 
most important, and in 14^ of the normal females ES was the 
most important. The females showed no typical steroid 
sulphate excretion pattern, other than that EPIS was the minor 
steroid sulphate. The typical urinary 17-OS sulphate excretion 
pattern for males was DHA > A > EPI > E, and is illustrated in
the gas chromatographic tracing in Fig, 29,
In all cases, the total urinary 17-OS excretion (i,e, the 
sulphate plus glucuronide fraction) for males was much higher 
than that for females in the respective age groups (Table 16), 
The overall mean excretion for the thirty-eight males (mean
age 32) was 14.09 mg/24 h, whereas the mean for the females
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Table 16
COMPARISON OF TOTAL URINARY 17-05 EXCRETION IN DIFFERENT
AGE GROUPS OF NORMAL MALES AND FEMALES
Age Group Males 
Mean - So Do
Females 
Mean - S.D.
p Value
17 - 19 13.88 - 2.08 4.90 - 2.52 < 0.01
20 - 29 18,64 - 7.33 8.35 ~ 1.55 < 0.001
30 « 39 15.57 - 6.69 5,27 - 1.93 < 0.001
4- 0 "" 49 6.54 -■ 2.88 3.92 ™ 1.93 < 0.025
Entire Group 14.09 t 7.81 5.96 - 2.57 < 0.001
(mean age 31.5) was 5.96 mg/24 h. In the present report the 
ratio of the total amount of aetiocholanolone (sulphate plus 
glucuronide) to the total amount of androsterone (sulphate 
plus glucuronide) was significantly greater (p < 0.005) for 
females than for males (Table 17). The values for the e/a 
ratios in this investigation are in agreement with those 
obtained by other investigators using other methods, following 
the same pattern,with the ratio for females being greater than 
that for males (Table 18). This ratio between the amount of 
aetiocholanolone to the amount of androsterone produced is 
partly under the influence of enzymes concerned with the 
reduction of the unsaturation involving the C-5 atom of the 
17-OS precursors and partly a reflection of the relative 
amounts of the various 17-03 precursors. Both DHA and 
testosterone are converted to androstenedione, which is 
converted into equal portions of A and E by /^-reductase 
located in the liver parenchymal cells (Baulieu and 
Mauvais-Oarvis, 1964a,b). The A^-Ba-reductase is located 
in the endoplasmic reticulum (porchielli and Dorfman, 1956; 
McGuire and Tomkins, 1958) and the A ^ -5(3-reductase in the 
soluble cytoplasm of these liver cells (Tomkins, 1956),
Those enzymes both require NADPH as the hydrogen donor end 
are susceptible to various precursors and hormonal influences. 
Exogenous DHA suppresses A^-5a-reductase and a rise i.n E 
develops, much as in malignancy of adrenals with excess DHA 
formation (Kirschner and Lipsatt, 1964). Adlercreutz et al. 
(1972) reported that, following administration of DHAS in
Table 17
COMPARISON or THE RATIOS OF e/a FOR MALES AND FEMALES
Age Group Male e/a ratio 
Mean - S.D.
Female e/ a ratio 
Mean - S.D,
p Value
17 - 19 0,66 - 0.03 (3) 1.11 - 0,62 (3) not significant
20 - 29 0,73 t 0,27 (15) 0.84 t 0,29 (13) < 0.10
30 - 39 0,74 - 0.42 (10) 1.31 - 0.74 (11) < 0,05
40 - 49 0.91 i 0,55 (8) 1.33 1' 0.44 (10) < 0.10
Entire Group 0,78 - 0.39 (38) 1.14 1“ 0.55 (37) < 0.005
The number in parenthesis represents the no. of subjects in each group
Table 18
COMPARISON OF e/a RATIOS FROM DIFFERENT AUTHORS
1 2 3 4 5
Male e/a ratio 0,78 0,82 0.97 0.70 0.75
Female e/ a ratio 1.14 0,87 1,11 0.86 1,07
• 1) Present report; internal standard, alumina column
chromatography and gd.c.
2) Feher (1966); paper chromatography. Zimmermann reaction.
3) Keutmann and Mason (1967): internal standard, g. 1. c.
4) Rivera et al, (1957); silica gel chromatography, g.l.c,
5) Vestergaard (1962); column chromatography, Zimmermann 
reaction.
patients with hyperchelesterolaemia or hyperlipaernia (these 
patients tend to have low plasma and urine levels of DHAS 
and other 17-03 sulphates), normal mean levels of plasma 
17-OS sulphates and normal, mean urinary DHA and androsterone 
excretion were reached, but the urinary excretion of aetio­
cholanolone increased to a value 2 - 3  times as high as 
those seen in both young and older age groups. Contrary to 
this, Oohnsan (1968) demonstrated a significant decrease in 
the e/a ratio of 11 out of 12 normal subjects after administra­
tion of large doses of testosterone. The mean reported 
secretion rate for testosterone in females is 0.14 mg/day 
and in males 7.0 mg/day (Baulieu and Mauvais-Oarvis, 1964b; 
MacDonald et al., 1965; Horton and Tait, 1966). Thus, the1— * * f t /
difference in the secretion rates of testosterone for males 
and females might help explain the difference in the e/ a ratio 
shown by males and fomales. Further evidence to support this 
theory is given by Oohnsen (1968) in his study of castrated 
males and males with testicular insufficiency. He reported 
that the e/a ratio of this group was substantially higher than 
that for normal men. Similarly, Keutman and Mason (1967) 
reported that the e/ a ratio of two castrated males was similar 
to that of normal females.
The contribution of the C^^ steroids to the e/ a ratio, 
although probably quite small, must be taken into consideration, 
The side chain of the 11-deoxy C^^ steroids has been shown to 
strongly favour reduction of the double-bond to give 5(3 
steroids, thus metabolism of 11-deoxy C^^ steroids to urinary
17-OS will elevate the e/a ratio. Those Cy^  steroids with 
an oxygen atom at the C-11 position have been shown to favour 
5(3 and 5a orientation respectively, depending on whether this 
atom is present as a ketone or hydroxyl (Slaunwhite Bj^^al., 
1964), However, these steroids with functional groups 
at C-11 retain them on metabolism to 17-OS, and are excreted 
as 11-OHA, 11-OHE, 11-0A and ll-OE. Therefore, they have 
no effect on the e/a ratio. This ratio is also affected by 
various chemicals; for example, triiodothyronine stimulates 
/^-5a-reductase resulting in an increase in A(Kirschner et al,, 
1963), Thus, it can be seen that the e/a excretion ratio 
does not result from a straightforward conversion of andro­
stenedione into equal amounts of A and E, but from a very 
highly complex origin with many factors influencing the final 
outcome.
In this present investigation, the effect of the menstrual 
cycle on the urinary excretion of 17-OS sulphates was not 
studied. There have been numerous publications on the 
relationship of the urinary excretion of these steroids to the 
menstrual cycle (see Loraine and Bell, 1971), For the most 
part, these studies have indicated that the excretion of 
17-oxosteroids does not undergo any fluctuations which might 
be related to the different phases of the menstrual cycle. 
Determination of the 17-oxosteroids in these previous 
publications has mainly been carried out with rather unspecific 
colorimetric methods. Using specific gas chromatographic 
techniques, however, Adlercreutz et al, (1967) were able to
show that the amounts of oestrone and oestradiol in the urine 
wore significantly correlated with those of androsterone and 
aetiocholanolone during the menstrual cycle. In addition, 
these investigators found a significant correlation between 
the excretion of DHA and Sp-pregnane-Sa^ZDa-diol during the 
menstrual cycle. Using similar specific gas chromatographic 
techniques, Janne (1971) reported that statistical analyses 
revealed a significant difference between the follicular (F) 
and the luteal (L) phases of the menstrual cycle in the 
excretion of epiandrosterone (L > F, p < 0.05) and DHA 
sulphates (L > F, p < 0.05). The total urinary excretion 
of the 17-OS sulphates was also significantly (P < 0.05) 
raised during the post-ovulatory phase of the menstrual 
cycle. The mean increase in the excretion of DHAS during 
the luteal phase of the menstrual cycle was 314 ~ 207 (S.D.) 
|ig/24 h, and that of total 17-08 sulphates 617 - 158 pg/24 h. 
The mean excretions of androsterone and aetiocholanolone 
sulphates were slightly, but not significantly, greater 
during the post-ovulatory phase of the menstrual cycle. 
Although these increases in the excretion of DHAS and EPIS 
during the luteal phase are statistically significant, they 
are not great enough to affect the results from the control 
group of thirty-seven normal women studied in this 
investigation.
In the following investigation into the urinary 
excretion of 17-08 sulphates and glucuronides by patients 
suffering from different types of porphyria, the results
obtained from the seventy-five control subjects were used 
to set the higher limit for normal urinary excretion levels 
of these steroids. Levels above this upper limit were 
regarded as abnormally high.
SECTION \/I
THE PLASMA 17-OXGSTEROID SULPHATES
Aa INTRODUCTION,
These forementioned investigations established the 
occurrence of irregularities in the urinary excretion of 
17-oxosteroids in certain patients with hepatic porphyria, 
and it was these considerations which motivated the current 
studies concerning the characterization and quantitation of 
conjugated steroids in human peripheral plasma. Considerable 
data have been accumulated on the nature of steroids found in 
human blood and plasma. Migeon and Plager (1954a,b) reported 
the identification and isolation of DHA in human plasma.
This was followed by the isolation and identification of 
androsterone (Clayton et al., 1955; Migeon, 1956). These 
steroids were shown to be present in blood plasma in conjugated 
form, and the fact that these conjugates were hydrolyzed by 
continuous ether extraction at pH 0.8 suggested them to be 
sulphate conjugates. The finding that the conjugates of DHA 
and androsterone in blood were cleaved by solvolysis, described 
by Burstein and Lieberman ( 1958), further suggested conjugation 
with sulphuric acid, Baulieu (1960) reported evidence for 
the presence of aetiocholanolone in the blood of normal subjects 
in addition to DHA and androsterone. In this same paper, 
chromatographic evidence was presented showing that these 
three 17-oxosteroids were sulphate conjugated. The presence 
in blood of 17-oxosteroids in forms other than solvolyzable or 
sulphate conjugates, has also been studied and it is generally 
agreed that the amount of 17-oxosteroids in the free form is 
very low; less than 2 pg/lOO ml plasma (Kellie and Smith, 1957;
Cohn et al,, 1961; Uieland et al,, 1955; Kirschner et al,, 
1965), The concentrations of glucuronides of 17-oxosteroids 
are also reported to be relatively low (Kellie and Smith, 1957; 
Migeon, 1950; Conrad et al,, 1961; de Neve and Uermeulen, 
1965; Baulieu, 1965 ), Thus, the bulk of the 17-oxosteroids 
in the plasma consists of sulphate conjugates, and the present 
investigation was directed to the study of these 17-0X0- 
steroid sulphates in human plasma, A gas chromatographic 
method based on that described by Wang et al, (1968) was 
developed for the quantitative determination of the sulphate 
conjugates of androsterone, aetiocholanolone, DHA and epi­
androsterone in plasma.
MATERIALS AND METHOD FOR THE DETERMINATION OF THE
17-OXOSTEROID SULPHATES IN PLASMA.
Materials.
Most of the chemical reagents, radioactive compounds and 
solvents have been described previously in the materials 
section of the urinary methods. Any additional chemical 
reagents used were BDH Analar grade reagents.
For this plasma method, the ethanol and methanol were 
supplied from BDH’s Aristar range of very high purity 
chemicals.
The isopentane (2-methylbutane) was also a BDH solvent, 
specifically purified for chromatographic purposes.
The chloroform was obtained from Reeve Angelas range 
of CT solvents for chromatography.
Preparation of Chromatographic Columns.
Sephadex Columns. The Sephadex LH-20 columns provided a simple 
and non-destructive chromatographic procedure affording a 
considerable purification of the fraction of plasma extract 
containing the steroid monosulphates. The Sephadex LH-20 was 
supplied by A.B. Pharmacia, Uppsala, Sweden. This Sephadex 
LH-20 is a lipophilic derivative of ordinary Sephadex formed 
by introducing 2-hydroxy-ethyl groups in ether linkage to the 
free hydroxyl groups of the regular Sephadex. This makes 
the Sephadex LH-20 more polar, resulting in greater retardation
of polar compounds like the 17-oxosteroid sulphates. All 
the sulphate conjugated 17-oxosterüids, when chromatographed 
on Sephadex LH-20 in chloroform/methanol, 1:1,containing 0.01M 
sodium chloride, had elution volumes larger than the total 
column volume. When this solvent system was used, the major 
serum lipids were eluted in the following order; phospholipids, 
triglycerides, cholesterol esters and cholesterol (Nystdm and 
Sjovall, 1965). The latter compound appeared in the eluato 
at approximately 10 - 20 ml. The steroid monosulphates 
analysed in this work were eluted between 25 - 50 ml, and the 
fraction used for this analysis was collected between 20 - 
58 ml of effluent. The only major impurity in the fraction 
of steroid monosulphates was part of the serum cholesterol. 
Further practical and theoretical aspects of the chromatographic 
behaviour of these sulphate conjugated steroids are discussed 
in a paper by Vihko (1966),
The chloroform/methanol mixture containing 0.01M sodium 
chloride was prepared by adding chloroform to a Ü.D2M solution 
of the electrolyte in methanol. Four grams of Sephadex LH-20 
were allowed to swell in 25 ml of the forementioned solvent 
system for three hours before introduction into the glass 
columns. Each glass column consisted of a IMo. 2 sintered 
glass filter and a glass column with dimensions of 310 mm x 
10 mm topped by a 150 ml reservoir. After washing the newly 
packed Sephadex with 100 ml of the solvent mixture, the columns 
were ready for use. The steroid monosulphates were collected 
in the 20 - 58 ml fraction, after the elution of the bulk of
the serum cholesterol. The free steroids emerged from the 
column somewhat earlier than cholesterol, partly associated 
with cholesterol peak, and thus were excluded from the fraction 
analysed. Analysis of the fraction representing 20 - 58 ml 
of the effluent, with omission of the solvolysis step, did 
not result in peaks corresponding to steroid peaks found 
after solvolysis of the fraction. In several studies, the 
fraction emerging earlier than 20 ml and the fraction between 
50 - 100 ml of the effluent were solvolysed, chromatographed 
on the alumina columns and analysed by g.l.c. No peaks 
corresponding to those of the steroids in fractions between 
20 “ 58 ml of the effluent were seen in the chromatograms.
After each chromatographic run, the columns were eluted 
with 100 ml of the solvent mixture and re-used.
Alumina Columns, In addition to solvolysis and subsequent 
washing, a further purification step was needed to remove 
that part of the plasma cholesterol that was eluted with the 
steroid sulphates. Cholesterol sulphate which has been shown 
to be present in blood (Drayer and Lieberman, 1965; Moser 
et al.9 1966) also emerged in the same fraction from the 
Sephadex LH-20 as the 17-oxosteroid sulphates. ' Chromatography 
on an alumina column was found to give the necessary purification, 
The alumina, Woelm neutral activity Grade 1, was supplied 
by Camlab, Cambridge, The activity of the alumina was further 
lowered by addition of B% by weight of distilled water. The 
column was prepared by loading 4 g of this weakened alumina in
benzene into the glass column which had previously been 
plugged with ethanol washed cotton wool. The top surface 
of the alumina was protected from disturbance by the addition 
of a thin layer of acid washed sand. The 17-oxosteroids 
were collected in 13 - 23 ml fraction of the effluent.
Cleansing of Glassware.
Special attention was paid to the cleaning of the 
glassware. All the glassware was washed with methanol, 
ethanol and water; then with detergent solution in an 
ultrasonic apparatus. It was finally rinsed with glass 
distilled water and ethanol.
Choice of Internal Standard,
The conditions which must be fulfilled before the choice 
of internal standard may be regarded as a suitable one have 
been discussed, with regard to the previous urinary methods.
In this plasma procedure, pregnenolone sulphate appeared to 
fulfil all these requirements., It was eluted in the same 
fraction as the 17-oxosteroid sulphates from the Sephadex 
columns and in the same fraction as the 17-oxosteroids from 
the alumina columns; the ratios of peak heights obtained by 
g*l*c, for the control solutions and for the processed 
solutions were constant (Table 19); it was easily separable 
from the 17-oxosteroids by g.l,c. on a variety of columns and 
its peak was free of extraneous contamination. Its structure 
is very similar to DMA, which is the most labile of the 17-oxo- 
steroids but, under the conditions employed, no significant
degree of breakdown was observed for any of the steroids 
investigated. On the question of whether there is any 
pregnenolone sulphate present in plasma or not, there is 
some disagreement. In 1965, Segue reported the identifica­
tion of pregnenolone sulphate in human peripheral plasma, 
but this was not supported by Vihko (1966) who used combined 
gas-liquid chromatography and mass spectrometry to identify 
the steroid sulphates in peripheral plasma. Using these 
same techniques, Ruokonen, Laatikainen, Laitinen and Uihko 
(1972) established the presence of free and sulphate-conjugated 
pregnenolone in human testis tissue. In this study, pregneno­
lone sulphate was not detected in any plasma samples from 
either sex. When pregnenolone sulphate was not added as an 
internal standard to plasma samples from both males and females, 
no peaks were formed on the gas chromatographic trace which 
would have contributed to the peak height of pregnenolone*
Method.
Radioactivity was measured in a Packard Tri-Carb liquid 
scintillation spectrometer, model 3320.
Peripheral venous blood (5 - 10 ml) was withdrawn with 
a non-greased syringe, transferred to a lithium heparin bottle 
and centrifuged. The plasma was separated and stored at -20° 
until analysed.
A known amount of pregnenolone sulphate (5 pg dissolved 
in 0.5 ml ethanol) was added as internal standard to each 
2 ml aliquot of plasma.
Extraction of Plasma.
The plasma steroid sulphates were extracted twice with 
4 ml ethanol, and the combined extracts were stored at -2D° 
overnight. This induced further protein precipitation to 
occur. The combined extracts were then centrifuged, and 
the clear supernatant was evaporated to dryness in a water 
bath at 35 - 38° under a stream of nitrogen.
Chromatography of Plasma Extract on Sephadex LH-20.
The dry plasma extract was taken up with 2 and 1 ml 
portions of CU01M sodium chloride in chloroform/methanol, 1:1, 
centrifuged and the supernatants of the two portions pooled. 
The combined supernatants were carefully transferred on to 
the top of the Sephadex column with a pasteur pipette.
After rinsing the top of the column with 1 ml of the same 
solvent system, the column was eluted with this solvent, and 
the effluent between 20 and 58 ml was collected in a round- 
bottomed flask and evaporated to dryness using the rota- 
evaporator.
Solvolysis,
The principles of Burstein and Lieberman (1958) were used 
in arriving at the following solvolysis procedure; Firstly, 
the round-bottomed flask containing the dried steroid sulphate 
fraction was rinsed out with 5 ml of sodium chloride saturated 
0.1N sulphuric acid and then again with 10 ml of ethyl acetate, 
The two rinsings were combined, shaken for fifteen minutes,
transferred into separating funnels and separated. To the 
5 ml of sodium chloride saturated sulphuric acid another 10 ml 
of ethyl acetate were added, and the procedure repeated. The 
two acidic ethyl acetate fractions were pooled and solvolysed 
at 39° overnight. After solvolysis, the ethyl acetate phase 
was washed with 5 ml portions of 20^ sodium carbonate solution 
in water until alkaline, and then with 5 ml portions of water 
until neutral. The neutralized ethyl acetate was dried over 
anhydrous sodium sulphate and taken to dryness under a stream 
of nitrogen.
Alumina Column Chromatography.
A column with dimensions of 200 mm x 8 mm, and having a 
reservoir for solvent at the top, was closed with a plug of 
glass wool and filled partly with benzene. To this column 
4 g of alumina weakened by 8% by weight of distilled water 
were added, followed by a thin layer of acid washed sand,and 
the solvent was allowed to flow until the top of the column 
was nearly dry. The dry steroid residue was dissolved in 
0.5 ml and 2 x 2.5 ml portions of '1% ethanol/benzene, and 
added to the top of the column. The column was then washed 
with 8 ml of '\% ethanol/benzene to remove most of the 
cholesterol in the sample. Finally, the steroids were eluted 
with 10 ml of the 1^ ethanol/benzene. This fraction was 
collected and taken to dryness under a stream of nitrogen.
Preparation of Trimethylsilyl Ethers(TMSE)^
The trimethylsilyl ethers were prepared by the method of 
Thomas and Walton (1958). This procedure, described on page 
84, was followed with the exception that only 0.2 ml of super­
natant solution was added to the dry steroid residue for 
formation of the TMSE. After derivative formation, the 
trimethylsilyl ethers of the steroids were dissolved in hexane 
to give a concentration of pregnenolone internal standard of 
approximately 0.05 pg/pl. Along with the unknown plasma 
samples, residues containing equal amounts of 17-08 and 
pregnenolone wore put through the preparation procedure, to 
check TMSE formation and correct peak height ratios.
Gas-Liquid Chromatography.
The conditions for gas-chromatographic analysis of the 
steroid trimethylsilyl ethers formed from purified plasma 
extract were the same as those applied to the analysis of the 
steroid trimethylsilyl ethers formed from the purified urine 
extract after sulphate solvolysis. These conditions have 
been reported in Section IV. The same glass column packed 
with 'àfo QF-1 was also used for the plasma analyses.
Calculation of Results.
Quantitation was achieved by comparing the ratios of the 
peak heights of pregnenolone to the other 17-08, with standard 
solutions containing pregnenolone, androsterone, aetiocholanolone, 
DMA and epiandrosterone in the proportions 1:1 ; 1 ; 1:1,.(see Fig. 30
for g.I.e. tracing of standard solution). Knowing the amount 
of pregnenolone added initially to the plasma, the following 
formula was used to calculate the number of pg of each steroid 
in a 100 ml of plasma:
pg of steroid per 100 ml plasma = ™ x ^ x 100
b e g
Where :
a = peak height of 17-OS in the analytical specimen.
b = peak height of pregnenolone in the analytical specimen.
c - peak height of 17-03 in the standard.
d = peak height of pregnenolone in the standard.
B = number of pg of pregnenolone added initially to the 
plasma sample.
g = volume of plasma taken for analysis.
All the plasma values for the 17-oxosteroid sulphates in this 
thesis are expressed in terms of the concentration of free 
steroid per 100 ml plasma, unless otherwise stated.
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G. INVESTIGATION OF RELIABILITY OF THE METHOD FOR
DETERMINATION OF THE 17-OXOSTEROID SULPHATES IN PLASMA,
The quantitative determination of steroids in biological 
samples by gas-liquid chromatography depends upon the linear 
response of the detector, the stability of the derivative, 
the careful purification of the steroids prior to the final 
g.loC, analysis and the accuracy of each step in the procedure.
Linearity of Detector*
The linearity of the detector response for all five 
steroids over a wide range of values has been demonstrated 
in Fig. 23, In accordance with the report of Grundy et al* 
(1965), the detector responses were directly proportional to 
the weights of the unsubstituted parent compounds. Thus, no 
correction factors were needed in the calculation of the g.l.c, 
results.
Stability of the TMSE derivatives.
The trimethylsilyl ethers were found to be stable for at 
least three days when stored in hexane solution in a stoppered 
test-tube.
Reliability of Procedure.
When an internal standard is introduced at the commencement 
of a method, it is necessary that the ratio of its amount to 
the amount of the steroids being measured remains constant 
throughout the analytical procedure. To establish whether
this was so, aliquots were taken from a solution containing 
the sulphate esters of androsterone, aetiocholanolone, DHA, 
epiandrosterone and pregnenolone. Some of these were 
solvolysed and used as controls, and the remainder were put 
through the steps of the method. The ratio of peak heights 
obtained by g.l.c. on the QF™=1 column for the control solutions 
and for the processed solutions were compared, and the results 
are shown in Table 19. These data show that there was little 
change in the peak height ratios throughout the procedure.
Specificity.
The specificity of the method depends on the primary 
isolation on the Sephadex LH-20 column of the sulphate esters 
of pregnenolone, androsterone, aetiocholanolone, DHA and 
epiandrosterone and the subsequent separation of interfering 
substances from these solvolysed steroids by alumina column 
chromatography, partition in an ethanol-water-isopentane 
system and, finally, gas-liquid chromatography. Experiments 
with free radioactive steroids indicated that the unconjugated 
steroids were contained in the first 20 ml of effluent from 
the Sephadex column and not in the fraction containing the 
reference mono-sulphates. Analysis of the fraction representing 
20 - 58 ml of the effluent with omission of the solvolysis step 
did not result in peaks corresponding to steroid peaks found 
after solvolysis of this fraction.
Evidence for the lack of interference from solvents and 
reagents was obtained by the analysis of a mixture of synthetic
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steroid sulphates in ethanol (Table 20)« The final g.l.c* 
analysis of this mixture after TMSE formation did not show 
peaks indicating any degradation of the steroid derivatives, 
or any interference in the steroid peaks» Further evidence 
to support this was provided by the fact that the recoveries 
of these synthetic steroids in relation to the recovery of 
pregnenolone sulphate, as calculated from these peak heights, 
were approximately 100^ for all the steroids»
The plasma 17-03 TMSE derivatives were identified by 
their retention times relative to pregnenolone TMSE, which 
were identical to those of authentic standards (Table 21)» 
When authentic steroids were added to plasma for recovery 
studies, no new peaks wore formed; only the increases of 
the respective peak areas were observed. Similarly, if no 
internal standard was added to the plasma, no peaks were 
found on the gas chromatographic traces which would have 
contributed to the peak height of pregnenolone TMSE.
The shapes of the peak in both analytical and standard 
were identical, with no evidence of contamination from 
unknown peaks.
Finally, a batch of plasma samples from a pool was 
treated, as described, and analysed using both stationary 
phases, 3^ QF-1 and 3^ MGS. The data in Table 22 show that 
the differences between the results obtained when those two 
phases were used were trivial.
CD — 1 CO
X Z)' y-
ri- CD ro
hJ y
w CO o
O y- 3> y-
rh ro n O m 3=- CL tX
CO t-j X zc co en CL
p 1-1 3> ro ur
E p. co CO d  c
CD CL i_i
y X
CD CO zr
c p
n (-■ Gi­
zr 1Ü ro
H zr
o p
3 y-
m CD
ri- CO
O
CD E
y CD
CD y
X) CO
zr 0=
CD CL CL X
CL y- co CO C3 co t% X
CO CD
O CO CL
zr oi_i
CD <
'59. CD
CL
CO
"n p.
1 zr
CO
D 3 -r)
CD 3 y
O D» CD y-
CL 1 I en CO en CL CD «
CO CL CD
rl- y- -0 ■<i -0 (0 CO 0
zr zr p 3 œ cn œ 00 CL y-
CD P y- cz CD X
zr P 3 l y IX
y o 3 CT CO
CD pi CL CD y-
CO P y CL
c P y1— 1 3 CL o
rl- CL -b
CD CL
y- CD CL
CD P < CD
X X- H* y-
XT CD P ro
y 3 y- y
CD y* 3
CO y- o y
CO zr 3 3 to tso r-o to 3
CD ly p
CD. o y-
c y*
CD CD o
CO zr 3
co0) y-
3 zr
D ro
c
D E
ri- zr O'! CTi en 03 3  X
o CD X
o M -O CD P
-b CD -O CD CD 3  3
CD
-b X 1 + t + 1 + : + i -J- p
y y CO
CD o CZ) (3 co C3 co c
CD o • ly
CD co CO co CO a  CD
CD CL co CJl en CJl 0 IX
Gi­ C
ro y
y CD
D
H-
D.
XT
CD
y
zr Zü
CD ro CD
h-' n
H- -b CD C3 CD O ■59, 0
-Q I" CD CO OO CO <
C 3 "59. *59. '59. '59. CDo P y
y- I-*
*
33
Z33
- <in1-4m
o-"I
3 0n„n
n
3TJ
rnzr.im
m
*•<zH
: cro—I 1-1 
n
cn
— 4
3 0
o1—1
o
C D
C
r-"O0333
•HriQj
I
Ï C O
Table 21
RETENTION TIMES OF 17-OS TMSE DERIVATIVES RELATIVE 
TO PREGNENOLONE TMSE
Steroid
Authentic Steroids 
n X S.D* n
^lasma Steroids
X S.D.
A 12 0.501 0.005 12 0.498 0.005
E 12 0.576 0.004 12 0.572 0.005
DHA 12 0.662 0.006 12 0.669 0.007
EPI 12 0.761 0.007 12 0.758 0.007
n - number of determinations 
X - mean relative retention time 
S.D. - standard deviation
The QF“1 column was used for these analyses.
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Precision.
The precision of the method was determined by performing 
replicate analyses on two plasma pools. In Table 23, the 
results obtained in the analyses of these pools are given.
From the values given in this table, it can be seen that the 
precision of the method is similar for all of the four 
steroids determined, covering a wide concentration range.
The mean coefficient of variation was 6^ « 2.8 (S.D.) with 
a range extending from 2 - 12^.
Accuracy.
The accuracy of the described method for the quantitative 
determination of the solvolyzable conjugates of androsterone, 
aetiocholanolone, DHA and epiandrosterone in human plasma was 
tested by adding synthetic sulphate conjugates of these 
steroids into samples from plasma pools and determining the 
amount of each steroid recovered after the whole procedure.
The endogenous amount of each of these steroids was first 
determined several times in the pools used for recovery 
experiments. In Table 24, the recoveries of added steroid 
sulphate conjugates are given. The average recoveries were; 
androsterone 96^ - 8 (mean - S.D.), DHA 94^ - 7, 
epiandrosterone 9A% ~ 7.
In the current study, aetiocholanolone could not be 
detected in the fraction of solvolyzable steroids in this 
pool. The average recovery of synthetic aetiocholanolone 
sulphate added to plasma from pool A was 94^ - 7,
Table 23
REPLICATE ANALYSES OF PLASMA POOLS
Steroids
Pool n A E DHA EPI
7 13.0 ï 11# . - 37.0 - Bfo 5.5 - 3%
5 10.0 - 109^  - 35.0 - 5fa 5.2 -
B 6 72.0 ï 6^ 31.0 i 5^ 101.0 - 8 ^  83.0 - 6fa
B 8 73.1 t 2% 28.0 - 12^ 100.4 - 3% 71,2 - 6%
B 6 74.0 - 6% 30.0 - 9% 105.0 - A% 75.6 - 6%
n - number of determinations
Replicate analyses of two plasma pools. Pregnenolone sulphate was 
added as internal standard and the steroids were taken through the 
procedure, as described. The final extracts were chromatographed 
on 3% QF-1. The results are expressed as pg of free steroid per 
100 ml of plasma pool - % S.D,
Table 24
RECOVERIES OF STEROID SULPHATE C0N0ÜGATES ADDED TO PLASMA
Steroid Initial concn.
pg free steroid/ 
2 ml aliquot
pg Steroid 
sulphate 
added
Equivalent 
pg free 
steroid 
added
pg Free 
steroid 
found
%
Recovery
ANDROSTERONE 0.26 1 0,68 1.00 109
2 1.35 1.46 89
5 3.39 3.39 89
10 6.78 7.00 99
15 10.18 9.79 94
Mean Recovery 96^ - 8
AETIOCHOLANOLONE 0 1 0.68 0.62 91
2 1.35 1.25 93
5 3.39 3.02 89
. 10 6.78 6.61 97
15 10.18 10.00 98
Mean Recovery 94^ - 4
DEHYDROEPIANDROSTERONE 0.74 1 0.68 1.46 106
2 1.35 1.96 91
5 3.38 3.94 95
10 6.76 6.85 90 '
15 lO.’lO 9.85 90
Mean Recovery 94^ - 7
EPIANDROSTERONE 0.11 1 0.68 0.81 103
2 1.35 1.46 100
5 3.38 3.14 90
10 6.76 6.08 88
15 10.18 9.38 91
Mean Recovery 94^ - 7
The steroid conjugates in ethanol were added to 2 ml aliquots of plasma from
Pool A. The values are expressed as pg of the free steroid per 2 ml aliquot.
The recovery from each step in the procedure of DMAS 
sodium salt was determined using tritiated DMAS. The 
recoveries of radioactivity in the individual steps of the 
procedure were as follows: (mean - S.D.): Sephadex
column chromatography 79^ - 6; extraction + Sephadex 
column chromatography and solvolysis 74^ - 3; the total 
procedure 65^ - 3 (Table 25a).
Table 25b shows the results for the recovery of radio­
activity when tritiated pregnenolone sulphate was added to 
plasma and taken through the whole procedure. These
absolute recoveries of 62^ - 5 and - 3 for pregnenolone 
sulphate were satisfactory and agreed with that obtained for 
DMAS.
Sensitivity,
In the present method, 2 ml of plasma were used in each 
analysis. The usual amount injected into the gas chromato­
graph and the usual setting of the attenuator allowed the 
measurement by planimetry of epiandrosterone TMSE* peak on 
the QF-1 column when the concentration of this steroid was 
greater than 5 pg/lOO ml plasma. This peak was the last 
one of the quantitated steroids to emerge from the column, 
thus having a least favourable form for measurement of peak 
height. The sensitivity of the method could be increased 
by initially using a larger volume of plasma, or by increasing 
the amount of the final solution of the steroid TMSE deriva­
tives which is used for g.l.c. In the majority of analyses, 
only 20^ of the final solution was used for g.l.c.
Table 25a
RADIOACTIVE RECOVERIES AFTER ADDITION OF 34 x 10 d.p.m,
DHA-7a-^H SULPHATE SODIUM SALT TO HUMAN PLASMA
PROCEDURE 
Recovery after n
% RECOVERY 
Mean - S.D,
Sephadex Column Chromatography 6 92 ^ 4
Extraction + Sephadex Col. Chromatography 6 79 - 6
Extraction + Sephadex Col, Chromatography + 
Solvolysis , 4 74 i 3
Total Procedure 5 55 i 3
Table 25b
RADIOACTIVE RECOVERIES AFTER ADDITION OF '44 x 10 d.p.m. 
PREGNEN0L0NE-7cc-^H SULPHATE AMMONIUM SALT TO HUMAN PLASMA
RECOVERY AFTER % RECOVERY
n Mean - S.D.
Total Procedure 6 6 2 - 5
(1 II 6 6 7 - 3
n - number of determinations
As stated earlier, the gas-liquid chromatograph has the 
potential for much greater sensitivity, but the use of very 
high sensitivities puts great demands on the purity of the 
solvents and reagents used in the method. Using the solvents 
recorded in the materials section of this procedure and 5 ml 
of plasma, the lower limit of detection of epiandrosterone 
sulphate in plasma was 2 pg/100 ml.
SECTION VII
PLASMA LEVELS OF 17-OXOSTEROID SULPHATES
IN NORMAL MALES AND FEMALES
A. INVESTIGATION OF THE LEVELS OF 17-OXOSTEROID SULPHATES
IN THE PERIPHERAL PLASMA OF NORMAL MEN AND WOMEN.
As with the control group for the urinary studies, this group 
of normal subjects was made up of members of staff, friends 
and ambulant patients who were free from any disorders which 
might have an effect on the levels of the 17-OS sulphates in 
plasma. These disorders have been mentioned previously in 
Section V,
Blood samples (10 ml) were obtained from fifty-three 
normal males whose ages ranged from 4 years to 72 years, and 
thirty-nine normal females whose ages ranged from 15 years to 
51 years. These blood samples were drawn off between 9.00 a.m. 
and 11.00 a.m., transferred into heparinized tubes and centri­
fuged immediately. The plasma was stored at -20 until 
analysed. The effect of storage at -20° for different lengths 
of time on the concentrations of the individual steroids was 
investigated. This was undertaken by analysing aix fresh 
samples from a newly formed fresh plasma pool, transferring 
the remaining plasma in 2 ml aliquots into small plastic 
containers and storing at -20° for different periods of time 
up to four months. After storage at -20°, these 2 ml plasma 
samples were thawed and analysed. The results are presented 
in Table 26. Using Student's 't'-test, no statistical 
significant difference was found on comparing the concentra­
tions of the steroids in the fresh samples with those that 
had been stored at -20°. Neither was the length of time of
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storage found to have an effect on the concentrations of these 
17-OS sulphates.
Each plasma sample from the ninety-two normal subjects 
was analysed once, and approximately one-third of the samples 
were analysed in duplicate. The results are presented in 
Tables 27a - 27e for females, and in 28a - 28h for males.
Figure 31 shows a typical g.l.c. tracing of the steroid 
sulphates from the plasma of a normal male. To study the 
possible effect of age on the concentration of the 17-OS 
sulphates, the normal subjects were divided into the following 
age groups:
1) age 0 - 9 years - 3 males, 0 females
2) age 10 - 19 years - 2 males, 5 females
3) age 20 - 29 years - 19 males, 12 females
4) age 30 - 39 years - 7 males, 9 females
5) age 40 - 49 years - 12 males, 8 females
6) age 50 - 59 years - 6 males, 4 females
7) age 60 - 69 years - 3 males, 0 females
8) age 70 - 79 years - 1 male, 0 females.
The mean levels and standard deviations of each individual 
steroid were calculated for each group. The maximum mean 
levels of all four steroids measured mostly occurred in the 
20 - 29 years age-group in both sexes, and thereafter they all 
showed a significant decline with increasing age. These 
findings agree with those reported by Migeon et al. (1957),
De Neve and Vermeulen (1965), Feher et al. (1966) and Wang 
et al. (1968). The concentrations of the four 17-05 sulphates
Table 27a
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL FEMALES
((ig. Free Steroid/lOO ml Plasma)
Subject Ago A E DMA EPI TOTAL
1 16 12.2 2.1 51.9 , 9.2 75.4
2 16 43.3 0 89.8 14.0 147.1
3 17 23.1 3.6 69.2 7.6 103.5
4 18 18.9 5.2 46.8 9.3 80.2
5 19 55.6 1.9 66.2 11.2 134.9
6 19 21.8 4.6 51.0 9.6 87.0
Range 16-19 12.2-55.6 0-5.2 46.8-89.8 7.6-14.0 75.4-147.1
Mean 17.5 29.1 2.9 62.4 10.1 104.6
S.D. 1.3 16.6 1.9 33.6 2.2 47.6
Table 27b
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL FEMALES
(jig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
7 20 121.4 4.2 160.4 30.8 316.8
8 20 79.3 7.5 109.6 23.6 220.0
9 20 194.2 10.0 211.5 46.4 462.0
10 20 129.0 11.9 145.8 39.2 325.6
11 22 40.6 13.4 94.3 9.7 158.0
12 22 28.4 10.2 78.1 11.1 127.8
13 25 34.9 10.8 91.0 9.7 146.4
14 26 45.9 5.9 140.7 16.1 208,5
15 26 23.3 3.7 74.2 16.5 117.7
16 26 68.5 6.3 165.7 22.4 262.9
17 28 10.5 0 62.2 9.6 82.3
IB 29 40.2 5.6 89.6 . . 13.6 148.0
Range 20-29 10.5-194.2 0-13.4 62.2-211.5 9.6-46.4 82.3-462.0
Mean 23.6 68.0 7.4 118.5 20.9 214.6
S.D. 3.3 54.4 3.9 45.6 12.1 110.0
Table 27c
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL FEMALES
(fig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI
"
TOTAL
19 30 43.6 5.9 46.4 14.5 110.4
20 30 39.3 1.5 94.0 20.3 155.1
21 31 4.5 0 41.9 8.8 55.2
22 33 25.6 2.0 42.3 13.6 83.5
23 35 36.6 3.8 49.2 15.0 104.6
24 36 22.3 3.4 58.9 5.2 89.8
25 30 44.2 3.6 ■ 98.6 13.9 160.3
26 39 16.6 4.2 46.2 11.3 78.3
27 39 50.6 6.8 89.9 13.9 161.2
Range 30-39 4.5-50.6 p-6.8 41.9-98.6 5.2-20.3 55.2-161.2
Mean 34.0 31.4 3.4 63.0 12.9 110.9
S.D. 3.5 15.1 2.1 25.2 4.2 39.2
Table 27d
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL FEMALES
(pg Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
28 40 16.5 7.0 18.1 10.5 52.1
29 41 32.4 0 59.8 2.6 94.8
30 42 41.9 1.8 50.6 3,0 97.3
31 44 16.1 4.2 46.4 10.3 77.0
32 46 11.1 0 26.1 0 37,2
33 47 19.8 0 30.2 2.0 52.0
34 48 22.6 0 84.9 19.2 126.7
35 49 5.0 2.6 16.8 10.8 35.2
Range 40-49 5.0-41.9 0-7.0 16.8-84.9 0-19.2 35.2-126.7
Mean 44,6 20.6 1.9 41.6 7.3 71.5
S.D. 3.3 11.7 2.5 23.4 6.4 32.8
Table 27e
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL FEMALES
([ig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
36 50 35.7 4.8 69.3 10.3 120.1
37 50 18.8 8.2 21.7 11.0 59.7
38 51 5.1 0 8.6 2.0 15.7
39 51 8.0 0 12.9 4.6 25.5
Range 50-51 5.1-35.7 0-8.2 8.6-69.3 2.0-11.0 15.7-120.1
Mean 50.5 16,7 3.2 28.1 6.9 55.2
S.D. 13.8 4.0 27.9 4.3 47.1
Table 28a
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(pg Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI
-------------
TOTAL
1 4 3.6 0 0 9.1 12.7
2 7 11.6 0 8.0 5.4 25.0
3 10 35.8 5.7 59.8 21.2 122.5
Range 4-10 3.6-35.8 0-5.7 0-59.8 5.4-21.2 12.7-122.5
Mean 7 17.0 1.9 22.6 11.9 53.4
S.D. 3 16.7 3.3 32.5 8.3 60.2
Table 28b
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES -
(pg Free Steroid/lOO ml Plasma)
Subject Age A E DHA ■ EPI TOTAL
4 13 53.5 0 44.9 20.2 118.0
5 14 65.4 7.7 95.8 23.2 192.1
Range 13-14 53.5-65. 4 0-7.7 44.9-95.8 20.2-23.2 118.0-192.1
Mean 13.5 59.5 3.9 70.4 21.7 155.0
S.D. 0.7 8.4 5.4 36.0 2.1 52.4
Table 28c
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(|ig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
6 22 101.9 5.7 276.8 21.2 405.6
7 22 108.4 5.6 322.0 33.5 469.5
8 22 98.0 3.3 181.1 33.2 315.6
9 23 28.0 0 58.8 11.2 98.0
10 23 38.9 0 112.4 7.0 158.3
11 23 69.1 9.5 355.5 17.8 451.9
12 24 31,6 0 72.1 15.4 119.1
13 24 96.5 21.3 144.7 15.2 277.7
14 24 72.6 6.7 217.3 15.5 312.1
15 25 108.7 13.3 204.6 38.9 365.5
16 25 32.1 0 110.3 6.8 149.2
17 25 76.0 17.0 158.2 14.1 265.9
IB 26 34.3 0 176.6 16.8 227.7
19 27 65.4 2.9 154.8 24.6 247.7
20 27 92.8 9.0 168.2 14.7 284,7
21 28 37.9 0 70.2 11.2 119.3
22 28 61.1 9.6 176.2 7.3 254.2
23 28 62.3 9.4 164.3 11.9 247.9
24 28 113.5 7.8 350.5 30.0 501.8
Range 20-29 28.0-113.5 0-21.3 58.8-355.5 6.8-38.9 98.0-501.8
Mean 24.9 69.9 6.4 182.9 18.2 277.5
S.D. 2.2 29c8 6.2 88.8 9.6 120.7
Table 28d
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(jig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
25 32 39.9 3.4 97.1 13.9 154.3
26 35 50.7 6.2 108.9 8.9 174.7
27 35 49.6 15.0 107.3 8.7 181.6
28 34 87.7 9.3 141.7 13.9 244.6
29 34 81.1 9.2 • 152.1 15.9 259.3
30 37 18.1 6.0 18.1 12.3 54.4
31 37 55.5 7.0 110.4 23.9 , 196.8
Range 30-39 18.1-87.7 3.4-15.0 18.1-152.1 8.7-23.9 54.5-259.3
Mean 34.8 53.5 8.0 105.1 13.9 180.6
S.D, 1.7 22.0 3.7 43.3 5.1 67.2
Table 28e
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(jig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
32 42 50.6 10.2 80.3 5.8 146.8
33 43 39.5 4.3 33.6 14.0 94.4
34 44 39.7 0 98.1 11.9 149.4
35 45 20.6 5.7 44.9 14.0 85.2
36 45 51.9 0 86.2 15.2 163.3
37 47 30.7 9.5 99.0 16.5 155.7
38 47 18.5 0 26.8 15.8 62.1
39 48 58.2 0 107.1 13.6 178.9
40 48 31.0 0 95.7 14.2 140.9
41 49 20.6 0 38.9 14,9 74,4
42 49 39.4 0 45.6 15.2 100.2
43 49 41.6 0 107.3 18.2 167.1
Range 40-49 18.5-58 .2 0-10.2 26.8-107.3 5.8-18.2 62.1-178.9
Mean 46.5 36.9 2.5 72.0 14.4 126.5
S.D. 2.7 12.9 3.9 31.2 3.2 40.5
Table 28f
LEVELS or PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(|ig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
44 51 22.3 6.0. 17.3 12.3 57.9
45 51 76.9 4.4 132.0 25.0 238.3
46 52 I, 20.2 0 52.9 2.8 76.0
47 52 29.3 0 58.7 ■ 2.8 91.0
48 52 32.1 0 56.6 5.6 94.0
49 59 20.6 5,9 24.4 15.3 66.3
Range 50-59 20.2-76.9 0-6.0 17.3-132.0 2.8-25.0 57.9-238.3
Mean 52.8 33.6 2.7 57.0 10.6 103.9
S.D, 2.8 21.8 \ 3.0 40.8 8.7 67.3
Table 28g
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(|ig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
50 61 31.8 3.7 75.3 11.3 122.1
51 62 17.3 0 58.3 13.2 88.8
52 69 5.6 0 0 8.4 14.0
Range 60-59 5.6-31.8 0-3.7 0-75.3 8.4-13.2 14-122.1
Mean 64.0 18.2 1.2 44.5 12.0 74.8
S.D. 4.3 13.1 2.1 39.5 10.5 55.4
Table 2Bh
LEVELS OF PLASMA 17-OXOSTEROID SULPHATES IN NORMAL MALES
(|ig Free Steroid/lOO ml Plasma)
Subject Age A E DHA EPI TOTAL
Overall
Range 4-72 3.6-113.5 0-21.3 0-355.5 2.8-38.9 14.0-501.8
Overall
Mean 36 48.4 4.5 109.1 15.2 177.9
S.D. 15.6 29.5 5.1 83.2 7.5 115.5
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were shown to vary widely among different normal subjects. 
The plasma concentrations of the individual 17-OS sulphates, 
which have been reported by other authors, have also shown 
considerable variation, and generally these values for the 
concentrations of the sulphate conjugates of androsterone, 
aetiocholanolone, DHA and epiandrosterone are in agreement 
with those previously reported (Table 29).
Table 29
COMPARISON OF REPORTED CONCENTRATIONS OF 17-OS SULPHATES
IN PERIPHERAL HUMAN PLASMA
Author(s) n A E DHA EPI TOTAL
Present Report 53M 4-108 0-21 0-355 2-33 12-502
39F 4-194 0-13 8-212 0-20 15-462
Wane et al. 
(1968)
41M 4-104 - 12-392 - -
51F 5-129 10-248
Uihko
(1956)
62M 2-107 - 19-323 0-32 -
54F 0-72 0-188 0-17
Baulieu
(1965a)
6M 0-23 0-23 40-150 - -
4F 0-85 0-8 36-130
De Neve and 
Vermeulen
9M 17-53 3-25 40-73 - 53-260
(1965) 3F 26-30 5-24 49-65 - 72-88
Oertel and 
Kaiser
6M 24—64 7-41 67-158 - -
(1962) 6F 23-46 16-34 44-106 — -
The values are expressed as pg of the free stereid/lOO ml plasma,
n - number of subjects studied. 
M - indicates male subject.
F - indicates female subject.
B. EFFECT OF AGE AND SEX ON THE CONCENTRATION OF THE
17-OXOSTEROID SULPHATES IN PLASMA.
The concentrations of all the steroid sulphates analysed 
significantly decreased with advancing age in both sexes.
It must be noted, however, that there were large variations, 
and in the youngest and oldest age groups of both sexes there 
were subjects having roughly similar plasma steroid concentra­
tions. The statistical significance of this decline of 
concentration with age was variable from steroid to steroid 
and between the sexes (Table 30). The most significant 
decline was shown by AS (p < 0.001) and DHAS (p < 0.005) in 
males, and by EPIS (p < 0,005) in females. The changes in 
the plasma levels of these 17-OS sulphates are in accord with 
the results reported earlier in this thesis for the urinary 
excretion pattern of these steroids.
Sex differences in the peripheral plasma concentrations 
of some of these 17-OS sulphates have been reported by De Neve 
and Vermeulen (1965) (total 17-OS), Feher et al. (1966) (DHA 
and a ) and Wang et al. (1968) (DHA), the values for males 
being higher. In this present study, the differences in the 
concentrations of the steroids between the sexes were 
statistically significant only for DHA (p < 0.01) and for the 
total plasma 17-OS sulphate fraction (p < 0.025), when the 
entire groups of males and females were compared. When the 
concentrations of the steroids from the individual age groups 
were compared between the sexes, the differences were variable,
Table 30
STATISTICAL SIGNIFICANCE OF THE DECLINE WITH INCREASING
AGE IN THE CONCENTRATIONS OF EACH OF THE STEROIDS
Steroids A E DHA EPI TOTAL
Male P < 0.001 p < 0.02 p < 0.005 p < 0.05 p < 0.005
Female P < 0.025 p < 0.02 p < 0.02 p < 0.005 p < 0.02
In Table 31, the significance criteria for the differences 
between the two sexes in different age groups are given.
In each case where there was a significant difference between 
the sexes, it was due to the higher mean concentration of the 
steroid in the male group. From this table, it can be 
observed that the differences of the steroid concentrations 
between the sexes were more marked in the middle age groups 
rather than in the younger or older groups. For instance, 
the levels of DHAS for males were significantly greater than 
those for females throughout the 20 - 49 years age range, 
but in the youngest and oldest group there was no significant 
difference. However, it must again be noted that the 
variations in the concentrations are very large in both sexes, 
and a great deal of overlap exists.
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Ce INVESTIGATION OF DIURNAL VARIATION IN THE PLASMA
CONCENTRATIONS OF THE 17-OXOSTEROID SULPHATES.
The concentrations of the 17-OS sulphates were examined 
in morning and evening plasma samples from twelve of the 
normal male control subjects. The first specimen of blood 
was drawn off at 9.00 a.m. and the evening specimen at 5.00 p.m. 
The variations in the plasma levels are shown in Table 32.
Due to the large individual variations of the concentrations 
of the steroids in these control subjects, it was not possible 
to apply a statistical test to the average levels obtained in 
the morning and evening samples. For this reason the various 
steroid values obtained in one subject were compared to his 
9.DO a.m. values, and the percentage increase or decrease of 
the 5.GO p.m. concentrations of the steroids were calculated.
In Table 32, increases in the steroid level in the evening 
sample are indicated by a + sign, and decreases by a - sign. 
Examination of this Table reveals no conclusive pattern in the 
plasma level of any individual steroid. Eight out of the 
twelve subjects demonstrated a decrease in the concentration 
of AS, ranging from 2.2% to 31%, with a mean of 12.5% - 5.7 
(S.D.). In the remaining four normal subjects, the concentra­
tion of AS rose with a mean value of 5.7% - 5.3 (S.D.). The
concentration of DHAS fell in nine out of the twelve subjects 
by a mean value of 6.7% - 5.9 (S.D.). The mean rise registered 
in the other three subjects was 17.1% - 8.6 (S.D.). These 
results are not in agreement with those reported by other workers,
COMPARISON OF THE CONCENTRATIONS OF THE 17-OXOSTEROID SULPHATES 
IN MORNING AND EVENING PLASMA SAMPLES
Subject Age
A
9 a.m. 5 p.m.
E
9 a.m. 5 p.m.
DHA
9 a.m. 5 p.m.
EPI
9 a.m. 5 p.m.
1 22 104.5 96.8 2.6 0 282.4 280.6 23.6 22.0
Difference -7.4% -100% - 0.6% -6 • 8%
2 23 39.1 37.6 0 0 114.0 110.7 7.0 7.0
Difference -3.8% ■- -2.9% 0%
3 24 96.5 107.6 21.3 26.3 144.7 118.3 15.2 11.0
Difference +11.5% +23.5% -18.2% -22.4%
4 27 92.8 66.1 9.0 8.5 168.2 162.2 14.7 16.4
Difference -28.8% -5.6% -3.6% +11.6%
5 28 
Difference
61.1 61.4 
+0.5%
9.6 10.6 
+10.4%
176.2 212.2 
+20.4%
7.3 9.2 
+26.0%
6 28 
Difference
37.9 42.0 
+10.8%
0 3,5
+100%
70.2 86.8 
+23.6%
11.2 12.7 
+13.4%
7 28 
Difference
118.7 101.9 
-14.1%
12.7 5.7
-55.1%
276.8 249.0 
-10.0%
21.2 15.5 
-26.9%
8 28 
Difference
113,5 110.0 
-3.1%
7.8 24.5
+214%
350.5 311.8 
-T1.0%
30.0 23.5 
-21.7%
9 34 
Difference
78.7 81.8 
+4%
9.3 9.2
-10.7%
141.7 152.1 
+7.3%
13.9 15.9 
+14.4%
10 35 
Difference
50.7 49.6 
-2.2%
6.2 15.0
+141.9%
108.9 107.3 
-1.5%
8.9 8.7 
-22.5%
11 42 
Difference
56.1 50.6 
-9.8%
11.0 10.2
-7.3%
82.6 80.2 
-2.9%
5.9 5.8 
-16,9%
12 52 
Difference
29.3 20.2 
-21.0%
0 0 58.7 52.9 
—9.9%
2.8 2.8 
-0%
Results expressed as pg free steroid/lOO ml plasma. The differences are 
expressed as a percentage of the concentration at 9.00 a.m.
Laatikainen and Uihko (1968) reported that the plasma concen­
trations of monosulphated DHA and androsterone, mono- and 
disulphated androst-5-ene-3p,17[3~diol and pregn-5-ene-3,20a- 
-diol have a diurnal variation which is similar for all of 
these conjugates, and follows a pattern in which the lowest 
plasma concentrations were observed at midnight or at 8.00 a.m. 
and the highest at noon or at 4.00 p.m. In contrast to this, 
Migeon et al. (1957) found that the highest concentrations of 
DHAS and AS were observed in the morning, with a decrease 
during the day. A similar pattern has been observed for the 
plasma concentration of cortisol by various researchers, 
including Migeon et al. (1962), Martin et al. (1963) and 
Silverberq et al. (1968). Using a frequent sampling technique, 
Weitzman et al. (1971) reported that the period during the 
three hours before awaking and the first hour of wakefulness 
represented the most intense time of adrenal-cortical activity 
and accounted for nearly half of the total cortisol secreted 
over 24 hours. In the following investigations pf the 
concentrations of these 17-OS sulphates in the plasma of 
normal and porphyric patients, the blood samples were drawn 
off in the morning whenever possible.
D. INVESTIGATION OF THE EFFECT OF THE MENSTRUAL CYCLE ON
THE PLASMA CONCENTRATIONS OF THE 17-OXOSTEROID SULPHATES.
The effect of the menstrual cycle on the levels of the 
sulphates of androsterone, aetiocholanolone, DHA and epiandro­
sterone in the plasma of four normal women with regular 
menstruation was investigated. Blood samples were obtained 
at 9.00 a.m. on various days throughout the complete menstrual 
cycle. The heparinized blood was centrifuged immediately and 
the plasma stored at -20° until the specimens were analysed 
in random order. The results are presented in Table 33. As 
repeatedly demonstrated, there were great differences.in the 
peripheral plasma concentrations of these compounds between 
individual subjects. However, in the same subject the 
concentrations of the individual steroids were very similar 
in the samples collected throughout the cycle and, using 
Student’s ’t’-test, no statistically significant difference 
in the levels of the steroids in the different phases of the 
menstrual cycle could be observed. Therefore, it was concluded 
that the concentrations of the plasma 17-OS sulphates are not 
dependent on the phase of the menstrual cycle. The biphasic 
pattern in the peripheral plasma concentrations of DHAS 
reported by Kumari et al. (1969) was not observed. The 
results obtained in this investigation were confirmed in 1971 
by Laatikainen and Vihko, who reported that the concentrations 
of AS, DHAS and EPIS determined on the 10th and 22nd days of 
the menstrual cycle did not differ significantly.
These assiduous investigations into the levels of the 
neutral 17-oxosteroid conjugates in the urine and the plasma
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of a large number of normal individuals, the effects of age, 
sex, time of day and the phase of the menstrual cycle on these 
levels, established a firm background of knowledge of the 
normal levels and excretory patterns of these 17-OS conjugates.
I
This provided a strong spring-board for researching into the 
abnormal deviations in steroid excretion which have been 
reported in patients suffering from acute intermittent 
porphyria and the extension, of these investigations to include 
patients suffering from other types of porphyria.
SECTION VIII
STEROIDAL STUDIES IN PATIENTS
WITH HEPATIC PORPHYRIA
A. INTRODUCTION.
The subjects of this study consisted of fifty-five 
patients suffering from several different types of hepatic 
porphyria, who were obtained from various parts of the United 
Kingdom. There were thirty-four patients with acute inter­
mittent porphyria, fourteen patients with porphyria cutanea 
tarda (symptomatica), five patients with hereditary copro­
porphyria and two patients with variegate porphyria. The 
diagnosis of the type of porphyria in every case was based 
on the criteria and classification given by Goldberg (1971).
The urinary 17-OS sulphate and glucuronide levels and the 
17-08 sulphate levels in the plasma were estimated in these 
male and female porphyric patients and compared with the 
corresponding levels obtained for normal males and females.
For many of these patients, it was only possible to obtain one 
complete 24-hour urine specimen, and thus statistical data is 
not available for every patient. In the event of steroid 
estimations being made on a single urine specimen, elevations 
were noted if the level of the steroid was greater than that 
found for the upper limit of the normals of that particular 
age group. It was also not possible to obtain a plasma sample 
from every patient whose urine was investigated. In addition 
to these steroid studies, the urine porphyrins and precursors 
of these porphyric patients were estimated.
Measurement of urinary $-aminolaevulic acid, porphobilinogen 
and porphyrins.
Urinary 6-aminolaevulic acid (ALA) and porphobilinogen (PBG)
were measured in 24-hour collections of urine by the method 
of Mauzerall and Granick (1956). Urinary uroporphyrin and 
coproporphyrin were measured on samples of the same collections 
of urine by the method of Rimington (1961). These analyses 
were carried out in the Department of Materia Medica, Stobhill 
General Hospital, Glasgow, by G.G, Thompson, by whose permission 
I produce these results. Normal human levels of urinary 
porphyrins, ALA and PBG have been recorded by Goldberg (1966) 
and Moore et al. (1972a).
B. STEROIDAL STUDIES IN FEMALES WITH ACUTE INTERMITTENT
PORPHYRIA.
The total number of female acute intermittent porphyric 
patients studied was twenty-three, of whom only four were in 
attack, eighteen were in remission for periods ranging from 
two years to twenty years and one was a latent AIP. Estimation 
of the steroids in the plasma and urines of these porphyric 
patients revealed fifteen patients who had abnormally high 
concentrations of several of the 17-OS conjugates either in 
the plasma or the urine (Tables 34a and 34b). In most of 
these subjects, these abnormally high concentrations of steroids 
were observed in both the urine and the plasma. Unfortunately, 
in some of the cases it was not possible to procure both a 
plasma specimen and a 24-hour urine specimen*
The most striking steroid abnormalities detected in the 
majority of the patients were the increased excretions of DHA 
and aetiocholanolone sulphates and aetiocholanolone glucuronide 
in the urine, and the elevated levels of DHAS in the plasma. 
Figures 32 and 33 depict typical g.l.c. traces of urinary and 
plasma steroids from female patients with AIP. In the g.l.c, 
trace of the urinary sulphate fraction in figure 32, the large 
peak (c) due to excessive amounts of DHA can be observed. 
Similarly, in figure 33, the large peak (b) is due to excessive 
quantities of aetiocholanolone sulphate in the plasma.
Increases in the excretions of androsterone and epiandrosterone 
sulphates, and androsterone and 11-oxy-17-0S glucuronides were
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detected to a lesser extent in the urines of some of the 
patients. Apart from DHAS, elevations in the levels of AS, 
ES and EPIS were observed in the plasma of several patients, 
especially those of the 20 - 30 age group.
Use was made of Student's 't' test in the comparison of 
the ratio of the urinary aetiocholanolone to urinary andro­
sterone (e/ a ) in the entire female AIP group with this ratio 
in the entire normal female control group. This e/ a ratio 
was found to be significantly greater (p < 0.005) for the 
porphyries than for the normals (Fig. 34a). Furthermore, 
the mean value of this ratio for the three patients who were 
suffering from an attack was not only significantly greater 
(p < 0.001) than that found for normals but was also, 
significantly greater (p < 0.005) than that ratio found for 
the patients in remission. Similar results were found on 
comparing these ratios for the total number of males and 
females with AIP in attack with those in remission and the 
total normal control group (Fig. 34b),
The ages of the four females in attack ranged from 
twenty-three to thirty-two years, the youngest of whom was 
Case 3, Analyses of six complete 24-hour urine specimens 
and six^plasma samples from this patient resulted in the 
detection of significant elevations of urinary ES (p < 0.001). 
DHAS (p < 0.001), EPIS (p < 0.001) and plasma AS (p < 0.005), 
ES (p < 0.001), DHAS (p < 0.001) and EPIS (p < 0.001). No 
elevations in the levels of any of the steroid glucuronides 
or in the total urinary excretion of 17-OS conjugates were 
detected. In fact, in this patient. Case 3, the urinary 
excretions of the glucuronide conjugates of androsterone and 
aetiocholanolone were significantly lower (p < 0.001 for both
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steroids) than those of normal females in this 20 - 29 age 
group. In contrast to this, Cases 4 and 8 who were investi­
gated during an attack, showed elevations of the total urinary 
17-OS excretion and elevations in the levels of several of 
the glucuronide conjugates. The excretion pattern of the 
urinary sulphate conjugates in Case 4 was very similar to 
that in Case 3, both showing elevations of ES, DHAS and EPIS.
In addition, Case 4 alse excreted elevated amounts of aetio­
cholanolone glucuronide and DHA glucuronide plus epiandro­
sterone glucuronide. In the plasma of Case 4, unlike Case 3 
where all four sulphates estimated were raised, the only 
elevation observed was in the concentration of DHAS. . 
Elevations of a similar magnitude in the steroidal levels 
in urine and plasma were also detected in Case 8, the third 
patient investigated in attack. In this 32-year old female, 
all four urinary steroid sulphates estimated were elevated 
(DHAS by five times the upper limit of the normal level for 
that age group); in the glucuronide fraction, aetiocholanolone 
was elevated, and in the plasma,AS and DHAS were both elevated. 
Case 5 was also investigated during an attack. This young 
woman,aged 28 years, had a major attack of AIP five years 
previous to these steroidal studies. From time to time since 
then she has suffered from very minor exacerbations when her 
urine took on the characteristic port-like colour common to 
many porphyries, and she experienced some mild abdominal pain. 
Complete 24-hour urine specimens were collected during 
remission and during a period when her urine was discoloured.
In all the urines analysed, it was observed that the levels of 
DHAS, EPIS, EG and total 17-OS were greater than the upper
limits found in normal female subjects of that age group, but 
only in the discoloured urine were the levels of 11-oxoaetio- 
cholanolone and 11-hydroxyaetiocholanolone elevated. The 
levels of the urinary steroids determined for the discoloured 
urines were generally greater than those found for the clear 
urines, but in both groups the elevations of DHAS, EPIS, EG 
and total 17-OS were very significant with p < 0.001, Lesser 
significant elevations were also observed in the levels of 
the conjugates of 11-OHE (p < 0.025), 11-OHA (p < 0,005),
11-OE (p < 0.01), 11-OA (p < 0.05) and DHA plus EPI (p < 0.02), 
The e/ a ratio was calculated for both the discoloured and the 
clear urines, and it was found that the ratio was at its 
maximum for the discoloured urine, fell to a mean value of 
1.15 for the clear urines, which is still significantly 
greater (p < 0.001) than that found for normal females in 
that same age group. In the discoloured urines, excessive 
quantities of ALA, PBG, uroporphyrin and corporphyrin were 
found, and it was these urines which had the highest values 
of e/ a ratio. In fact, fairly good linear correlations were 
obtained between the values of the e/ a ratio and the levels 
of the perphyrins and precursors in the individual urines.
As the value for the ratio fell, the corresponding levels of 
ALA, uroporphyrin, coproporhyrin and PBG decreased with 
correlation coefficients (r) of 0,78, 0.84, 0,81 and 0,75 
respectively (Fig. 35).
These four patients, who were in attack, all excreted 
excessive quantities of uroporphyrin, coproporphyrin, ALA and
The correlation be tween*  the urinary ratio of E/A and the 
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PBG in their urine.
These steroid abnormalities were not confined to those 
patients suffering from an attack but were also found in 
patients in various stages of remission. An example of this
is Case 1, who is a young woman aged 26 years. She was 
admitted to hospital in 1966 with a severe attack of AIP,
The attack had apparently been precipitated after her attendance 
at a party where she had taken alcohol for the first time, but 
it later transpired that she had also taken several barbiturate 
tablets for symptomatic relief early in her illness. She 
made a gradual recovery from this attack and six weeks later 
was discharged from hospital, but was readmitted two years 
later with another acute attack with abdominal pain, vomiting 
and constipation. Once again, she made a gradual recovery 
and since then she has remained entirely symptom free.
Levels of her urinary 17-OS conjugates were reported by 
Goldberg at al, (1969) eight months after her last attack. 
Significant elevations of EG, DHAG plus EPIG, DHAS and EPIS 
were found. Two years later, the urinary levels along with 
the plasma levels were re-examined by the author. During 
this period, no attacks are known to have occurred. The 
urinary levels of ES, DHAS, EPIS and total 17-OS excretion 
were found to be elevated above the normal limit. No 
elevations were observed in the glucuronide fraction of the 
urine. Investigation of the plasma of this subject revealed 
elevations in the concentrations of all four 17-OS sulphates. 
Particularly striking was the massive increase of aetiocholanolone
sulphate which usually occurs in normals at concentrations of 
0 - 1 2  pg/lGG ml of plasma, but in this patient had increased 
to 435 pg/lGO ml of plasma. Although this patient had been 
symptom-free for the last four years, she still excreted 
excessive quantities of ALA, PBG, coproporphyrin and uro­
porphyrin in the urine.
Case 2 is an identical twin of Case 1, and was also 
admitted to hospital in 1966 with a similar but less severe 
attack. She also had consumed alcohol at the same party for 
the first time and, like her sister, had also taken barbiturate 
for symptomatic relief early in her illness. She made a 
gradual recovery and since then has not experienced any further 
symptoms. Goldberg et al, (1969) reported the levels in the 
urine of her 17-OS conjugates, two-and-a-half years after her 
last attack. They found significant elevations in the levels 
of EG, DHAG plus EPIG and EPIS, but the levels were not as 
high as those levels found in her sister. Examination of a 
urinary specimen from this patient in 1971 by the author 
resulted in the detection of elevations in the levels of 
aetiocholanolone, DHA and epiandrosterone in the urinary 
sulphate fraction but no elevations were observed in the 
glucuronide fraction. In fact, the glucuronide levels were 
noted to be lower than the levels of the normal subjects of 
this age group. The total urinary excretion of the 17-GS 
conjugates was also found to be just below the normal lower 
limit for the 2G - 29 age group. Analysis of this patient’s 
plasma revealed increased levels of all the 17-GS sulphates 
but not to such high levels as those of her twin sister.
Those lower levels of steroids in this patient compared to 
her sister were also associated with a clinically less severe 
involvement of the disease and a lower level of urinary 
excretion of porphyrins and precursors, although these levels 
are still much greater than those of normal subjects.
One latent acute intermittent porphyric patient. Case 21, 
was studied. This patient was a 52-year old woman who 
suffered from hypertension. Elevated levels of coproporphyrin 
and uroporphyrin were found in her urine but the ALA and PBG 
levels were normal. No abnormalities were detected in the 
17-05 excretion in the urine of this patient.
All the remaining patients with AIP were in various 
stages of remission ranging from two years to twenty years, 
and presented a wide range of steroid abnormalities. Two 
of these patients. Cases 10 and 13, excreted excessive 
quantities of all four porphyrins and precursors. Both also 
excreted excessive quantities of total 17-05 conjugates in the 
urine. In Case 10, elevations were not detected in the 
urinary sulphate fraction or in the plasma but were confined 
to the glucuronide fraction, where aetiocholanolone and all 
four 11-oxy-17-0S were found to be raised. Similar elevations 
of the 11-oxy-17-05 were observed in Case 13, This patient 
also had increased urinary excretion of both DHA5, DHAG plus 
EPIG and increased concentration of DHA5 in the plasma.
Eight patients out of the entire group did not display 
any elevations of the urinary excretion of the 17-05 conjugates 
or of the concentrations of the 17-05 sulphates in the plasma.
All of these patients, with the exception of one who was a 
latent AIP, were in remission. Of these eight, three patients 
(Cases 6, 18 and 19) excreted elevated amounts of ALA and PBG, 
two (Cases 14 and 21) excreted elevated quantities of urinary 
porphyrins and three (Cases 11, 12 and 17) excreted normal 
amounts of uroporphyrin, coproporphyrin, ALA and PBG.
Seven patients from the entire group had normal excretions 
of the porphyrins and precursors and, as just mentioned, three 
of them had normal steroid levels. It might be noted that 
the only abnormality observed in the steroid levels of Case 
22 was the slight elevation beyond the upper limit of normal 
of the 11-oxo-aetiocholanolone glucuronide. Of the three 
remaining cases with normal porphyrin and precursor excretion 
in the urine, Case 5,which has been discussed previously, had 
significant elevations of urinary ES, DHAS, EPIS, EG and DHAG 
plus EPIG (the plasma was not analysed during remission);
Case 20 had increases in the levels of urinary AS and EG with 
no increases in the plasma, and Case 23 had elevations in the 
levels of ES, DHAS and EG in the urine and AS and DHAS in the 
plasma.
c. STEROIDAL STUDIES IN MALES WITH AIP.
A total of eleven males with AIP were investigated. Of 
these eleven, three were examined during an attack, and the 
remaining at various stages of remission (Table 35). Only 
one patient. Case 34, from the entire group revealed normal 
levels of porphyrins and precursors in the urine. This 
subject was seventy-nine years old and had been in remission 
for over twenty years. The steroid levels observed in the 
urine and plasma of this subject were also normal. One other 
subject. Case 31, from this group had normal steroid levels. 
This patient also has been in remission for some time but, 
unlike Case 34, excessive quantities of ALA, PBG and copro­
porphyrin were detected in the urine.
The most striking steroid abnormality detected in the 
urine was the increased excretion of aetiocholanolone sulphate 
and glucuronide, and DHA sulphate. In the plasma, DHAS was 
the steroid that was most consistently raised in this group 
of patients. These excessively high levels of DHAS in the 
urine and plasma are represented by the large peak (c) in the 
typical g.l.c. traces of male patients with AIP depicted in 
Figs. 36 and 37. These abnormalities are similar to those 
observed in the female AIP group. As with the female group, 
the mean e/ a ratio for the male AIP patients was significantly 
greater (p < 0.001) than that obtained for the entire male 
control group (Fig. 34a).
In this study, three male patients were investigated 
during at attack of AIP. Case 24 was a young man aged thirty.
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who had suffered from several acute attacks. During this 
last attack, excessive excretions of ALA, PBG, uroporphyrin 
and coproporphyrin were detected in his urine. The concen­
tration of uroporphyrin reached a value of 2578 pg/l, and 
coproporphyrin a value of 452 pg/l during this attack. The 
normal values for the concentration of uroporphyrin and copro­
porphyrin in urine are 1.3 - 0,8 pg/l (mean - S.D.) and 
53.7 - 44.8 pg/l, respectively (Moore et al., 1972a). 
Significant elevations in the urinary levels of EG (p < 0.001), 
ES (p < 0.001) and DHAG plus EPIG (p < 0,001) were recorded 
but the total urinary 17-OS level was within the normal range 
of that age group. Calculation of the urinary e/ a ratio
j.
produced a value of 2.27 - 0.28, which is significantly 
greater (p < 0.001) than that calculated for the normals of 
the same age group. One year after this last attack, another 
24-hour urine specimen from this patient was examined. This 
analysis revealed that the total 17-OS level in the urine had 
fallen from 19,6 - 1.6 mg/24 h during the previous year’s 
attack to a value of 11.5 mg/24 h; no abnormally high steroid 
conjugate levels were observed in the urine, and the urinary 
e/ a ratio had decreased to 1,52, but it must be noted that 
this value is still greater than the mean for the control 
group. Determination of the ALA, PBG, uroporphyrin and copro­
porphyrin content of the urine revealed excessive amounts of 
all four compounds, but these levels were lower than those 
previously recorded during the previous year’s attack.
The second patient to be examined in attack was Case 27,
a 42-year old man who had suffered several mild attacks of AIP. 
Only one complete 24-hour urine specimen and one plasma specimen 
were obtained from this patient, and steroidal analyses revealed 
large increases of all the urinary sulphate conjugates; a 
small increase in the urinary level of DHAG plus EPIG, an 
elevation in the total urinary 17-GS excretion and, finally, 
an increase in the concentrations of DHAS, AS and EPIS in the 
plasma. These steroid abnormalities were accompanied by 
increased excretion of ALA, PBG and uroporphyrin in the urine.
Case 26 was the third patient who was investigated 
during an attack. This subject, who is aged thirty-seven 
years, has suffered from repeated acute attacks, principally 
of abdominal pain, but on occasion also with weakness and 
paralysis, since 1950. In the six years since 1966, he has 
been admitted to hospital on numerous occasions, on each of 
which he has had tachycardia and mild hypertension, and there 
has been a striking rise of ALA and PBG in the urine. In a 
previous investigation of this subject, Goldberg et al. (1969) 
reported that the urinary DHAS of this patient was significantly 
raised (p < 0.01) during an acute attack. Further investiga­
tions of the urinary steroid levels of this patient by the 
author are presented in Table 35. Analyses of several 24-hour 
urine specimens during another more severe attack confirmed 
the previous findings by Goldberg et al. (1969) of abnormally 
high levels of some of the urinary steroids in this patient.
In a series of eleven 24-hour urine specimens obtained during 
an attack, significant elevations were found in the levels of 
DHAS (p < 0.001), of DHAG plus EPIG (p < 0.001) and of EG
(p < 0,005). The total urinary 17-03 excretion during the 
attack was also found to be significantly elevated (p < 0,05). 
The e/ a ratio was calculated for these urines, and it too was 
found to be significantly greater (p < 0.001) than that 
calculated for the normals of the same age group. Analyses 
were also carried out on 24-hour urine specimens of this 
patient when he was in remission. They revealed levels of 
the steroids whose mean excretion values were not greater 
than the upper limits of normal, but the mean levels of DHAS 
and EG still remained significantly greater (p < 0,05 and 
p < 0.02, respectively) than those of normals of the same age 
group. There was no significant change in the value- of the 
e/ a ratio when the patient was in remission.
Since the main precursors of these excretory metabolites 
in the urine are secreted by the adrenal cortex and, in 
particular, since DHAS has been shown to be quantitatively one 
of the most important products secreted by the adrenal cortex 
(Baulieu et al., 1965), it was decided to study the effects of 
dexamethasone use to suppress adrenal function in this AIP 
patient. Administration of dexamethasone suppresses ACTH 
secretion and, thus, ACTH-dependent steroid production by the 
adrenal cortex. In particular, this will lead to the 
suppression of the production of DHA, and DHAS, which is the 
principal steroid synthesised by the human adrenal cortex 
(Wieland et al., 1963), being secreted in amounts of the order 
of 10 - 15 mg/24 h and which appears to be the major source 
of the 1l-deoxy-17-OS found in the urine. Following 
dexamethasone administration to this AIP patient, highly
significant reductions in the levels of all the urinary 
17-OS conjugates, except aetiocholanolone sulphate, were 
observed. In addition, concurrent reductions in the 
levels of the porphyrins and precursors in the urine were 
also observed (Table 36). These findings were accompanied 
by a noticeable improvement in the clinical condition of 
the patient. The possible relationship between the 
administration of dexamethasone to this AIP patient and 
the significant fall in the levels of the urinary porphyrins 
and precursors will be discussed in the final section of 
this thesis.
Table 36
THE EFFECT OF DEXAMETHASONE TREATMENT ON A MALE PATIENT 
WITH ACUTE INTERMITTENT PORPHYRIA
(each figure is the mean - S.D. of 22 individual measurements)
Urinary levels
(mg/24 h)
1. Porphyrins & Precursors Before
treatment
Dexamethasone
treatment
Significance
(P<)
Uroporphyrin 3.93 i 1.19 0.53 + 0.28 0.001
Coproporphyrin 0.49
+
0.28 0.26
+
0.17 0.02
5-aminolaevulic acid 61.14 + 23.24 29.54
+
13.81 0.001
Porphobilinogen 126.30
+
27.86 80.52 + 26.89 0.001
2, Steroids ]
Total 17-oxosteroids 11.89
+
3.91 7.66
+
1.73 0.001
Sulphates
+Dehydroepiandrosterone 4.44 + 2.48 0.32 0.21 0.001
Androsterone 0.63 + 0.18 0.34
+ 0.13 0.001
Aetiocholanolone 0.39
+
0.14 0.34 t 0.14 N.S.
Epiandrosterone 0.51
+
0.25 0.09 t 0,09 0.001
Glucuronides
Dehydroepiandrosterone + 
Epiandrosterone 1.94 + 1.00 0.14 + 0.12 0.001
Androsterone 2.20 + 1.02 0.75 i 0.34 0.001
Aetiocholanolone 5.76 + 1.81 2.47
+
1.71 0.001
D. STEROIDAL STUDIES DM PATIENTS WITH HEREDITARY
COPROPORPHYRIA.
Hereditary coproporphyria (HCP), like acute intermittent 
porphyria, is a hepatic porphyria which is characterized from 
the other hepatic porphyrias by the excessive excretion of 
coproporphyrin in the faeces and the urine at all times, 
accompanied by an elevation in porphyrin precursor excretion 
in acute attack.
In this study, five patients, one male and four females, 
suffering from HCP, were investigated. The results of 
estimation of urinary 17-OS conjugates are presented in Table 
37. Three of these patients were suffering from an acute 
attack at the time of the investigation. The only male HCP, 
Case 35, to be studied was aged forty-eight, and he had 
originally been investigated in 1966 because his sister was 
severely ill with HCP. He had a history of nervousness for 
a number of years, and rather large quantities of alcohol had 
been consumed to relieve the symptoms. No history of abdominal 
pain, vomiting, constipation or tachycardia was apparent. No 
discolouration had ever been observed in his urine, but analysis 
of his urine and stool revealed grossly elevated levels of 
coproporphyrin with normal urinary levels of ALA, PBG and uro­
porphyrin. None of the steroid conjugates measured in the 
urine were elevated above normal, but the e/ a ratio was greater 
than the mean normal ratio for that age group.
The youngest patient investigated in this study was a
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twenty-year old female - Case 36. Her first attack had 
occurred at the age of seventeen, when she was admitted to 
hospital suffering from colicky, abdominal pain and diarrhoea.
No family history of the disease was apparent and, previous to 
this attack, the patient had been healthy. Physical examination 
revealed considerable tenderness in the right iliac fossa,and 
appendicBctomy was carried out using thiopentone sodium to 
induce anaesthesia. The appendix was of normal appearance. 
Post-operatively, she vomited considerably and developed a 
mild pyrexia. At this stage, it was noted that she was two 
months pregnant. Four weeks after the appendicectomy, she 
became slightly icteric and, three weeks later she developed 
a bullous eruption on the light exposed parts of her body. 
Analyses of her urine and faeces at this point revealed the 
excretion of massive amounts of coproporphyrin. These 
eruptions on the skin subsided after one week and, thereafter, 
she remained comparatively well until she was delivered of a 
still-born child. Her good health continued throughout her 
second pregnancy but, one week after the delivery of a normal 
healthy child, she became acutely ill with abdominal pain and 
vomiting. Her blood pressure rose to 22o/l30 mm Hg and she 
suffered several epileptic seizures. Determinations of the 
17-oxosteroid levels in two twenty-four hour urine specimens 
prior to the patientas acute attack revealed an elevation in 
the excretion of the 11-OA glucuronide but not in any of the 
11-deoxy-17-0S. In these two urines, the concentrations of 
coproporphyrin and uroporphyrin were raised, but those of ALA
and PBG were not. During the acute episode, five complete 
24-hour urine specimens were analysed. The level of the 
11-OAG was found to remain elevated, but not at such high 
levels as was observed in the two urines collected prior to 
the attack. Significant elevations in the urinary levels 
of ES and EPIS (p < 0,025 for both) were observed. These 
were accompanied by the excretion in the urine of large 
amounts of ALA and PBG. During the attack, the urinary 
ratio of e/ a was significantly greater (p < 0.001) than that 
found for the urines collected before the commencement of the 
acute episode, and some positive correlation was found 
between the urinary e/ a ratio and the urinary level of ALA 
(r = 0.82) and between the urinary e/ a ratio and the urinary 
level of PBG (r = 0.78) (Fig. 38), These lines have the 
equations y = 18.40x - 2.00 and y = 27.60x - 5.18, 
respectively.
The duration of the attack was approximately ten days 
end, thereafter, rapid improvement in her condition was 
observed. Since that time, there has been no reappearance 
of any of the symptoms. Porphyrin analyses of her family 
revealed three examples of the disorder in latent form.
Case 39, a thirty-year old housewife, was also investigated 
during a period of attack. The first symptoms, persistent 
lower abdominal pain, anorexia, constipation and symptoms of 
cystitis, occurred after hysterectomy and appendicectomy. She 
had difficulty in sleeping and became increasingly agitated and 
depressed. This patient had a history of nervousness and
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depression, and anorexia nervosa had been diagnosed at the age 
of 21 years. Following hysterectomy, post-operative management 
included treatment with a variety of drugs including buto- 
barbitone, promethazine, papaveretium and several antibiotics.
The patient's condition worsened with time, and a diagnosis of 
agitated depression with hysterical features was made. She 
was further treated with amylobarbitone and imipramine, but her 
condition deteriorated with the appearance of confusion and 
paranoia. Her urine had been noted to be dark during her 
surgical admission but it was not until much later, when excessive 
amounts of PBG were found in the urine, that the significance 
of this finding was appreciated. The analyses of her urine 
and faeces resulted in a diagnosis of an acute attack of 
hereditary coproporphyria being made. Duplicate steroidal 
determinations in one of the 24-hour specimens obtained during 
an attack revealed small elevations in the levels of ES and 
11-OEG and a massive elevation in the level of the 11-hydroxy- 
aetiocholanolone glucuronide. The value estimât,ed for the 
urinary excretion of this steroid was 12,5 mg/24 h, which is 
more than twelve times the maximum value estimated for normal 
subjects of the same age group. In contrast to this great 
elevation of the levels of the 11-oxygenated aetiocholaholone 
' glucuronides, there was no 11-oxygenated androsterone glucuronides 
detectable in the patient's urine.
Having established the diagnosis of hepatic porphyria, 
therapy with barbiturates and other drugs was immediately ceased, 
and treatment with chlorpromazine instituted. Within 24 hours.
the persistent abdominal pain had disappeared but her mental 
state remained abnormal for an additional month. Two months 
later, after a gradual improvement of her mental health, she 
was discharged from hospital. Since then, investigation of 
other members of her family have revealed two latent 
hereditary coproporphyrias, her mother and a sister, who 
excreted excessive amounts of coproporphyrin in the urine 
and faeces.
The third patient, Case 38, who was investigated during 
an attack, was another young lady aged 25 years. Seven 
complete 24-hour urinary specimens were obtained from this 
patient during the acute episode. Estimations of the 
porphyrins and precursors in these urines revealed highly 
elevated levels of coproporphyrin, uroporphyrin, ALA and PBG 
in all seven urines analysed. When the fractionated urinary 
17-oxosteroids were determined in these urines, it was found 
that the levels of EPIS (p < 0,02) and EG (p < Of, 001) were 
significantly elevated. The total urinary 17-OS excretion 
was within the limits of the normal females of that same age 
group. Calculation of the urinary e/ a ratio for this patient 
gave a value of 2,0 - 0,2, which is significantly greater 
(p < 0,001) than that for normals (Fig. 39). As with Case 36, 
there was some degree of linear correlation between the fall 
of the levels of ALA and PBG in the urine and the fall of 
the urinary e/ a ratio (Fig. 40). The relationship
between the urinary level of ALA and the urinary ratio of 
e/ a has a coefficient of correlation r = 0.81 and an
equation y = 27.47X - 34,72, Similarly, the relationship
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betuBsn the urinary level of PBG and the e/ a ratio gave a 
coefficient of correlation r = 0.75 and an equation 
y = 45.62x - 14.66.
The final patient to be investigated in this group of 
HCP subjects was Case 37, a 28-year old housewife who first 
presented in 1966 during her second pregnancy with a urinary 
tract infection. After treatment with sulphonamides, her 
urine was noted to be dark and was found to contain increased 
amounts of PBG. Her only other symptom was depression of
2 years duration. Quantitative porphyrin analysis showed 
large amounts of coproporphyrin in both urine and faeces.
The pregnancy ended with a neonatal death, the cause of which 
was uncertain. During the early stages of her third 
pregnancy, this patient once again presented with a further 
attack of depression, but this settled quickly and pregnancy 
culminated with the birth of a normal baby. Since that time, 
no further bouts of depression or any other symptoms of 
porphyria have been experienced. The urine which was used 
for steroid estimations was obtained fourteen months after 
the last attack of depression. Elevations in the levels 
of the fractionated 17-oxosteroids were not observed. 
Quantitative porphyrin analysis of the same urine showed 
increased levels of uroporphyrin and coproporphyrin but not 
of ALA and PBG. No evidence of hereditary coproporphyria 
has been found in other members of her family.
E. STEROIDAL STUDIES ON PATIENTS WITH VARIEGATE PORPHYRIA.
Variegate porphyria is a hereditary hepatic porphyria, 
biochemically characterised by highly elevated amounts of 
urinary uroporphyrin and coproporphyrin, faecal proto­
porphyrin, coproporphyrin and X-porphyrin, and variable 
elevation of ALA and PBG in the urine. No conclusions as 
to whether abnormalities in the steroid levels might exist 
in VP could be reached as only two patients were investigated 
in this study. One was a fifty-three year old woman who 
had been in remission for eight years* She had suffered 
the last attack in 1962 after hysterectomy. Quantitative 
analysis of her urine revealed normal excretion of porphyrins 
and precursors, and also normal levels of 17-05 conjugates. 
The other was a twenty-four year old male who had been in 
remission for three years. Although urinary levels of ALA, 
PBG and porphyrins were elevated, no similar abnormalities 
were observed in the 17-05 conjugate levels, either in the 
plasma or the urine (Table 38).
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F. STEROIDAL STUDIES ON PATIENTS WITH NON-HEREDITARY
PORPHYRIA CUTANEA TARDA.
Non-hereditary porphyria cutanea tarda (PCT), also 
known as symptomatic porphyria, is a hepatic porphyria which 
is often associated with alcoholism. In this study, a 
total of fourteen patients (eleven males and three females) 
were investigated. The diagnosis of PCT was based on the 
typical clinical picture, skin sensitivity to 400 nm 
radiation, evidence of liver disease and a high urinary 
excretion of uroporphyrin and, to a lesser extent, copro­
porphyrin. Determination of the urinary excretion of the 
fractionated 17-OS conjugates revealed no abnormally high 
levels of any of these steroids in this entire group
(Table 39). Similarly, determinations of the 17-OS sulphates
in the plasma of these patients revealed no abnormally high 
concentrations of these steroids. The mean urinary e/ a 
ratio for the eleven males with PCT was 0.77 - 0.'39, which
is not significantly different from that found for normal
males. The mean e/ a ratio for females with PCT was also 
found not to differ significantly from that for normal 
females. Thus, it seems that the steroid abnormalities 
observed in other hepatic porphyrias, AIP and HCP, are not 
to be found in PCT (Fig. 41). However, it must be noted
that in 80^ of the PCT patients examined, the total urinary 
excretion of the 17-OS conjugates was lower than the mean 
total urinary excretion of normals from that same age group.
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whereas in the plasma the reverse is true, with 89^ of the 
PCT patients whose plasma was examined having a greater 
level of total 17-03 sulphates than the mean total level of 
sulphate conjugates in the plasma of normals from the same 
age group. A possible explanation for this observation is 
put forward in the discussion section of this thesis.
SECTION IX
DISCUSSION
DISCUSSION
The results of these studies imply that there is a close 
association between the hereditary hepatic porphyrias and 
abnormal steroid metabolism. The earlier report by Goldberg 
et al. (1969) that certain of the 17-OS conjugates in the urine 
of acute intermittent porphyries are significantly elevated 
during attack, is extended to include patients suffering from 
hereditary coproporphyria. There are several theories which 
might explain these increased urinary excretions of specific 
17-OS conjugates. They could be caused by an increase in the 
metabolic clearance rate due to a decrease in the degree of 
plasma protein binding of the steroids. It is possible to 
hypothesise that perhaps there are differences in the degree 
of protein binding of various steroids in normals and in patients 
with hereditary porphyria. However, the detection in this 
investigation of increases in the concentrations of some of 
the sulphate conjugates of these 17-05 in plasma suggests that 
the urinary elevations are not due to increased excretion rates 
but are caused by increased production of a steroid or steroids. 
Care has to be exercised in comparing the 17-05 sulphate levels 
in the plasma with the urinary excretion of the conjugates of 
the 17-05, since these conjugates can have a number of origins 
other than the plasma 17-05 sulphates. Although the major 
components of total plasma 17-05 are AS and DMAS, the contribution 
to the total urinary 17-05 excretion of the minor quantities of 
free 17-05 can be considerable. This is due to the vast
differences in the metabolic clearance rates (Tait, 1963) 
between the free steroids and the steroid sulphates (Sandberg 
et al., 1964; Wang et al., 1967; Wang and Bulbrook, 1968).
Wang and his colleagues (1967) reported that the ratios of the 
metabolic clearance rates of DHA and testosterone and their 
respective sulphates were approximately 40, indicating that 
the steroid sulphates are cleared much more slowly than the 
free compounds. Plager (1965) has reported that the sulphates 
of DHA, androsterone and aetiocholanolone are bound to human 
plasma albumin, which has a large number of binding sites 
which have a great affinity for steroid sulphates. . These 
observations suggest the possibility that steroid sulphates in 
plasma act as physiological reservoirs for the unconjugated 
steroids. Thus, DHAS has been shown to be converted reversibly 
in vivo to DHA (Roberts et al., 1961; Sandberg et al., 1964; 
Slaunwhite et al., 1967), and more recently Rosenfeld and his 
colleagues (1972) have demonstrated that the major source of 
the plasma free DHA is production from DHAS.
The significance of the elevations of the concentrations 
of the plasma 17-08 sulphates is difficult to assess. It is 
generally agreed that the physiologically active steroid is 
the free unconjugated form and Plager (1965) has reported that 
11 mg of DHAS are required to increase the concentration of 
protein-free (i.e. unbound) DHAS by 1^. Thus, the possibility 
arises that these plasma elevations detected in the porphyric 
patients are just increases in the reservoir of protein bound 
conjugated steroids, and thus have no physiological effect.
This criticism can be partially answered by the fact that 
aetiocholanolone glucuronide was one of the steroids whose 
urinary level was most consistently raised. Consistent 
elevations were also detected in the urinary levels of DHAG 
+ EPIG. These observations imply that elevated levels of 
the free 17-OS do exist in the liver, since the liver is the 
site for steroid glucuronidation.
Another very important question which arises, is whether 
these steroid elevations are an effect or the cause of the 
acute attacks observed in the hereditary hepatic porphyrias.
The fact that the levels of these 17-OS do in many cases 
remain elevated for many years after an acute attack, 
indicates that these elevations are not brought about by 
increased pituitary-adrenal activity due to the stress of an 
attack. Further evidence to support this view is provided by 
the observation that the 11-oxygenated-17-0S, which are mainly 
metabolised from the adrenal secreted 1ip-hydroxyandrostenedione 
and hydrocortisone which are raised in humans in stressful 
situations (Mason, 1968), are found to be normal in the majority 
of these patients in which the 11-deoxy-17-0S elevations were 
detected. These findings suggest that there is a long-term 
abnormality in steroid metabolism present in patients with 
hereditary hepatic porphyria, especially AIP. This does not 
rule out the possibility that stress does play some part in the 
provocation of the acute attack in susceptible individuals. 
Elevations in the urinary excretion of 17-OS have been reported 
to occur in humans involved in such stressful situations as
air-craft flight (Pincus and Hoagland, 1943), emergency 
hospital duty (Pincus, 1947), motor-racing (Frost et al.,
1951), final examinations (Connel et al., 1958). Similar, 
and in some cases more pronounced elevations in the levels 
of the 17-hydroxycorticosteroids in urine and in plasma have 
been detected in a variety of psychological and emotional 
disturbances by a large number of investigators (for review, 
see Mason, 1968). It is possible in those patients in whom 
no exogenous factors such as drugs, contraceptive steroids, 
alcohol or a diet very low in carbohydrate and protein, may 
be implicated with the onset of an acute attack, some stressful 
situation or emotional disturbance could result in stimulation 
of ACTH secretion leading to increased production of 17-08 and 
hydrocortisone. The already high concentrations of circulating 
17-08 sulphates in the plasma could be intensified to such an 
extent that onset of an acute attack would result. Birke 
et al. (1955) have reported that post-operative values of the 
urinary excretion of DHAS are greatly elevated compared to 
normal, and it might be worthwhile to note that in many patients 
with hereditary hepatic porphyria, the first acute attack 
occurred after some surgical procedure (Goldberg et al., 1969; 
Eales, 1971; Case 39, this Thesis), However, in the majority 
of these cases, the patient had undergone thiopentone 
anaesthesia or had received drug therapy in the post-operative 
phase, and it seems more likely that the main precipitating 
factor in the acute attack was the drug, especially if it was 
a barbiturate. This does not rule out the possibility that
increase of adrenal activity due to operative trauma was a 
contributory factor in provocation or aggravation of the 
acute attack. In his study of 145 attacks in 120 patients 
suffering from UP and AIP, Eales (1971) found fifteen examples 
of attacks being precipitated or aggravated by emotional 
stress in four individuals. In this publication, Eales also 
reported that many of these patients who had suffered acute 
attacks after thiopentone anaesthesia had undergone previous 
thiopentone anaesthesia, often repeatedly, without ill effect. 
These observations indicate that, although the cardinal role 
of the barbiturates in the genesis of the severe attacks has 
been established, there are nevertheless other unknown 
contributory factors, possibly hormonal in nature, which must 
be accounted for.
The concept of permissibility of hormone action has been 
extensively reviewed by Ingle (1954). The permissive effect 
of the glucocorticoid hydrocortisone on the induction of ALA 
synthetase by AIA in the liver of adrenalectomize.d animals has 
been demonstrated by Marver et al. (1956c). They found that 
adrenalectomized mice did not become porphyric when treated 
with AIA, but only when treated with both AIA and hydrocortisone. 
Although the evidence indicates that the glucocorticoids cannot 
themselves induce, they may be important in bringing about the 
metabolic conditions to permit the inducing steroids or chemicals 
to induce. Matsuoko et al. (1968) suggested that hydrocortisone 
potentiated the action of drugs, since in normal intact rats the 
steroid increased the extent of induction by sub-optimal doses
of AIA and, if given one hour before AIA, it reduced the lag 
period preceding the increase in ALA.S activity. These 
observations, together with the facts that adrenalectomy 
prevents AIA-induced proliferation of the smooth endoplasmic 
reticulum (Moses et al., 1970) and AIA-induction of hepatic 
tyrosine and tryptophan transaminases (Wetterberg et al.,
1970) are consistent with a permissive role for hydrocortisone 
which is known to have general stimulatory effects on hepatic 
RNA and protein synthesis as well as causing relative specific 
induction of some enzymes (see Cox and Mathias, 1969, for 
review). Of interest concerning the action of hydrocortisone 
in this connection is the study of Mills and Topper (1969) who 
found that 4-day old explants of mammary alveolar epithelial 
cells require hydrocortisone for the formation of an extensive 
rough endoplasmic reticulum which is needed for the synthesis 
of casein. Also of interest, are the electron-microscopic 
observations made by Rancourt and Litwack (1968), whose results 
indicated that hydrocortisone, as early as 15 minutes after 
injection, provoked changes in the endoplasmic reticulum 
involving conversion of much of the long parallel arrays of 
rough endoplasmic reticulum to vesiculated smooth endoplasmic 
reticulum. These experiments suggest that the glucocorticoids 
may be active in the formation of changes in the endoplasmic 
reticulum, and these changes may have to precede the induction 
of some of the inducible liver enzymes. In the chick embryo 
liver tissue culture system, there is apparently no requirement 
for hydrocortisone; neither does hydrocortisone cause induction
of porphyrin synthesis (Granick, 1966). Although adrenalectomy 
prevented induction of ALA.S and the drug detoxifying system by 
AIA in rat liver, it did not prevent induction of the drug 
metabolising enzymes by phenobarbitone (ichii and Yago, 1969; 
Marshall and MacLean, 1959; Marshall, 1971). These pheno- 
barbitone-stimulated increases in cytochrome P45G, cytochrome 
bg, microsomal protein, phospholipid and NADPH-cytochromic 
reductases were completely blocked by Haemin (Marver, 1969).
It is possible to hypothesize several relationships 
between these glucocorticoids and the effects of some of these 
porphyrinogenic drugs. These glucocorticoids may act by 
enhancing the activity of the inducer or by bringing about 
metabolic conditions which permit the inducer to induce. It 
is known that the production of haem may be enhanced by agents 
which stimulate gluconeogenesis (Rose et al., 1961). The 
stress of fasting may increase the synthesis and secretion of 
glucocorticoids, which increases the activity of a number of 
liver enzymes concerned with gluconeogenesis and,which permit 
more readily induction of ALA synthetase. The studies of 
Drews and Brawerman (1967) suggest that this involvement of 
the glucocorticoids in the induction of a number of liver 
enzymes is due to their effect on the mRNA’s. Using DNA-RNA 
hybridization, they observed that 3 hours after hydrocortisone 
administration to adult rats, the mRNA’s of the liver were 
altered, implicating an early selective effect of the hormone 
on the synthesis of mRNA's coding for the relatively few 
enzymes that were induced. A different interpretation of
glucocorticoid action on the induction of certain liver enzymes 
has been suggested by Tomkins et al,, (1969). They proposed 
that the steroid acts not at the transcriptional level but 
rather at the translational level to inhibit the action of a 
repressor on the synthesis of the enzyme.
It also must be noted that drugs and steroids are 
metabolised by the same cytochrome P-450-containing enzyme 
system in the liver microsomes and thus competition for the 
binding sites of P-450 would result (Conney et al., 1968;
Tephly and Mannering, 1968; Kupfer and Orrenius, 1970).
By competitive inhibition of steroid hydroxylation, drugs 
like AIA, DDC and phénobarbital, which are strong porphyrino­
genic drugs and have been shown to bind strongly to P-450 
(De Matteis, 1970; Tschudy and Bonkowsky, 1972), might 
enhance metabolism of steroids by pathways leading to production 
and accumulation of active inducers. However, the numerous 
studies of the effects of AIA and DDC on hepatic enzymes and 
metabolic pathways other than those of porphyrin ,biosynthesis, 
provide evidence for far-reaching and numerous metabolic effects 
of these substances (see Tschudy and Bonkowsky, 1972, for review). 
This myriad of changes in the levels of enzymes brought about 
by porphyrinogenic drugs, as well as the consideration of the 
changes in steroid metabolism, raises the fundamental question 
as to which changes are related to porphyria and which are 
unrelated?
One way of attempting to answer this question is to 
determine which of the biochemical changes observed in
experimental porphyria also occur in the most closely analogous 
type of genetically determined hepatic porphyria. Unfortunately, 
there is a lack of study of steroid metabolism in experimental 
porphyria, but an example of such a correlation is observed in 
the abnormalities of lipid metabolism which occur in both the 
experimental disease and variegate porphyria (Taddeini et al., 
'1964). In the experimental porphyria, the following observations 
have been made: rats treated with AIA showed an increase of
hepatic fatty acid synthesis (Labbe et al,, 1961)j rabbits 
treated with AIA or DDC develop increased serum levels of total 
lipids and phospholipids (Taddeini et al., 1964); mice treated 
with AIA or DDC or griseofulvin develop hypercholesterolaemia 
due to increased hepatic synthesis (De Matteis, 1966; Wada 
et al., 1969). Hypercholesterolaemia is also found in UP and 
in approximately 40^ of patients with AIP (Taddeini et al.,
1964; Stein and Tschudy, 1970), It is of interest to note 
that hypercholesterolaemia and hyperlipaemia in patients have 
for some time now been associated with abnormal steroid 
metabolism. Heilman et al. (1959) were amongst the first to 
suggest a role of androgen hormones in cholesterol metabolism.
. A significant increase in epiandrosterone excretion by hyper- 
cholesterolaemic subjects has been reported by Dingman and Lim 
(1963), who suggested that the abnormality was due either to a 
derangement in the steroid hydroxylating enzymes responsible 
for the hepatic degradation of androgenic hormones or to an 
increased secretion of a specific androgen. In contrast to 
this, Adlercreutz et al. (1968; 1972) observed a tendency 
towards lower plasma levels and urinary excretion of several
steroids, especially DHAS in a small group of patients with 
hypercholesterolaemia or hyperlipaemia. These investigators 
stated the need for further investigation to clarify whether 
the alterations in steroid metabolism in the hypercholestero- 
laemic and hyperlipaemia subjects were of aetiological signifi­
cance or were only a secondary or parallel phenomena to the 
disturbances of lipid metabolism or vascular changes common 
in these diseases. An exactly similar problem exists in the 
porphyrias in assessing whether the alterations in steroid 
metabolism are of aetiological significance or not. A 
number of clinical observations do suggest that endocrine 
secretions, particularly steroids, represent one class of 
natural agents which in appropriate circumstances may exacerbate 
the chemical and symptomatic abnormalities of hepatic porphyria. 
These observations are: the onset of the acute attack seldom
occurs before the age of puberty; there is a female predominance; 
many of the acute attacks in women are associated with the luteal 
phase of the menstrual cycle or with pregnancy; the main age of 
onset is in the third decade for females and the third or fourth 
for males; the disease rarely occurs after middle age; chemical 
as well as symptomatic relapse results as a consequence of sex 
hormone administration in some patients. It was these striking 
clinical associations which led Granick and Kappas (1967a,b;
1968) to examine the possibility that naturally occurring 
steroids might be involved in the regulation of ALA synthetase, 
the rate controlling enzyme of haem synthesis. In normal liver, 
this enzyme is closely controlled by some fine mechanism as the
hepatic haem requirement in the liver is fairly small, being 
about 15^ of that required by the bone marrow to replace the 
haemoglobin lost through red coll breakdown. In adult bone 
marrow, approximately 210 mg of haem are formed daily. For 
this amount of haem, the ALA.S has to make 358 mg of ALA.
In the hereditary hepatic porphyrias, the liver may readily 
produce this much and more ALA (Granick and Sassa, 1971).
These investigators postulated that, when the requirement 
for haem was increased by the drug detoxifying system, the 
hepatic ALA synthetase activity could be stimulated by certain 
endogenous steroids, resulting in increased synthesis of ALA, 
culminating in an increase in haem. They even suggested that 
there may be some natural steroids that normally serve to 
maintain a certain rate of haem synthesis by inducing the 
synthesis of ALA synthetase.
During the past few years, evidence has accumulated 
showing that a number of natural steroid metabolites of the 
5p-H type, such as aetiocholanolone, aetiocholandiol, pregnan­
diol, pregnantriol and pregnanolone, induce the de novo 
synthesis of ALA synthetase in chick embryonic liver cell 
in vivo and in vitro, and thus stimulate porphyrin synthesis. 
Similar results with Sp-H steroids have been obtained recently 
in mammalian systems, including bone marrow cells from human 
subjects and from mice and rats (Necheles and Rai, 1969;
Gordon et al., 1970; Sardesai et al., 1970). The porphyrin- 
inducing action of some of these steroids was maximal at 
concentrations as low as ID ^M, and hence was as great as the 
most active of the non-steroid porphyrinogenic compounds
previously studied. Furthermore, in these studies Granick and 
Kappas showed that the glucuronide derivatives of even potent 
inducers are devoid of activity and that steroid induction of 
ALA is inhibited by concomitant addition of haem and certain 
other metalloporphyrins. The significance of these steroidal 
studies is very great, as they demonstrate that a number of 
steroids which were previously considered to be waste metabolites 
of adrenocortical and gonadal hormones with no primary function 
of their own may, in fact, exert considerable influence over 
haem synthesis in liver and erythroid cells, and it was on the 
basis of these studies that Granick and Kappas (1967a) applied 
the operon concept of Jacob and Nonod (1961) to an hypothesis 
explaining the regulation of haem biosynthesis by steroids in 
the hepatic cells. In this hypothesis, they suggest that any 
process which led to (a) impaired glucuronidation of the 
steroids, such as inhibited or defective UDP-glucuronyl 
transferase or limited UDPGA formation, or (b) enhanced intra­
cellular hydrolysis of formed conjugates by excessive p-glucu- 
ronidase activity, or (c) steroid production in amounts 
exceeding the body*s capacity to dispose of them, would lead 
to induction of ALA synthetase and increased production of ALA 
and other precursors of haem. This original hypothesis was 
further modified into the form shown in Figure 17, when further 
investigations indicated that haem represses the synthesis of 
ALA.S and thus its own synthesis at the translational level 
rather than at the transcriptional level. However, the recent 
finding of Schneck et al. (1971) that haem had no apparent effect
on porphyrin synthesis when added to chick embryo liver cultures 
preinduced with AIA has raised some doubt that this hypothesis 
is always valid. Similarly, in rat liver it has been reported 
by Kurashima et al. (1970) that haem administered 2 - 1 0  hours 
after AIA does not decrease total induction by AIA but alters 
only the relative proportions of enzyme in mitochondrial and 
cytoplasmic fractions of the cell by preventing appearance of 
newly synthesised enzyme in the mitochondria. A redistribution 
phenomenon of this type may have been the post-transcriptional 
effect of haem observed by Sassa and Granick (1970), who 
apparently measured ALA.S activity in isolated mitochondria.
It may be of interest at this point to note that steroids have 
been reported to affect the permeability of mitochondria 
(Gallagher, I960).
After Granick and Urata's discovery in 1963 that hepatic 
ALA.S is an inducible enzyme, the possibility that a genetically 
mediated induction of this enzyme might explain the excessive 
excretion of porphyrin precursors in AIP was investigated 
(Tschudy et al., 1965; Nakoa et al., 1966; Perlroth et al., 
1966; Dowdle et al., 1967). Their findings demonstrated that 
a mutation in man can augment the expression of a specific 
enzyme. However, it is still not known whether the mutation 
is primarily in a control gene or whether the induction of 
hepatic ALA.S is secondary to a structural gene mutation.
Tschudy et al. (1965) postulated that the genetic abnormality 
in AIP was a defect of a regulator gene which normally controls 
the synthesis of ALA.S. A similar lack of repression of the
synthesis of ALA.S related to a constitutive regulator operon 
mutation, in accord with the concept of Jacob and Nonob, is 
suggested by Watson et al. (1964b) to provide a reasonable 
explanation of the genetic and biochemical manifestations of 
erythropoietic porphyria. The resemblance of the clinical 
and biochemical features of AIP to those of VP and HCP suggests 
that a similar metabolic abnormality must be present in all 
three, and it seems doubtful whether a single regulator-gone 
defect could account for the differences in the pattern of 
porphyrin excretion which is observed in the three conditions 
(see Fig. 8). Tschudy and Bonkowsky (1972) have suggested 
that, since induction of ALA.S in liver by compounds which 
cause experimental porphyria may result in 50-fold or greater 
increase in the level of this enzyme, under these conditions 
the other enzymes beyond ALA.S in the pathway which are normally 
present in excess become rate limiting for haem biosynthesis, 
and the patterns of metabolites accumulated and excreted may 
reflect the relative levels of these enzymes. This hypothesis 
appears unlikely to explain more than one form of genetically 
transmitted porphyria since, with rare exceptions (Taddeini 
and Watson, 1968), excretory patterns are reported to be "true 
to form* in families with each of these disorders (Waldenstrom, 
1957; Schmid, 1966). Thus, if a mutation leading to increased 
ALA synthesis were to explain all these disorders, this defect 
would have to be combined with additional mutations (which is 
statistically improbable) to explain the different excretory 
patterns of porphyrins and precursors which typify each disorder.
An alternative to this hypothesis was proposed by Kaufman 
and Marver (1970), who suggested that each of the porphyrias 
primarily results from partial blockage in haem biosynthesis 
at a locus distal to ALA. In view of the role of haem in the 
feed-back regulation of ALA.S (Granick, 1966; Kappas and 
Granick, 1968; Marver et al., 1968; Hayashi et al., 1968;
Sassa and Granick, 1970), the partial block in haem biosynthesis 
may result in a decrease in the level of available haem, 
resulting in secondary induction of ALA.S, The marked 
increase in the porphyrin precursors, ALA and PBG, in relation 
to the normal or near normal porphyrins in the urines of 
patients with AIP, suggests that the conversion of PBG to 
uroporphyrinogen by the enzyme URO-I-synthetase is defective. 
Heilmeyer and Clotten (1969) observed a decreased hepatic 
production of porphyrins from ALA in patients with AIP, but 
Nakao et al. (1966) reported that PBG disappearance catalysed 
by liver homogenate from a patient with AIP was similar to that 
of controls. In the case of HCP, the defect would presumably 
be in the conversion of coproporphyrinogen III to proto­
porphyrinogen by the enzyme coproporphyrinogen oxidase, and in 
VP the conversion of protoporphyrinogen to haem. These partial 
blocks of haem biosynthesis could be the consequence of diminished 
activity of enzymes involved at specific steps in the pathway, 
loss of intermediates due to alterations in membrane permeability 
of the hepatocytes (Taddeini and Watson, 1968) or the mitochondria, 
or the excessive irreversible conversion of the reduced porphyrino­
gens to the oxidised porphyrins. It was Falk et al.(1959) who
first demonstrated that oxygen tension influences different 
biosynthetic steps in different ways, and thus the Ox/Redox 
environment within subcellular organelles may play a regulatory 
role. Thus, the transformation of coproporphyrinogen III to 
protoporphyrinogen is oxygon dependent, whilst chelation of 
protoporphyrin with iron to form haem is favoured by relatively 
anaerobic conditions. Rimington (1963) has also postulated 
that the increased excretion of porphyrins in PCT result from 
excessive oxidation of porphyrinogens and diversion of these 
intermediates from haem biosynthesis. This same author (1966) 
has also pointed out the fact that some of the enzymic steps 
of the haem biosynthetic pathway take place within the mito­
chondria and others in the cytoplasm, and thus intermediates 
have per force to diffuse from one location to another. This 
alone can act as a rate limiting and regulating mechanism, 
especially as substrates may at some stages be protein bound 
and their diffusion will thus be modified accordingly, perhaps 
even resulting in a partial block of the haem bio.synthetic 
pathway.
This hypothesis of partial block in haem biosynthesis 
proposed by Kaufman and Marver (1970) has been argued against 
on the basis that haem synthesis is actually increased in 
experimental porphyria (Marver, 1969). However, this 
experimental model need not be completely relevant to the 
human genetic disease. Recent investigations by Strand et al. 
(1970) have confirmed that AIP is indeed distinguished from VP 
and HCP by decreased activity of hepatic URO-I-synthetase.
This does not rule out the possibility, however, that in families 
with AIP decreased URO-I-synthetase constitutes an unrelated 
variation in enzyme activity that may modulate primary over­
production of ALA. Such genetically determined relatively 
common variations in enzyme proteins occur in heterogeneous 
populations and are referred to as enzyme polymorphisms 
(Harris, 1970). Further investigation in a large family with 
AIP by Meyer et al. (1972), provided further data which suggested 
that decreased URO-I-synthetase activity reflected the primary 
genetic defect in AIP, which then may result in secondary 
induction of hepatic ALA synthetase, leading to over-production 
of ALA and PBG. This hypothesis of a partial block in haem 
biosynthesis also at the moment seems to provide an acceptable 
explanation for the primary abnormality in the other two forms 
of hereditary hepatic porphyria, with the secondary elevation 
of ALA.S accounting for the increase in ALA and PBG excretion 
which occurs in both during attack and the site of the block 
explaining the differing pattern of porphyrin excretion.
The acceptance of this hypothesis raises the question 
concerning the role of the steroids in the aetiology of the 
porphyrias; namely, does the involvement of steroids require 
the postulation of another metabolic abnormality in the hepatic 
porphyrias or is it possible to explain the steroidal abnormalities 
observed within the frame-work of Kaufman and Marver*s hypothesis? 
Does the enzymic change observed by Gillette et al. (1970) in 
AIP patients result from a genetic change and, if so, are there 
two enzyme defects, one basic and one accessory, involved in 
some cases of AIP?
In 1970, Gillette et al. reported that in AIP patients the 
5a-H pathway for steroid metabolism was greatly diminished, 
indicating a gross deficiency of steroid A^-5a-reductase 
activity, which resulted in preferential formation of the 5(3-H 
type metabolites. This finding would seem to agree with the 
results of this thesis obtained in the studies on the urinary 
levels of the 17-OS conjugates. In these studies, the ratio 
of the urinary level of aetiocholanolone (5(3-H steroid) to the 
urinary level of androsterone (5a-H steroid) was found to be 
significantly greater for the patients who were suffering from 
hereditary hepatic porphyria (AIP and HCP investigated) than 
for the normals or for patients with acquired porphyria cutanea 
tarda. During an acute attack, the e/a ratio was observed 
usually to be at a maximum. These results suggest that 
hereditary hepatic porphyries have an imbalance in their steroid 
metabolism, resulting in an overall increase in the 5(3-H type 
steroid metabolite. However, this specific abnormality of 
steroid metabolism in porphyries is probably not due to direct 
genetic change affecting the activity of the A ^-Soc-reductase 
but more likely to be caused by the indirect effects of various 
precursors and hormonal influences to which the A^-reductases 
are very susceptible. As a result of these influences, which 
include thyroid hormone (Heilman et al., 1959; McGuire and 
Thomkins, 1959), glucocorticoids (Wilson and Schenker, 1964), 
the urinary e/a ratio may be shifted. One such endogenous 
compound which might greatly influence the e/a ratio, especially 
in the hereditary hepatic porphyrias, is DHA which has been
reported to suppress A^-Boc-reductase (Kirschner and Lipsett, 
1964) and which is one of the main plasma precursors of the 
urinary androsterone and aetiocholanolone (Baulieu and 
Mauvais-Jarvis, 1964a,b). The sulphate conjugate of DHA was 
also the 17-OS in the plasma which was the most frequently 
and most strikingly raised in the steroid investigations in 
the plasma of the hereditary hepatic porphyric patients.
This increase in the plasma levels of DHAS, resulting in an 
increase in the level of free DHA in the liver, leading to 
suppression of A^-5a-reductase, provides a possible 
explanation for the deficiency of A^-5a-reductase observed 
by Gillette et al. (1970) and Kappas et al. (1971) in AIP 
patients and the significant increases in the urinary e/ a 
ratios of the hereditary hepatic porphyries examined in 
this thesis. It may be of interest to note that DHA has 
been reported to inhibit glucose-6-phosphate dehydrogenase 
activity, with a resultant decrease in the synthesis of 
NADPH which is required by the A^-reductases (Lopez and 
Krehl, 1967). It is possible that this mechanism plays a 
part in the inhibition of the A^-Boc-reductase activity or 
perhaps helps in the accumulation of steroids in the liver. 
Although these 5(3-H type steroids appear to be produced in 
excess due to a secondary effect of some earlier abnormality 
in the steroid pathway, i.e. overproduction of DHA or DHAS, 
there is the possibility that they do have an aggravating 
role to play in hepatic haem synthesis. A number of groups 
have shown that the 5p-H type steroids, known to be potent
inducers of ALA synthetase in chick embryo liver and erythro­
poietic tissue (Granick and Kappas, 1967a,b; Levers et al., 
1967), also stimulate haem and globin synthesis in mammalian 
bone marrow (Necheles and Rai, 1969; Sardesai et al., 1970; 
Levere and Mizoguchi, 1971). However, attempts to demonstrate 
induction by these steroids in mammalian liver have been 
unsuccessful (Song et al., 1970; Sardesai et al., 1970;
Tschudy and Bonkowsky, 1972), perhaps because of some difficulty 
in getting the relatively polar steroids to accumulate in the 
liver cells in adequate concentrations. There is also the 
possibility that in mammalian liver a more specific structure 
or even a completely different structure is required for the 
inducing steroid. In their studies of perfused rat liver,
Bock and his colleagues (1971) found that the sharp decrease 
observed in the activity of ALA synthetase could not be 
prevented by testosterone or aetiocholanolone, whereas the 
C-21-hydroxylated steroids, dexamethasone and hydrocortisone, 
were able to maintain the synthetase at the level in vivo. 
Despite these findings in the rat liver, the results of this 
thesis suggest that the 5(3-H type steroids or their precursors 
do play some part in the induction of the increased activity 
of ALA synthetase observed in AIP and HCP. In the two cases 
of HCP which were examined in attack, fairly good linear 
correlation was obtained between the urinary e/ a ratio and 
the urinary levels of ALA and PBG. The urinary e/ a ratio was 
at its maximum during the attack when the levels of ALA and 
PBG in the urine were at their highest, and then gradually 
decreased with corresponding decreases in the levels of ALA
and PBG. Unlike AIP patients, the urinary levels of ALA and 
PBG in HCP are only elevated during an attack, whereas AIP 
patients may be in remission for many years and still be 
excreting excessive quantities of ALA and PBG in the urine.
Of all these patients who were excreting excessive amounts of 
ALA and PBG, only one was found which did not show any 
elevations in any of the 17-OS measured, either in the urine 
or in the plasma. A similar linear correlation between the 
urinary E/a ratio and the excretion of ALA and PBG was found 
for one patient. Case 5, with AIP (Figure 35). As with the 
HCP patients, these correlations were found in urines collected 
during and after the acute attack. These observations do 
indicate that increased amounts of 5p-H type 17-OS may play 
a part in bringing about the abnormal synthesis of porphyrins 
and precursors which occurs in the porphyrias. Unfortunately, 
the mechanism through which the effects of these steroids are 
mediated is completely unknown. Consideration of previous 
research in this field of investigation suggests that out of 
the many possible mechanisms, the two most likely are: the
excess steroids would act directly as derepressors of the 
operon allowing de novo synthesis of ALA synthetase, or 
indirectly by inhibition at some later point in the haem 
biosynthetic pathway; perhaps bringing into effect the 
partial block in the pathway, as hypothesised by Kaufman and 
Marver (1970).
The observations made on Case 26, a male AIP, are 
suggestive that the steroid effect takes place by the former
mechanism. During attack, this patient excretes excessive 
amounts of ALA, PBG, uroporphyrin and coproporphyrin and 
excessive amounts of 17-OS conjugates, of which DHAS and EG 
were the most strikingly elevated. The fact that the amount 
of preformed uroporphyrin and coproporphyrin in the urine is 
significantly increased must be considered in respect to a 
partial block in the transformation of PBG to uroporphyrinogen 
by the enzyme URO-I-synthetase. The amount of uroporphyrin 
and coproporphyrin represents but a small percentage of the 
PBG formed. Thus, it is likely that the amount of activity 
in the liver, although significantly reduced, nevertheless 
suffices to convert a small proportion of the greatly increased 
PBG to uroporphyrinogen and thence to coproporphyrinogen.
Since DHA and its sulphate have been shown to be quantitatively 
one of the main steroids secreted by the adrenal cortex 
(Baulieu et al., 1965) and since in the investigation of this 
patient the most striking steroid abnormality was the raised 
levels of DHA conjugates, it was suggested that treatment with 
dexamethasone, which suppresses ACTH release leading to 
reduction in the activity of the adrenal cortex (Sirett and 
Gibbs, 1969), might alleviate the symptoms of porphyria.
After dexamethasone administration, there was a significant 
fall in the urinary levels of the 17-03 conjugates with a 
corresponding sharp and significant fall in the levels of 
both porphyrins and precursors. If. DHA or one of its
metabolites had been acting as an inhibitor at the point in the 
pathway of the conversion of PBG to uroporphyrin (i.e. the step 
at which Kaufman and Marver have suggested there is a partial
block of hasm synthesis) resulting in secondary induction of 
ALA synthetase and increased production of ALA and PBG, a 
decrease in the level of this steroid inhibitor due to the 
dexamethasone effect would not have resulted in such a 
dramatic fall in uroporphyrin excretion, as was observed 
with this patient (see Table 35). Therefore, it seems 
likely that this steroid or one of its metabolites acts 
directly on the activity of the ALA synthetase. This 
decrease in the urinary excretion of the 17-03 conjugates 
and porphyrins and precursors was accompanied by a corres­
ponding clinical improvement in the condition of the patient. 
The possibility that this lowering of porphyrin and precursor 
excretion and clinical improvement was a spontaneous event, 
independent of the administration of dexamethasone, must not 
be dismissed. There also exists the other possibility that 
its effect may be due to other factors in this system 
unconnected with steroids, since dexamethasone administration 
has been shown to lead to a significant depression of citric 
acid levels in humans (Wajchenberg et al,, 1959). This 
depression of citrate could lead to a depression of succinate 
with a subsequent decrease in the entry of succinyl CoA 
substrate into the haem biosynthetic pathway.
This steroid, DHA and its sulphate, have been shown by 
Goldberg et al. (1969) to cause a striking rise of hepatic ALA 
synthetase when injected into rats. Further indirect 
evidence that some steroids or their metabolites are implicated 
in the control of ALA synthetase and porphyrin metabolism in
humans is provided by the reports of Koskelo et al. (1966) and 
Burton et al. (1957), which indicate that the oral contraceptive 
pill can upset porphyrin metabolism resulting in increased 
urinary excretion of porphyrins and precursors. Likewise, 
there are several reports of attacks of hereditary hepatic 
porphyria being provoked by oral contraceptives (Redeker, 1953; 
Wetterberg, 1954; Dean, 1955; Baxter and Permowicz, 1957; 
McKenzie and Acharya, 1972). Kappas et al. (1959) have also 
shown that plasma taken from women on the contraceptive pill 
and from AIP patients in attack or remission caused an induction 
of porphyrins which was blocked by UDP glucuronic acid addition 
in chick tissue culture. Plasma taken from normal individuals 
had no effect on porphyrin production in the tissue culture. 
Despite these suggestive findings, it remains to be shown 
whether sex steroids or some endogenous steroid metabolite 
directly cause the induction of ALA synthetase in human liver. 
Most of the steroidal observations in vivo could conceivably be 
explained, for instance, by inhibition by these steroids at some 
later point in the haem biosynthetic pathway with secondary 
induction and overproduction resulting from this, but the 
observations on the effects of dexamethasone on one male AIP 
patient in this thesis and the overall concept of the mechanism 
of the steroid effect resulting from the in vitro investigations 
of a large number of different groups, do suggest that the effect 
of the steroid on hepatic haem synthesis in human porphyria is 
mediated through an induction process with the specific steroid 
acting as a derepressor of the operon, resulting in de novo
synthesis of the enzyme ALA synthetase, with the genetically 
determined partial blocks in the haem synthesis in the liver 
explaining the different porphyrin and precursor excretion 
patterns which are characteristic of each of the diseases, 
as hypothesised by Kaufman and Marver (1970).
In their examination of a large family with AIP, Meyer 
et al. (1972) discovered two seemingly unaffected siblings 
with normal urinary excretion of ALA and PBG but who had low 
erythrocyte URO-I-synthetase similar to their affected siblings. 
In one of these two siblings, an acute attack of AIP developed 
spontaneously six months after completion of their study. 
Similarly, no clinical or chemical manifestations of porphyria 
could be found in the parents, but the father was identified 
as the transmitter of the genetic defect by the finding that 
his erythrocyte URO-I-synthetase activity was reduced to a 
level comparable to that of the siblings with manifest porphyria. 
These examples are good illustrations of the wide variability 
in the expression of this genetic disorder, and points to the 
probable role of some other factor in bringing out the clinical 
and chemical manifestations of the disease. In all possibility, 
this other factor could be the involvement of the adrenal cortex 
(or even the hypothalamus) and steroid metabolism with the 
porphyrias. A wide variety of different factors, including 
a large number of different drugs (barbiturates, sulphonamides, 
griseofulvin, dichlorophenazone, oral contraceptives), alcohol 
abuse, infections, dietary factors, hormonal factors, pregnancy, 
sunburn and emotional stress, have all been implicated as
precipitating and aggravating factors in acute episodes of the 
hepatic porphyrias (Eales, 1971), and there is the distinct 
and attractive possibility that their effects are mediated 
through interaction with an endogenous regulatory system of 
steroid metabolism in the liver. The following factors are 
known to act directly on steroid metabolism in the liver: 
sexual state, stage of development, treatment with hormones 
(sex hormones, anabolic steroids, corticosteroids, thyroid 
hormone), a wide variety of drugs, state of nourishment, 
conditions of stress and the rate of blood flow through the 
liver (for review, see Schriefers, 1969). This list is very 
similar to that of factors involved in the precipitation of 
hepatic porphyria, and it is possible that these forementioned 
factors result in the over-production or accumulation of a 
specific steroid metabolite with strong ALA.S inducing activity. 
In normals, this would result in an increase in production of 
haem, leading to an increase of the haemoproteins (P-450), which 
are components of the microsomal drug and steroid detoxification 
system, ultimately resulting in increased polarisation of the 
specific steroid metabolite, conjugation and excretion. In 
patients with porphyria who have inherited a partial block in 
haem synthesis, this induction effect of the steroid would 
just result in accumulation and excretion of the precursors 
formed previous to the partial block with, perhaps, a slight 
increase in the production of haem, but not enough to produce 
the additional haem required for increasing the levels of these 
drug and steroid metabolising microsomal cytochromes for the
detoxification of the inducing steroid. This concept is 
supported by the fact that, when haem synthesis is partially 
inhibited by 3-amino-1,2,A-triazole (Tschudy and Collins,
1957), induction of P-450 by phénobarbital is impaired (Baron 
and Tephly, 1969). Beattie and Stuchell (1970) reported an 
increase in the cytochrome content of mammalian liver mito­
chondria after administration of AIA (a very potent porphyrino­
genic compound in experimental animals), but this is not in 
agreement with the results of other investigators who have 
shown that AIA causes an increased turnover rate of microsomal 
haem in the liver (De Matteis, 1970; Meyer and Marver, 1971). 
Thus, AIA appears to prevent a rise of P-450 by augmenting 
turnover of either the total enzyme or its haem moiety.
This failure to increase the level of drug and steroid 
metabolising enzymes allows an inducer to persist in the liver 
for a longer length of time. A similar situation could occur 
in hereditary hepatic porphyries, with the failure to increase 
the level of drug-(steroid)-metabolising enzymes being due to 
the partial block in the pathway, and thus allowing the inducing 
steroid to persist in the liver for a longer length of time.
If microsomal haem is involved in the repression of ALA . 
synthetase, the above situation in porphyries may result in a 
decreased haem pool which might interfere in the closed 
negative feedback loop by haem, which is assumed to operate 
in the repression of ALA.S, thus augmenting the original 
inducing effect of the steroid.
This type of steroid effect need not only apply for
hereditary porphyria but might also have an effect on acquired 
porphyrias, like PCT symptomatica or the cutaneous porphyria 
which occured after inadvertant ingestion of wheat containing 
the fungicide hexachlorobenzene,in many people in Turkey. 
Although the examination of the levels of the 17-OS in the 
urine and plasma of PCT patients in this thesis did not reveal 
any abnormally elevated levels, as in the hereditary hepatic 
porphyries, there have been many reports by other investigators 
associating the administration of steroids, especially 
oestrogens, with PCT (Hurley and English, 1963; Warin, 1963; 
Becker, 1965; Copeman et al., 1966; Felsher and Redeker, 1966; 
Levere, 1966; Thivolet et al., 1967; Vail, 1967). The 
majority of these patients were given the hormonal preparation 
for prostate carcinoma, and an interval of several months or 
years had elapsed between the commencement of therapy and the 
appearance of cutaneous symptoms. Raised levels of hepatic 
ALA.S in PCT patients have been reported by Levere (1966) and 
by Moore et al. (1972b). It seems unlikely, due to the time 
interval between commencement of oestrogen administration and 
appearance of symptoms, that the oestrogens themselves induce 
the ALA.S. Granick and Kappas (1967b) reported that oestradiol 
and related naturally occurring and synthetic oestrogens are 
only weak inducers in chick liver cell culture. Later, in 
1970, Rifkind et al. showed that the progestational components 
of the contraceptive pill induced hepatic ALA.S activity, and 
the inducing effect was not significantly altered by the 
addition of oestrogens. Although there is the possibility
that, due to species differences, oestradiol or related 
compounds might in humans have a potent porphyrinogenic 
inducing activity, it seems more probable that they exert 
more indirect effects; for example, on the levels of other 
inducers (steroid ?). Oestrogens are known,at least in rats,
to decrease metabolism of some steroids and drugs in the 
microsomal drug metabolising system (Conney et al., 1965;
Kato and Onoda, 1970) and to alter metabolism of steroids by 
other pathways (Yates et al., 1958; Chatterton et al., 1970), 
perhaps resulting in an increase in an inducing steroid. It 
is these indirect effects of the oestrogens which are probably 
responsible for the precipitation of mild attacks observed in 
AIP after administration of a variety of exogenous oestrogens 
(Redeker, 1963).
There is also evidence that prolonged administration of 
these oestrogenic compounds may impair liver excretory function 
(Combes et al., 1963; Mueller and Kappas, 1964; Kottra and 
Kappas, 1967). Eisalo et al. (1964) described Impaired liver 
function after administration of oral contraceptives, apparently 
due to their oestrogenic component. A significant elevation 
of urinary coproporphyrin and ALA has also been found in 
pregnancy, especially when associated with hepatic disease 
(Koskelo and Toivonen, 1968) and in women taking oral contra­
ceptives (Koskelo et al., 1966). These findings suggest that 
impairment of liver excretory function may be partly responsible 
for increased urinary excretion of porphyrins and precursors, 
and for the appearance of symptoms of photosensitivity in PCT.
This also raised the question of whether or not the 
mechanism of induction of an attack in hereditary porphyria 
by oestrogens may occur, in part at least, indirectly by 
establishing a condition of liver damage resulting in a 
lowering of conjugation and excretion of steroids. An 
indirect mechanism of this type may, perhaps, explain the 
reason for the length of time taken by the majority of these 
oestrogenic agents to cause increased porphyrin excretion and 
symptoms of PCT, and the reason for the persistence of the 
biochemical manifestations in spite of the withdrawal of the 
causative agent once the metabolic disorder is established 
(Becker, 1965; Copeman et al., 1966; Zimmerman et al.,
1966). Further support for this suggestion is provided by 
the observations that the clinical and biochemical evidence 
of liver damage is much more common in PCT than in the other 
varieties of hepatic porphyria, and by the reports that 
increased porphyrin excretion and appearance of symptoms of 
photosensitivity are observed in chronic liver disorders in 
which there is no history of alcoholism, or of prolonged 
exposure to any of the hormonal preparations, drugs or toxic 
factors associated with hepatic porphyria (Brunsting, 1954;
Tio et al., 1957; Braun and Berman, 1959).
Another important factor which may play a secondary 
aggravating role in PCT, is the faulty regulation of steroid 
conjugation resulting in an accumulation of free steroids in 
the liver. Shanley et al. (1969) have reported that conjuga­
tion of aetiocholanolone was found to be impaired both in 
patients with symptomatic porphyria (PCT) and in non-porphyric 
patients with liver disease, compared to normal subjects.
Similarly, Zumoff et al. (1966; 1967) found that steroid
glucuronide formation in patients with liver cirrhosis was 
reduced between 41^ and 87^ of normal. In this thesis, 
examination of the levels of the 17-OS in the plasma and in 
the urine of PCT patients revealed no abnormal elevations 
as in the hereditary hepatic porphyrias, but it is of 
interest to note that in 80^ of the PCT patients examined, 
the total urinary excretion of the 17-OS was lower than the 
mean total urinary excretion of 17-OS of normals of the 
corresponding age group. In the plasma, the reverse was 
true, with 89^ of the PCT patients whose plasma was examined 
having a greater level of total plasma 17-OS sulphates than 
the mean total plasma 17-05 level of normals of the same age 
group. These observations do suggest that there may be some 
impairment of steroid conjugation or excretion in the liver 
in these patients with PCT symptomatica, resulting in slight 
increases in the concentrations of these steroids in the plasma 
or an even greater accumulation of the free steroids in the 
liver, where they might be partly responsible for the induction 
of the increased activity of ALA synthetase, which was found by 
Moore et al. (1972b).
Despite studies of structure-activity relationships within 
individual groups of chemically related compounds (Talman et al., 
1957; Marks et al., 1965), the wide variety of chemical 
structures which can lead to induction of hepatic ALA synthetase 
has not so far permitted any unifying hypothesis concerning a
common chemical mechanism by which all these compounds act. 
Indeed, currently available information suggests that different 
groups of compounds may operate by different mechanisms.
However, there is the possibility that the effects of the 
majority of these drugs are mediated through a change of 
steroid metabolism, or distribution, or an increase in the 
biological half-life of the steroid, resulting in an intra­
cellular accumulation of an active inducing steroid in 
concentrations sufficient to impair repressor control of 
the synthesis of ALA.S.
Drugs and steroids are metabolised by the same cytochrome 
P-450-containing enzyme system in liver microsomes (Conney et 
al., 1968; Kupfer and Orrenius, 1970) and, from observations 
on the effect of castration, adrenalectomy and steroid hormones 
on enzyme activity (Kato and Gillette, 1965), it has been 
suggested that the levels of microsomal enzyme activity are 
controlled by the concentrations of circulating steroid 
hormones (Conney, 1967; Orrenius et al., 1968; Qrrenius et 
al., 1969), The studies of Kato and Onoda (1970) on the 
regulation of the activity of drug oxidation in rat liver 
microsomes, suggested that androgens and oestrogens regulate 
drug hydroxylations, partly through the content of P-450 in 
the microsomes and principally through the capacity of P-450 
to bind with the drugs. They reported that castration of 
male rats decreased the P-450 content of the microsomes, but 
this could be restored to normal by treatment with testosterone. 
It has also been shown that certain drugs and steroids, when
incubated together with liver microsomes, inhibit each other’s 
oxidative metabolism in a competitive manner (Tephly and 
Mannering, 1968). Such competition could also occur in vivo; 
Orrenius and his colleagues (1968; 1969) have postulated that
the induction of enzymes by drugs is mediated through changes 
taking place in an endogenous, steroid hormone controlled 
regulatory system as a result of interference with endogenous 
steroid metabolism. A similar regulatory mechanism might 
control the enzyme ALA synthetase,and potent porphyrinogenic 
drugs,like ALA, phénobarbital, DDC, which bind strongly to 
cytochrome P-450 (Jefcoate et al., 1969; De Matteis, 1970; 
Tschudy and Bonkowsky, 1972), might competitively inhibit 
steroid hydroxylation and thus enhance metabolism of steroids 
by pathways leading to active inducers (derepressors) of ALA 
synthetase. This inhibition of steroid hydroxylation by 
drugs, when incubated in vitro with liver microsomes in the 
presence of NADPH, has been demonstrated by Kuntzman et al. 
(1965) and by Schneidman et al. (1965). This hypothesis 
would explain the lack of ALA synthetase induction by AIA in 
adrenalectomised animals (Matsuoka et al., 1968; Moses et al.,
1970) and the permissive effect of hydrocortisone on the 
induction of hepatic ALA synthetase in these animals (Marver 
et al., 1966c). An example of the disturbances in steroid 
metabolism which can be caused by these porphyrinogenic drugs 
was demonstrated by Southern et al. (1969), who reported that 
phenetharbital induces a moderate fall in the metabolic 
clearance and production rate of testosterone and a decrease
in the urinary excretion of androsterone, aetiocholanolone and 
the 11-oxy-17-0S. These changes are associated with a rise 
in the excretion of more polar metabolites of testosterone,
A similar interference with endogenous steroid metabolism 
may well explain the provocations of acute attacks in hereditary 
hepatic porphyria due to dieting (Welland et al,, 1964;
Felsher and Redeker, 1967; Knudsen et al., 1967; Eales, 1971) 
and the increased induction of porphyrins in experimental 
animals which have been starved (Marver et al., 1966a,b).
There is a close association between carbohydrate metabolism 
and steroid turnover. Under conditions of fasting, there are 
changes in the supply of NADPH from the hexose monophosphate 
shunt, and a reduced hepatic content of pyridine nucleotide 
may contribute to the decreased rate of inactivation of the 
steroids by the various WADPH-dependent reducing enzymes. 
Hendrikx et al. (1968) reported that fasting subjects showed 
a fall in the urinary excretion of 17-OS, but this was 
accompanied by a modest increase in the plasma levels of DMA 
and androsterone sulphates. The hydrogenation of the steroids 
may be diminished by a low hepatic level of NADPH, owing to a 
fall in liver glycogen, which in turn leads to an insufficient 
supply of hydrogen from decrease in glucose-6-phosphate 
(Schriefers, 1967). Alternatively, starvation may be 
associated with a decreased activity of the various steroid- 
-inactivating enzymes (Foy and Schneiden, 1962). Experiments 
in rats show that fasting results in a fall in hepatic steroid 
A^-reductase (Herbst et al., I960) and 20-hydroxysteroid
dehydrogenase, both NADPH-dependent enzymes, and a reduced 
capacity of the liver to synthesise steroid glucuronides due 
to a limited formation of UDPGA (Schriefers et al., 1955a;
1966), This diminished supply of UDPGA, and hence glucuronide 
synthesis, is due to the lower levels of hepatic glycogen and 
glucose-6-phosphate, which fall to 10 - 20^ of the control 
values on starvation. Like the hydrogenation, the capacity 
of the liver for formation of excretable steroid glucuronides 
may be brought back to values near normal in the case of fasting 
animals by the administration of glucose. Whether this type 
of mechanism, i.e. an increased capacity of the liver for 
hydrogenation and glucuronide conjugation of steroids, is 
responsible for the blocking of drug induced experimental 
porphyria in animals by high carbohydrate administration is 
not known. These findings in experimental porphyria were 
extended to patients with AIP (Welland et al., 1964; Felsher 
and Redeker, 1967) and UP (Perlroth et al., 1968; Eales, 1971) 
by the demonstration that a high intake of carbohydrate or 
protein, or both, can decrease porphyrin and precursor 
excretion. The data of Felsher and Redeker (1967) also 
indicates that a high carbohydrate diet can protect, some 
patients at least, against drug-induced attacks of AIP.
The ability of glucose to block the induction of certain 
enzymes was originally demonstrated in micro-organisms by 
Flagasanik (1961) and later this same effect, termed the 
'glucose effect', was demonstrated to occur for enzymes in rat 
liver by Peraino and Pitot (1964). A number of these hepatic
enzymes which are repressed by glucose are involved in amino 
acid catabolism and gluconeogenesis, and in a number of systems 
this 'glucose effect' involves changes in the levels of insulin 
and glucagon and complex interaction with other hormones, 
particularly glucocorticoids (Dost et al., 1968; Hanoune et al.,
1971). In patients suffering from hepatic porphyria, it is 
not known whether the beneficial effects of administration of 
a high protein or carbohydrate diet are mediated through this 
'glucose effect' and hormonal influences, as suggested by 
Tschudy et al. (1964) and Marver et al. (1966b),or through a 
more direct mechanism resulting in increased capacity of the 
liver for detoxification and conjugation of inducing steroids.
These results and observations considered in this discussion 
indicate that the effects of many of the factors involved in 
the provocation and aggravation of the hepatic porphyrias may 
be mediated through interaction with an endogenous regulatory 
system of steroid metabolism in the liver. The liver is the 
centre of steroid metabolism and may be regarded as the 
antagonist to the endocrine glands, hypophysis and hypothalamus, 
which form a functional unit for the homeostatic regulation of 
the plasma levels of hormones. As mentioned previously, 
steroid metabolic activity of the liver is not constant but 
can be affected by a large variety of exogenous and endogenous 
factors which interfere with the normal metabolism and 
detoxification of the steroids. Some of these factors may 
well result in an increase in the activity of a specific steroid 
which induces the synthesis of ALA synthetase (in fact, there is
the possibility that the synthesis of this enzyme is under 
constant stimulation by an inducing steroid, in order to 
fulfil the requirement for haem under conditions of normal 
cellular activity). In the normal cell, this increase in 
activity of inducing steroid can be adequately dealt with by 
the corresponding increase in haem, resulting in greater 
feed-back repression of ALA synthetase or an increase in 
the haem-containing detoxifying enzymes. In the porphyric 
hepatic cell with its inherited defect of a partial block in 
the biosynthesis of haem (Kaufman and Marver, 1970; Meyer 
et al., 1971), the rise in the level of the inducer is not 
matched by a corresponding rise in haem production. With no 
increase in feed-back repression by haem or rise in the 
detoxifying enzyme system to combat this steroid inducer, 
further stimulation of the de novo synthesis of ALA synthetase 
will take place, accompanied by further increases in the 
steroid inducer if the original disturbance of steroid 
metabolism is still present. This cascading effect may have 
far reaching influences, causing disturbances in the function 
of the hypophysis, hypothalamus and steroid hormone-producing 
organs, culminating in the initiation of an acute attack.
The relationship of these disturbances in steroid metabolism 
and resultant excess production of porphyrins and precursors 
to the multitude of clinical abnormalities, especially the 
neurological symptoms which have been observed in patients 
with hepatic porphyria, has not yet been established and 
awaits further investigation.
With respect to one clinical symptom, fever, which is 
sometimes present in a mild form during acute attacks of 
porphyria, it may be of potential interest to note that 
certain Sp-H steroids which have strong porphyrinogenic 
action in liver cell culture (Granick and Kappas, 1967a) 
also have strong fever-producing action in man (Kappas and 
Palmer, 1963; 1965). Bendy et al. (i960) have reported 
steroid excretion patterns in a series of subjects suffering 
from fever in association with abdominal pain, joint pains 
and leucocytosis. They found elevated levels of urinary 
aetiocholanolone in a proportion, but in by no means all of 
such patients. These steroids with the 5p-H configuration 
also have been shown to have haemolytic activity, and induce 
marked changes in the permeability of lysosomes releasing 
p-glucuronidasB (Weissman, 1965; Weissman and Keiser, 1965).
It remains possible that the steroids with the Sp-H structure 
have similar disruptive action on nerve membrane, and perhaps 
in excess they might provide in part a possible explanation 
for the neurological disturbances and nerve fibre destruction 
sometimes observed in porphyria.
Lastly, this study of 17-OS and porphyrias raised one 
very important question concerning the regulation of haem 
biosynthesis in the cell. In animals, the control of haem 
biosynthesis appears to be primarily a control on the rate of 
biosynthesis of the enzyme ALA synthetase, and it is generally 
agreed that haem acts as a feed-back repressor of the synthesis 
of ALA synthetase. Since approximately 31 mg of haem are
formed daily in the liver, it seems likely that the haem 
biosynthetic pathway is under a constant stimulus. In vitro 
experimental work by several separate research groups 
indicates that certain steroids of physiological origin are 
capable of acting as derepressors, allowing the commencement 
of the transcription of the structural gene for the synthesis 
of ALA synthetase, and it seems very probable that in vivo 
a specific steroid may serve to maintain a certain rate of 
haem synthesis by inducing the synthesis of ALA synthetase.
This specific steroid may well be DMA or a close metabolite 
of DMA, since the elevations of this steroid and its metabolites 
were the most striking abnormalities observed in this study 
of patients with hepatic porphyria. Furthermore, several 
general aspects of the behaviour of DHA and its sulphate have 
intrigued investigators for many years. DHA is secreted by 
the adrenal cortex in episodic bursts synchronously with 
hydrocortisone, and in amounts comparable to those of hydro­
cortisone. Likewise, DHAS is also secreted by the adrenal 
cortex in relatively large amounts and, apart from its role 
as a precursor in the placental production of oestrogen which 
is clearly established, no true hormonal effects have yet been 
described for DHAS. Compared to the free steroids and 
glucuronide conjugates, DHAS has a large half-life in the body, 
and thus a relative large quantity of sulphate conjugate of 
DHA is present at all times in the plasma, and there is 
evidence that this pool or reservoir of DHAS can maintain the 
plasma free DHA at a significant value above zero during periods 
when no free DHA is secreted by the adrenals. This is the
crucial difference between the behaviour of the two major 
adrenocortical secretory products, DHA and hydrocortisone, 
since the plasma concentration of hydrocortisone remains at 
values indistinguishable from zero for several hours in the 
late evening and early morning, whereas the concentration of 
DHA remains relatively high in relation to its peak values 
during the day (Rosenfeld et al., 1972). This seems
strange when one compares the known effects of DHA (which 
are the inhibition of glucose-6-phosphate dehydrogenase and 
A^-Boc-reductase activity) to the far reaching effects of 
hydrocortisone on the body. This raises the intriguing 
possibility that DHA or a close metabolite may be as necessary 
to the human organism as hydrocortisone, and what could be 
more necessary than its action as a constant stimulus for the 
biosynthesis of haem?
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